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Chapter I 
INTRODUCTION 
The cardiovascular system 
The cardiovascular system is a transport system that carries blood and 
lymph to and from tissues of the body. The constitutive elements of these 
fluids include cells, nutrients, waste products, hormones, and antibodies. 
The cardiovascular system consists of a pump represented by the heart 
and blood vessels, which provide the route by which blood circulates to 
and from all parts of the body. The heart pumps the blood through the 
arterial system under significant pressure; blood is returned to the heart 
under low pressure with the assistance of negative pressure in the 
thoracic cavity during inspiration and compression of the veins by 
skeletal muscle. The blood vessels are arranged so that the blood 
delivered from the heart quickly reaches a network of narrow, thin-
walled vessels, the blood capillaries, within or in proximity to the tissue 
in every part of the body (Fig. 1.1). 
14 
 
 
Fig. 1.1: The cardiovascular system. 
In the capillaries, a two-directional exchange of fluid occurs between the 
blood and tissues. The fluid, called blood filtrate, carries oxygen and 
metabolites and passes through the capillary wall. In the tissues, these 
molecules are exchanged for carbon dioxide and waste products. Most of 
the fluids re-enters the distal or venous end of the blood capillaries. The 
remaining fluid enters lymphatic capillaries as lymph and is ultimately 
returned to the bloodstream through a system of lymphatic vessels. Two 
pathway of circulation are formed by the blood vessels and heart: 
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 Pulmonary circulation conveys blood from the heart to the lungs 
and from lungs to the heart. 
 Systemic circulation conveys blood from the heart to other tissues 
of the body to the heart. 
The blood vessels are classified into arteries, veins and capillaries. 
Arteries are the vessels that deliver blood to the capillaries. The smallest 
arteries, called arterioles, are functionally associated with networks of 
capillaries into which they deliver blood. The arterioles regulate the 
amount of blood that enters these capillary networks. Together, the 
arterioles associated with capillary network, and postcapillary venules 
form a functional unit called the microcirculatory or microvascular bed 
of that tissue. Veins, beginning with the postcapillary venule, collect 
blood from the microvascular bed and carry it away. Because an artery 
conducts blood from the heart, its wall must be sufficiently strong to 
withstand the sudden thrust imposed on it with every heart beat. The 
walls of the artery are, therefore, thicker and stronger than those of veins 
of similar diameter. All blood vessels are composed by three layers, from 
the lumen outward (Fig. 1.2): 
16 
 
 
Fig. 1.2: Schematic diagram of the major structural features of blood vessels. 
 The tunica intima, the innermost layer of the vessel, consists of 
three components: (a) a single layer of squamous epithelial cells, 
the endothelium; (b) the basal lamina of the endothelial cells (a 
thin extracellular layer composed chiefly of collagen, 
proteoglicans, and glycoprotein); (c) the subendothelial layer, 
consisting of loose connective tissue. The subendothelial layer of 
the intima contains a sheetlike layer or lamella of fenestrated 
elastic material called internal elastic membrane. Fenestrations 
enable substances to diffuse readily through the layer and reach 
cells deep within the wall of the vessel. 
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 The tunica media, or middle layer, consists primarily of 
circumferentially arranged layers of smooth muscle cells. This 
layer is relatively thick and extends from the internal elastic 
membrane to the external elastic membrane. The external elastic 
membrane is a layer of elastin that separates the tunica media from 
the tunica adventitia. Variable amounts of elastin, reticular fibers, 
and proteoglycans are interposed between the smooth muscle cells 
of the tunica media. The sheets or lamellae of elastin are 
fenestrated and arranged in circular concentric layers. All of the 
extracellular components of the tunica media are produced by the 
smooth muscle cells. 
 The tunica adventitia, or outermost connective tissue layer, is 
composed primarily of longitudinally arranged collagenous tissue 
and a few elastic fibers. These connective tissue elements 
gradually merge with the loose connective tissue surrounding the 
vessels. The tunica adventitia of large arteries and veins contains a 
system of vessels called vasa vasorum that supplies blood to the 
vascular walls themselves, as well as a network of autonomic 
18 
 
nerves called nervi vascularis that control contraction of the 
smooth muscle in the vessel walls. 
The relative contributions of different components of the vessels wall 
vary throughout the circulation, but an endothelial monolayer is 
present in all vessels. The endothelial cells lie parallel to the direction 
of blood flow which allows them to sense changes in shear stress. 
There are extensive gap junctions between endothelial cells allowing 
direct passage of small molecules. In contrast, the smooth muscles of 
the media layer are perpendicular/circumferential allowing them to 
control vessel radius. There is normally only a small distance, 
containing the internal elastic lamina, between endothelium and 
smooth muscle layer which facilitates diffusion of substances between 
the two. Arterioles only contain a single layer of smooth muscle cells, 
whereas large may have up to 20 layers. 
The structural differences among arteries and veins are primarily the 
degree of development of the media and adventitia, especially the 
former. For any given size, arteries tend to have a much stronger and 
ticker media, veins are more poorly developed one. Also the walls of 
arteries contain fairly prominent elastic tissue. 
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1.1 Arteries: general features 
Arteries are generally divisible into elastic and muscular types, 
although the media of most arteries contains some of both types of 
tissue. Elastic tissue allows the wall of an artery to be distended by the 
sudden thrust of blood from the heart and then to contract again, 
which helps force the blood forward, with no initiation of energy by 
the wall of the vessel. The large arteries near the heart typically 
contain a great deal more elastic tissue than do the smaller, more 
distal ones; in general, the greater the pressure in an artery, the more 
elastic tissue there is. For example, the pressure in the great trunk 
(pulmonary trunk) going to the lungs is much less than that in the 
great trunk (aorta) carrying blood to the body as a whole; therefore the 
wall of the aorta contains far more elastic tissue than the pulmonary 
trunk. Elastic tissue serves the double purpose of cushioning the 
sudden rise of pressure induced by the heart beat and of smoothing, by 
its automatic recoil, what would, in an elastic system, be a sudden 
drop in pressure. In the largely arteries, particularly the aorta, most of 
the strength of the wall is provided by elastic tissue. If this undergoes 
degenerative changes, or is destroyed by disease, the arterial wall may 
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bulge, either in one spot or all around. As branches of the aorta are 
traced distally, the relative amount of elastic tissue becomes less and 
relative amount of smooth muscle more. The elastic tissue of the 
peripheral arteries tends to smooth the pressure and lessen the velocity 
of the blood. The smooth muscle, controlled by the autonomic 
nervous system, can contract or relax to vary the caliber of the vessel 
and, thereby, the blood flow through it. Even rather large vessels, for 
instance, the chief arteries of the arm and thigh, contain sufficient 
smooth muscle to reduce to a dangerous level the blood flow through 
them if they are incited to maximal contraction. The smallest arteries, 
arterioles (lumen diameter <300µm) have a media composed almost 
entirely of smooth muscle and are particularly contractile. They are 
responsible for blood pressure (BP) control and regional distribution 
of blood flow, through effects on vascular resistance [180]. Based on 
Poiseuille’s law, vessel resistance is inversely proportional to the 
radius (lumen diameter) to the fourth power (r
4
) and accordingly small 
changes in lumen size result marked changes in resistance [181]. The 
lumen diameter of resistance arteries is a function of vasomotor tone 
(vasoconstriction/vasodilation) and the structural characteristics of the 
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vessel. Vasomotor control underlies acute rapid adaptation of vessel 
diameter, due mainly to vasoconstriction exerted by the active 
contraction of vascular smooth muscle cells (VSMC) in the vessel 
media, whereas alterations in structure constitute a dynamic process 
occurring in response to chronic hemodynamic variations. Initially 
structural changes are adaptive, but subsequently become maladaptive 
resulting in alterations in media thickness and lumen diameter 
[181,182]. This process, called vascular remodeling, contributes to the 
pathophysiology of vascular diseases, including hypertension [183, 
184]. 
There are both intrinsic and extrinsic mechanisms regulating vessel 
diameter. Circulating vasoactive mediators such as angiotensin II and 
cathecholamines, as well as locally released mediators from the 
autonomic nervous system, confer extrinsic regulation of smooth 
muscle contraction. Intrinsic regulation of vessel diameter is mainly 
mediated by two mechanosensitive mechanisms. One is the sensing of 
shear stress on the endothelium caused by an increase in blood flow. 
This leads to a release of vasodilators from the endothelium, which 
relaxes the smooth muscle cells. The other mechanism involves 
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stretch sensing by the smooth muscle cells themselves, resulting in 
narrowing of the vessel lumen. The latter mechanism is referred to as 
myogenic tone. 
1.2 The vascular endothelium    
In the adult human body, a circulatory system consists of about 
60,000miles of different-sized vessels that are lined by a simple 
squamous epithelium called endothelium. The endothelium is formed 
by a continuous layer of flattened, elongated and polygonally shaped 
endothelial cells that are aligned with their long axes in the direction 
of the blood flow. The endothelium has long been viewed as an inert 
cellophane-like membrane lining the circulatory system with its 
primary essential function being the maintenance of vessel wall 
permeability [196], but subsequent studies led to the current view of 
the endothelium as a dynamic, heterogeneous, disseminated organ that 
possesses vital secretory, synthetic, metabolic, and immunologic 
functions [196]. At the luminal surface, they express a variety of 
surface adhesion molecules and receptors, so endothelial cells play an 
important role in blood homeostasis. The functional properties of 
these cells change in response to various stimuli. This process, known 
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as endothelial activation, is also responsible for the pathogenesis of 
many vascular diseases. 
Endothelial cells are active participants in a variety of interactions 
between the blood and underlying connective tissue and are 
responsible for many properties of the vessels. These properties 
include the following: 
 The maintenance of a selective permeability barrier, which 
allows selective movement of small and large molecules from 
the blood to the tissues and vice versa. This movement is 
related to the size and charge of the molecules. The 
endothelium is permeable to small hydrophobic (lipid-soluble) 
molecules (e.g. oxygen, carbon dioxide) that readily pass 
through the lipid bilayer of the endothelial cell membrane (a 
process called simple diffusion). However, water and 
hydrophilic (water-soluble) molecules (e.g., glucose, amino 
acids, electrolytes) cannot diffuse across the endothelial cell 
membrane. These molecules and solutes must be either actively 
transported across the plasma membrane and released into the 
extracellular space (transcellular pathway) or transported across 
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the zonula occludens between two epithelial cells (paracellular 
pathway). The former uses numerous small pinocytic vesicles 
(a clathrin-independent form of endocytosis) to transport bulk 
material from the blood into the cell. In addition, some specific 
molecules (e.g. LDL, cholesterol, transferrin) are transported 
via receptor-mediated endocytosis (a clathrin-dependent 
process), which uses endothelial-specific surface receptors. In 
some blood vessels, larger molecules are transported through 
fenestrations within the endothelial cells visible in transmission 
electron microscope (TEM) preparations. 
  The maintenance of a nonthrombogenic barrier between blood 
platelets and subendothelial tissue is done by producing 
anticoagulants (agents that prevent coagulation such as 
thrombomodulin and others) and antithrombogenic substances 
(agents that prevent or interfere with platelet aggregation and 
release of factors that cause formation of clots, or thrombi, such 
as prostacyclin [PGI2] and tissue plasminogen activator). 
Normal endothelium does not support the adherence of platelets 
or the formation of thrombi on its surface; conversely, damage 
25 
 
to endothelial cells causes them to release prothrombogenic 
agents (agents that promote thrombi formation) such as von 
Willebrand factor or plasminogen-activator inhibitor. 
 The modulation of blood flow and vascular resistance, that is 
achieved by the secretion of vasoconstrictors (endothelin, 
angiotensin-converting enzyme [ACE], prostaglandin H2, 
thromboxane A2) and vasodilators (nitric oxide [NO], 
prostacyclin).  
 The regulation and modulation of immune responses is done by 
controlling the interaction of lymphocytes with the endothelial 
surface, which is mainly achieved through the expression of 
adhesion molecules and their receptors on the endothelial-free 
surface as well as by secretion of three classes of interleukins 
(IL-1, IL-6 and IL-8). 
 Hormonal synthesis and other metabolic activities are done by 
the synthesis and secretion of various growth factors, for 
example, hemopoietic colony-stimulating factors (CSFs) such 
as granulocyte-macrophage CSF (GM-CSF), granulocyte CSF 
(G-CSF) and macrophage CSF (M-CSF); fibroblast growth 
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factor (FGF); and platelet-derived growth factor (PDGF). 
Endothelial cells also synthesize growth inhibitors such as 
heparin and transforming growth factor β (TGF-β). Endothelial 
cells function in the conversion of angiotensin I to angiotensin 
II in the renin-angiotensin system that controls blood pressure, 
as well as in the inactivation or conversion of a several 
compounds conveyed in the blood (norepinephrine, thrombin, 
prostaglandins, bradykinin, and serotonin) to inactive forms. 
 Modification of lipoproteins occurs by oxidation. Lipoproteins, 
mainly LDLs with high cholesterol content and very low-
density lipoproteins (VLDLs), are oxidized by free radical 
produced by endothelial cells. Modifies LDLs, in turn, are 
rapidly endocytosed by macrophages to form foam cells, which 
are a characteristic feature in the formation of atheromatous 
plaques. 
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1.2.1 Regulation of vascular tone by the endothelium 
The endothelium not only provides a structural barrier between the 
circulation and surrounding tissue, but ECs also secrete mediators 
that influence vascular hemodynamics in the physiologic state. 
Thus, ECs contribute to the regulation of blood pressure and blood 
flow by releasing both vasodilator and vasoconstrictors agents, that 
are collectively called endothelium-derived autacoids, because 
they are generally short-lived and locally acting (Fig. 1.3 and 1.4). 
 
Fig. 1.3: Molecular mechanisms of blood vessel vasodilation. 
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Fig. 1.4: Molecular mechanisms of blood vessel vasoconstriction. 
The best characterized endothelial-derived autacoids are the 
vasodilators nitric oxide (NO) and prostacyclin (PGI2), and the 
vasoconstrictor peptide endothelin 1 (ET-1). More recently, 
endothelium-derived hyperpolarizing factor (EDHF) and reactive 
oxygen species (ROS) showed vasorelaxant effect as well. Both 
NO and PGI2 contributes to vessel dilation with two different 
mechanisms: NO induces smooth muscle relaxation by activating 
soluble guanylyl cyclase (sGC). This increases intracellular 
concentration of cyclic guanosine monophosphate (cGMP), which 
in turn, activates the G kinase and reduces the intracellular 
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concentration of Ca
2+
 ([Ca
2+
]i) in smooth muscle and results in 
relaxation. PGI2 binds to receptors on the smooth muscles; 
stimulates cAMP-activated protein kinase A (PKA), which in turn 
phosphorylates myosin light chain kinase (MLCK); and prevents 
activation of the calcium-calmodulin complex. In addition, EDHF 
acts on Ca
2+
-dependent potassium channels causing 
hyperpolarization of smooth muscle cells and their relaxation. On 
the other hand, ET-1, and other members of endothelin family 
(ET-2 and ET-3), is the most potent vasoconstrictors, which 
interacts with its ETA receptor on vascular smooth muscles. The 
vasoconstriction reduces the luminal diameter of these vessels and 
increases vascular resistance; consequently systemic blood 
pressure is also increased. 
1.2.2 The L-arginine/NO/cGMP/PKG pathway in vascular 
tissue 
The endothelial-derived relaxing factor (EDRF) was historically 
one of the early compounds discovered in the endothelial cells, that 
was causing relaxation of blood vessels. For years, researchers had 
difficulty characterizing EDRF chemically. It is now known that 
30 
 
most of the vascular effects of EDRF can be attributed to nitric 
oxide (NO) and its related compounds, which are released by 
endothelial cells in arteries, blood capillaries, and even lymphatic 
capillaries. Since then, it has been shown that NO is a gaseous 
signal molecule of key importance for the cardiovascular system 
and the brain [197]. NO, which is unstable and decomposes within 
ten seconds, regulates a variety of cellular functions by diffusion 
from its originating cell to surrounding cells. It regulates the blood 
vessel diameter, because it acts as endogenous vasodilatatory gas 
continuously synthesized in ECs by endothelial nitric oxide 
synthase (eNOS or NOS III). In response to receptor-dependent 
agonists (bradykinin, acetylcholine, ATP) and physicochemical 
stimuli (shear, stretch), nitric oxide synthase catalyzes the 
oxidation of one of the terminal guanidine groups of L-arginine to 
produce NO, with the stoichiometric formation of L-citrulline (fig. 
1.3) [198]. Molecular cloning and sequence analysis has led to the 
identification of three broad categories of NOS isoenzymes, which 
are: neuronal NOS (nNOS or NOS I), inducible (iNOS or NOS II), 
and endothelial (eNOS or NOS III). The nNOS isoform has a 
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widespread distribution in both the central and peripheral nervous 
system, as well as in a number of non-neuronal cell types. The 
iNOS isoform was initially identified in activated macrophages, 
but has since been found to be expressed by virtually all nucleated 
cells if they are subjected to the appropriate stimuli. The 
endothelial NOS isoform was first identified in vascular 
endothelial cells, and as such has a ubiquitous distribution, 
although its expression has also been demonstrated in several non-
endothelial cell types. 
Endothelial-derived NO diffuses to the adjacent smooth muscle, 
where it interacts with different receptor molecules, of which the 
soluble guanylyl cyclase (sGC) is the best characterized and 
presumably most important one with regard to control of vessel 
tone and smooth muscle proliferation. sGC contains heme iron in 
the ferrous (II) state, which is required for the binding and 
interaction with NO to cause enzyme activation. Upon binding 
with NO, cyclic guanosine monophosphate (cGMP) formation 
increases substantially. cGMP activates the cGMP-dependent 
kinase I which in turn increases the open probability of Ca
2+
-
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activated K
+
 (BK)-channels, thereby inducing a hyperpolarization 
of the smooth muscle cells and inhibition of agonist-induced Ca
2+
 
influx. In addition, activated cGK-Iβ phosphorylates the inositol 
trisphosphate (IP3)-receptor-associated G-kinase substrate (IRAG), 
thereby inhibiting agonist-induced Ca
2+
 release and smooth muscle 
contraction. Another cGK-I substrate found in many cell types is 
the 46/50 kDa vasodilator-stimulated phosphoprotein (VASP). 
cGK-I phosphorylates VASP specifically at serine 239, and this 
reaction can be exploited as a biochemical monitor for the integrity 
and activity of the NO-cGMP pathway [199]. 
1.2.3 Role of PKG in the regulation vascular tone 
During the past few years, it has become clear that cGMP kinases 
regulate some switches that control essential cellular circuits. The 
cGMP-dependent protein kinases (cGKs) belong to the family of 
serine/threonine kinases and are present in a variety of eukaryotes 
ranging from the unicellular organism Paramecium to Homo 
sapiens [266, 267]. Mammals have two cGK genes, prkg1 and 
prkg2, that encode cGKI and cGKII. The N terminus (the first 90–
100 residues) of cGKI is encoded by two alternatively spliced 
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exons that produce the isoforms cGKIα and cGKIβ. The enzymes 
have a rod-like structure and are activated at submicromolar to 
micromolar concentrations of cGMP [268, 269]. They are 
composed of three functional domains: an N-terminal (A) domain, 
a regulatory (R) domain, and a catalytic (C) domain. The 
regulatory domain contains two tandem cGMP-binding sites that 
interact allosterically and bind cGMP with high and low affinity. 
Occupation of both binding sites induces a large change in 
secondary structure (270) to yield a more elongated molecule (271, 
272). The catalytic domain contains the MgATP- and peptide-
binding pockets. This latter domain catalyses the transfer of the γ 
phosphate from ATP to a serine/threonine residue of the target 
protein. The N terminus has three functions: (1) dimerization: 
cGKs are homodimers that are held together by a leucine zipper 
present in the N terminus; (2) activation/inhibition: binding of 
cGMP to both sites in the R domain induces a conformational 
change that releases the inhibition of the catalytic center by the N 
terminus and allows phosphorylation of substrate proteins. 
Activation of heterophosphorylation may be preceded by 
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autophosphorylation of the N terminus. Autophosphorylation 
increases the spontaneous activity of cGKI and cGKII [273–276] 
and is initiated by the binding of low cGMP concentrations to the 
high affinity site of cGKI [277, 278]; (3) targeting: the enzymes 
are targeted to different subcellular localizations by their N 
termini. Together with the Iα isozyme, the Iβ isozyme is highly 
expressed in smooth muscle, including uterus, vessels, intestine, 
and trachea [279]. Platelets, hippocampal neurons, and olfactory 
bulb neurons contain mainly the Iβ isozyme [279]. The Iα and Iβ 
cGKs are soluble enzymes and interact with different proteins 
through their distinct N termini. The main role of cGKI is the 
control of smooth muscle tone. NO and other NO-generating 
organic nitrates stimulate the soluble guanylyl cyclase, increase 
cGMP levels, and thereby relax vascular and other smooth 
muscles. The relaxing effect of these compounds involves the 
activation of cGKI as shown by deleting the cGKI gene in mice 
[280]. cGKI-deficient mice are hypertensive at 4-6 weeks. In these 
mice, precontracted smooth muscle strips are not relaxed by 
acetylcholine or NO, although both compounds increase smooth 
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muscle cGMP levels. Deletion of cGKI did not affect cAMP-
induced relaxation of vascular smooth muscle supporting the 
conclusion that cAMP and cGMP use different signal pathways in 
smooth muscle. 
Smooth muscle tone is regulated by the rise and fall of [Ca
2+
]i. 
Contraction is initiated by receptor-mediated generation of IP3 that 
releases Ca
2+
 from intracellular stores followed by an influx of 
extracellular Ca
2+
 through voltage-dependent Ca
2+
 channels (281, 
282). The rise in [Ca
2+
]i initiates contraction by activation of the 
Ca
2+
/calmodulin-dependent MLCK, which phosphorylates RLC 
and, consequently, activates myosin ATPase. A decrease in [Ca
2+
]i 
inactivates MLCK and induces dephosphorylation of RLC by 
MLCP. Smooth muscle contraction is modulated also at constant 
[Ca
2+
]i by changing the sensitivity of contraction to [Ca
2+
] [283]. 
cGKI interferes both with the increase in [Ca
2+
]i and with the Ca
2+
 
sensitivity at several levels (Fig. 1.5). 
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Fig. 1.5: Mechanisms leading to relaxation of smooth muscle by cGMP 
kinase-I. 
Some evidence indicates that cGKIα inhibits the generation of IP3 
in smooth muscle and Chinese hamster ovary cells [289] by 
interfering with the inactivation of Gαq [290] or the activation of 
phospholipase Cβ3 [291]. However, the biological significance of 
these findings remains unclear because a direct correlation 
between the cGMP-dependent phosphorylation of a target protein 
and decreased IP3 synthesis has not been established. An additional 
mechanism that lowers [Ca
2+
]i is the direct phosphorylation of 
Ca
2+
-activated maxi-K
+
 (BKCa) channels by cGKI. Phosphorylation 
increased channel opening at constant [Ca
2+
]i [284, 285]. The 
cGKI isozyme that phosphorylates BKCa channels is not known. 
Opening of BKCa channels hyperpolarizes the membrane and 
PDE 
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closes a number of channels, including L-type calcium channels, 
thereby reducing Ca
2+
 influx. This mechanism contributes to the 
regulation of vascular tone, as shown in wild type and cGKI 
deficient mice [292]. The cGKI-dependent regulation of BKCa 
channels depended on specific splice variants [286] and may be 
mediated indirectly by cGKI-dependent activation of an associated 
protein phosphatase 2A [287, 288]. 
1.2.4 Regulation of NO production 
The nitric oxide synthase (NOS) present in vascular endothelial 
cells is a multi-domain enzyme consisting of an N-terminal 
oxygenase domain (amino acids 1–491) that contains binding sites 
for heme, L-arginine (Glu361) [395] and tetrahydrobiopterin (H4 
B), and a reductase domain (amino acids 492–1205) containing 
binding sites for FMN, FAD, NADPH and calmodulin (CaM) 
[396]. 
The eNOS is constitutively expressed and is generally regulated by 
Ca
2+
/CaM as well as by phosphorylation [397], which activates 
eNOS. Conversely, the protein Caveolin-1 (Cav1) inhibits enzyme 
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activity by antagonizing CaM binding. Although eNOS is 
constitutive enzyme, numerous physical (receptor-independent 
agonists) and chemical (receptor-independent agonists) stimuli 
affect eNOS levels in vitro and in vivo. Application of a receptor-
dependent agonist to endothelial cells is followed by a burst of NO 
production (15–20 times the basal production) that peaks after 30–
60 seconds of stimulation and, generally, returns to baseline within 
a few minutes, despite the continuous presence of the agonist. 
Such responses are accompanied by similar changes in [Ca
2+
]i and 
are abolished by either the removal or chelation of extracellular 
Ca
2+
. By contrast, following the application of ﬂuid shear stress to 
endothelial cells, NO production is enhanced twofold over basal 
values and is maintained as long as the stimulus is applied. 
Although the acute application of shear stress to endothelial cells 
maintained under static conditions does increase [Ca
2+
]i, this 
response is transient and generally lasts only a few seconds [200]. 
Such a short pulse of Ca
2+ 
is unlikely to be the intracellular 
stimulus for the maintained generation of endothelium-derived 
NO. However, other signal transduction cascades are activated by 
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the mechanical stimulation of endothelial cells. Perhaps, the most 
important of these for the regulation of NO production results in 
activation of phosphatidylinositol 3-kinase and, subsequently, 
serine kinases Akt and protein kinase A, which phosphorylate a 
serine residue in the reductase domain of eNOS (Ser1177 of 
human eNOS and Ser1179 of bovine eNOS) and increase eNOS 
activity [201, 202]. Although this process, which also involves the 
formation of an eNOS signaling complex and the association of 
heat shock protein 90 with eNOS [203], has been referred to as the 
‘Ca2+-independent activation of eNOS’, chelation of intracellular 
Ca
2+
 also abolishes the increase in eNOS activity induced by shear 
stress. This indicates that the increase in NO production is still, 
strictly speaking, Ca
2+
-dependent but that eNOS can be activated at 
resting [Ca
2+
]i [201]. Several additional eNOS phosphorylation 
sites (Ser114, Thr495 and Ser633) might regulate eNOS activity 
and/or localization but it is unclear whether mechanical stimulation 
of endothelial cells affects phosphorylation of these residues. Wall 
shear stress not only increases the activity of eNOS but also 
modulates its expression by enhancing transcription and 
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prolonging mRNA stability [204]. In general, ‘arterial levels’ of 
laminar shear stress (4–20 dynes cm2) are reported to increase 
expression of eNOS whereas either low or oscillatory shear 
stresses do the opposite [205, 206]. Unidirectional and oscillatory 
ﬂow differentially affect eNOS expression; unidirectional shear 
stress increases expression of eNOS mRNA via a transcriptional 
mechanism whereas oscillatory shear stress appears to control 
eNOS expression through posttranscriptional regulatory events 
[205]. By contrast, cyclic stretch has little or no effect on eNOS 
expression. Thus, it appears that endothelial cells can discriminate 
speciﬁc hemodynamic forces and translate them into distinct 
responses. 
1.2.5 How the endothelium senses mechanical stimuli    
Physiologically the most relevant determinants for the continuous 
activation of the endothelium are hemodynamic stimuli. 
Particularly important are the viscous drag that is generated at the 
luminal surface of endothelial cells by the streaming blood (wall 
shear stress) and the cyclic strain of the vascular wall that results 
from the pulsatile changes in blood pressure. 
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The first step in this process is thought to be activation of a 
mechanoreceptor that senses changes in membrane tension on the 
luminal surface of the endothelial cells. Endothelial cells contain 
mechanosensitive ion channels, that respond primarily to changes 
in membrane tension and renders them appropriate transducers for 
forces derived from osmotic or hydraulic gradients and shear 
stress. 
The open probability of these, mainly cation-selective, channels 
might be modulated by membrane potential and various ligands. 
Stress-activated ion channels might also be activated by virtue of 
cytoskeletal interconnections, rather than directly through the 
plasma membrane [207]. There are reports that disruption of the 
actin cytoskeleton attenuates the generation of NO induced by 
shear stress [208]. The intermediate ﬁlament vimentin might have 
a central role in this because it is rapidly displaced in response to 
the application of shear stress [209], and ﬂow-induced dilatation is 
markedly attenuated in mice that lack the gene that encodes 
vimentin [210]. These and similar observations indicate that rather 
than there being a speciﬁc mechanoreceptor expressed on 
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endothelial cells, the entire cytoskeleton might act as a 
mechanoreceptor. Indeed, endothelial cells contain a complex 
network of microtubules, intermediate ﬁlaments and actin ﬁbers 
that traverse the cell. These are tacked down to the basement 
membrane at cell–cell contacts and end in caveolae and 
characteristic adhesion complexes. Focal adhesion points, caveolae 
and cell–cell contacts are all signaling ‘hot spots’ that contain a 
vast number of signaling molecules. Such a construction 
(tensegrity architecture) within the cell means that there is tension 
across the entire endothelial cytoskeleton. Shear stress or stretch at 
the cell surface elicits a redistribution of these forces, which is 
translated into a chemical signal at the end of a ﬁlament/ﬁber 
[211]. Signaling molecules, including integrins within caveolae 
[212], the lateral zone of cell–cell adhesion points [213] and focal 
adhesion contacts [214] are activated rapidly by ﬂuid shear stress 
and cyclic stretch. Forces can also be directly transmitted from the 
cell surface to the nucleus across ﬁlaments that interconnect 
physically, which raises the possibility that mechanical stimuli 
might be passed on to the nucleus either in the absence of, or 
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simultaneously with, mechano-chemical signaling processes [215]. 
There might also be cross-talk between mechanosensitive 
pathways and growth factor receptors because the application of 
ﬂuid shear stress to endothelial cells enhances the tyrosine 
phosphorylation of the receptors for vascular endothelial growth 
factor [216] and insulin [217]. Shear stress is also reported to 
induce the release of vasoactive compounds, such as ATP and 
bradykinin that activate endothelial cells and enhance autacoid 
production by binding to their respective receptors [218]. Thus, in 
endothelial cells mechanotransduction does not occur via a single 
pathway; rather it reﬂects the integrated response of multiple 
signaling networks that are spatially organized throughout the cell. 
1.3 The vascular smooth muscle cells (VSMCs) 
Vascular smooth muscle cells (VSMCs) are one of the major 
components of blood vessels responsible for the maintenance of 
vessels structure and functions [219]. VSMCs maintain contractile 
tone by a highly organized architecture of contractile/cytoskeleton 
proteins and associated regulatory components within the cell 
cytoplasm and establish distensibility by synthesis, secretion, and 
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organization of extracellular matrix (ECM) components with 
elastic recoil and resilience properties [220]. VSMCs within the 
vascular continuum have the ability to adapt expression of proteins 
involved in contraction and ECM synthesis according to intrinsic 
and extrinsic cues during different developmental stages and in 
disease or response to injury. This ability is due to a phenomenon 
known as VSMC phenotypic modulation and is a major feature 
that distinguishes VSMCs from terminally differentiated cells 
[221]. Vascular smooth muscle cell phenotypic modulation is the 
ability to switch phenotypic characteristics from a migratory 
synthetic phenotype in embryonic tissue patterning to a quiescent, 
contractile phenotype in maintenance of vascular tone in mature 
vessels. Importantly, during vascular remodeling in response to 
injury VSMCs can switch back to a synthetic phenotype 
characterized by increased VSMC proliferation and ECM 
synthesis. Although the ability to switch phenotypes may have 
evolved as an adaptive survival mechanism for VSMCs to adjust 
physiological responses due to changing hemodynamic demands or 
to repair damage after vascular injury, phenotypic modulation has 
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important implications both during development and during 
vascular disease [221]. 
Acute regulation of vascular diameter depends on the 
activation/deactivation of the contractile machinery involving 
actin-myosin interaction in VSMCs. In fact, vascular smooth 
muscle contraction is an active process wherein the myosin light 
chains must be phosphorylated before shortening can occur. This 
phosphorylation is performed by myosin light chain kinase 
(MLCK), which is activated by Calcium-Calmodulin (Ca-CAM). 
Tension maintenance in vascular smooth muscle is a graded 
phenomenon in that there is no twitch tension and the vessels can 
generate and maintain tension along their entire length. Vascular 
smooth muscle has a relatively unique ability to maintain tension 
with relatively low ATP consumption using a mechanism called 
Latch [222]. The latch mechanism is where the vessel’s cross 
bridges remain attached under tension but without being 
phosphorylated. This results in a slowly cycling bridge that 
consumes about seven fold less ATP to maintain tension at a 
constant length. Therefore, vascular smooth muscle is very 
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economical when it maintains tension because of a low cost for 
maintaining latch bridges. The contractile apparatus and signaling 
mechanisms in the vascular smooth muscle generally work to 
produce slow and maintained responses to the signals the vessels 
receives. Importantly the phosphorylation mechanisms for tension 
generation are also modulated by thin filament proteins of 
caldesmon and calponin. These regulatory proteins and 
mechanisms make it such that tension in vascular smooth muscle is 
graded and highly controlled by several factors mediating length 
and rate of shortening. It is when these control mechanisms go 
awry that vascular pathologies occur. 
Normally, arterial SMCs of adults are contractile and are not very 
responsive to growth factors or growth regulatory molecules on 
cell migration and proliferation [223]. In response to altered 
mechanical stress, numerous contractile proteins that exist in 
normal adult arterial walls gradually disappear, such as smooth 
muscle myosin heavy chain isoforms, α-actin, h-caldesmon, and 
calponin, while non-muscle myosin heavy chain, which mainly 
expresses in fetal vessel walls, re-expresses in activated VSMCs 
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[223-225]. As a result, this modulation leads to a prominent 
structural reorganization with loss of myofilaments and formation 
of an extensive endoplasmic reticulum and a large Golgi complex 
termed synthetic phenotype. Thus, the cells lose their ability to 
contract, increase their secretion of proteins, and become more 
responsive to growth factors produced via autocrine and paracrine 
of medial SMCs in response to increased mechanical stress (high 
blood pressure), which, in turn, further stimulates medial SMC 
hypertrophy and /or intimal hyperplasia of the arterial walls [223, 
226, 227], leading to a narrowing of lumen diameter. 
Indeed, the lumen diameter of resistance arteries is governed not 
only by the magnitude of vasoconstriction, but also by the 
structural characteristics of the vessel wall, influenced by vascular 
remodeling processes [228]. At the molecular and cellular levels 
remodeling involves changes in cytoskeletal organization, cell-to-
cell connections, and altered growth/apoptosis, senescence, 
calcification and rearrangement of VSMCs [229, 230]. At the 
extracellular level, remodeling is influenced by changes in matrix 
protein composition and reorganization of proteoglycans, collagens 
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(type I and III), and fibronectin, which provide tensile strength, 
and elastin, responsible for vascular elasticity [231]. These sub-
cellular, cellular, and extracellular matrix (ECM) events manifest 
as structural changes with modifications in lumen diameter, wall 
thickness, and media and adventitia cross-sectional areas, 
processes that define remodeling. With respect to resistance 
arteries, the most widely used classification of vascular remodeling 
is that described by Mulvany et al. [232], where changes in the 
passive luminal diameter may be increased (outward) or decreased 
(inward) and media mass (cross-sectional area) may be increased, 
unchanged or reduced (hypertrophic, eutrophic, hypotrophic 
respectively) [232, 233] (Fig. 1.6).  
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Fig. 1.6: Classification of vessel remodeling: changes in diameter (inward) 
and cross-sectional area (outward). 
Whether increased pressure itself or other factors are responsible 
for the initiation of vascular remodeling remains unclear, but the 
endothelium probably plays an important role as it a sensor of 
hemodynamic and humoral factors and is a moderator of signals to 
underlying VSMCs critically involved in the remodeling process 
[234]. Remodeling allows arteries to withstand an increased 
pressure load and under physiological conditions (e.g. aging and 
exercise) is adaptive. Pathological remodeling occurs when the 
adaptive process is overwhelmed, resulting in rigid, stiff, and 
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poorly compliant vessels, typically observed in hypertension. 
Molecular and cellular mechanisms implicated in changes in 
vasomotor tone and structural remodeling in hypertension involve 
multiple cell types, complex signaling pathways, and multiple 
local and circulating factors.  
1.4 Regulation of vascular function and structure in 
arterial hypertension 
Smooth muscle cells constitute the bulk of the arterial wall, 
playing a key function in vascular resistance and blood flow. Basal 
vascular tone and contractility are increased in hypertension. The 
contractile machinery of vascular smooth muscle, actin and 
myosin, is activated in a Ca
2+
-dependent and Ca
2+
-independent 
manner. The key event in VSMC excitation-contraction coupling is 
an increase in intracellular free [Ca
2+
]i in response to agonist-
induced activation of receptors coupled to phospholipase C (PLC), 
responses that are up-regulated in experimental and human 
hypertension [228, 234-236]. In addition to VSMC-derived factors 
regulating tone, endothelium-derived factors, such as prostacyclin, 
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PGH2, and thromboxane A2 act as endothelium-derived contracting 
factors (EDCF) that counteract the vasodilator effect of NO [237]. 
Increased generation of EDCFs has been demonstrated in human 
essential hypertension [238, 239] and in spontaneously 
hypertensive rats (SHR) [237], and further contributes to increased 
vascular tone in hypertension. 
Smooth muscle myosin can also be phosphorylated in a Ca
2+
-
independent manner by additional kinase like Rho kinase (ROCK) 
[240], integrin-linked kinase (ILK) [241] and zipper-interacting 
protein kinase (ZIPK) [242]. These Ca
2+
-independent processes 
influence contraction by increasing Ca
2+
 sensitization and by actin 
filament remodeling. Rho kinase (ROCK1 and ROCK2) are 
serine/threonine kinases and are down-stream effectors of the 
small GTPase RhoA. RhoA is abundantly expressed in VSMC and 
is rapidly activated by vascoconstrictors, such as Ang II via the 
G12/13 family of G proteins and Gq [243]. RhoGEFs, which 
catalyzes exchange of GDP for GTP on RhoA, are sensitive to 
G12/13 such as Arhgef11 (PDZ-RhoGEF), and hence play an 
important role in RhoA activation [244]. Increased RhoA/Rho 
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kinase activity leads to decreased MLCP activation and consequent 
sustained vasoconstriction and blood pressure elevation. 
Ang II-induced hypertension in rodents exhibits increased vascular 
RhoA/Rho kinase activation, without changes in expression [245]. 
This is associated with increased activity of Arhgef1, implicated to 
be important in RhoA hyperactivation, vasoconstriction, and 
hypertension [246].  
In addition to the Ca
2+
-dependent and –independent modulation of 
MLC20 phosphorylation, changes in organization of actin 
filaments, intermediate filaments, and microtubules play an 
important role in the acute phase of VSMC contraction. Increased 
polymerization of actin, tyrosine phosphorylation of paxillin, 
activation of small GTP-binding proteins Rho and Cdc42 and 
conformational changes in focal adhesion sites result in stiffening 
and reorganization of the cytoskeleton [230]. This dynamic 
arrangement of the actin cytoskeleton is key in maintaining 
vascular tone and plasticity, especially important in the regulation 
of vascular diameter related to pressure-dependent myogenic tone. 
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In hypertension, resistance arteries undergo vascular remodeling 
characterized by reduced vascular lumen with increased media 
thickness [229, 232, 247]. Myogenic tone, the intrinsic ability of 
vessels to constrict in response to increased intraluminal pressure, 
contributes to structural alterations within the arterial wall. On the 
other hand, structural narrowing of the lumen may amplify 
vasoconstriction. Eutrophic vascular remodeling, characterized by 
reduced outer diameter and lumen with no change in media mass 
and cross-sectional area [247, 248], is observed in patients with 
mild-moderate hypertension. With chronic vasoconstriction and 
longstanding or severe hypertension, blood vessels develop 
hypertrophy in response to increased wall stress. Chronic 
vasoconstriction associated with deposition of extracellular matrix 
which characterizes hypertensive vascular remodeling may lead to 
a smaller lumen as the constricted state becomes embedded in the 
newly deposited extracellular matrix [248]. Changes in the 
interaction between extracellular matrix components and integrins 
on the cell membrane of smooth muscle cells may also contribute 
to the remodeling of arteries in hypertension [249]. Other 
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mechanisms that may participate include inward growth 
encroaching on the lumen associated with apoptosis of cells in the 
periphery of the vessel wall. Some studies have implicated tissue 
transglutaminases that participate in the interactions of fibrillar 
components in extracellular matrix (ECM) that attach smooth 
muscle cells and play a role in signal transduction. VSMC growth 
may predominate over apoptosis, and in this scenario, remodeling 
may be hypertrophic [247-250]. This type of vascular remodeling is 
characterized by an increased media cross section and media to 
lumen ratio (M/L). The process of remodeling is dynamic and 
eutrophic and hypertrophic remodeling may occur simultaneously 
in different vascular beds. Hypertrophic remodeling of resistance 
arteries is more common in renovascular hypertension, diabetes, 
acromegaly, and hyperaldosteronism [251-253]. Inflammation and 
matrix deposition are critically involved in these processes and 
activation of the RAS also plays a role in the development of 
hypertension-induced vascular remodeling [254].    
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1.4.1 Endothelial dysfunction in hypertension   
By definition, endothelial dysfunction is a functional and 
reversible alteration of endothelial cells, resulting from impairment 
in nitric oxide availability. Endothelial cells normally regulate 
vascular tone by releasing relaxing and constricting factors such as 
NO, arachidonic acid metabolites, ROS, and vasoactive agents. 
They also produce EDHF that induce endothelium-dependent 
relaxation through hyperpolarization of underlying VSMCs 
independently of NO. EDHF-mediated responses are important in 
hypertension, where they provide a vasorelaxation reserve for 
endothelial dysfunction due to decreased NO bioavibility [237]. 
Endothelial dysfunction is a hallmark of hypertension and may 
reflect the premature aging of the intima exposed to chronic blood 
pressure increase. It is characterized by impaired vasomotor 
responses, VSMC proliferation and migration, ECM, protein 
deposition, platelet activation, vascular permeability, and a pro-
inflammatory and prothrombotic phenotype [254-256]. Of the 
many factors important in the protection of the endothelium are 
endothelial progenitor cells (EPCs). EPCs are bone-marrow-
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derived cells capable of developing into mature endothelial cells 
[257]. They contribute to vascular homeostasis through direct cell-
to-cell contact and through autocrine and paracrine actions. EPCs 
mobilize out of bone marrow in response to peripheral tissue 
hypoxia and injury and release EPC-activation factors, such as 
hypoxia-inducible factor-1 (HIF-1), VEGF, erythropoietin and NO 
to facilitate endothelial healing, regeneration and 
reendothelialization after vascular damage [258]. The multidrug 
resistance-related protein-1 (MRP1) has been identified as a 
negative regulator of EPC function and survival and MRP1 
inhibition has been suggested as a novel strategy to increase EPC 
survival [259]. The number of circulating EPCs may reflect 
endothelial function since decreased numbers are associated with 
reduced arterial elasticity, and decreased endothelial integrity 
[260]. Circulating EPCs are reduced in hypertension [259, 260]. 
Studied in cultured EPCs suggest that ROS are involved in Ang II-
mediated EPC senescence [261]. In addition to EPCs, 
microparticles have been considered as biomarkers of vascular 
status. Microparticles are tiny fragments of cellular membranes 
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that are generated from activated or apoptotic cells [262]. 
Microparticles circulate in healthy individuals and their levels 
increase in cardiovascular and athero-thrombotic diseases [262]. In 
patients with hypertension plasma levels of microparticles 
correlated with systolic and diastolic blood pressure [263]. In 
patients with diabetes, endothelial microparticle levels are a strong 
predictor of myocardial infarction and correlate with arterial 
stiffness and endothelium-mediated vasodilation [264]. They also 
relate to the extent and severity of coronary stenosis in patients 
with coronary syndromes [264]. In vitro endothelial microparticles 
are released in response to inflammatory stimuli such as TNF-α, 
thrombin, uremic toxins, ROS, and PAI-1, which are increased in 
hypertension. Although the precise mechanism leading to in vivo 
generation of microparticles is not fully understood, there is 
evidence that eNOS uncoupling and low shear stress [265], which 
are features of endothelial dysfunction in hypertension, enhance 
their production. They in turn may contribute to some extent to 
endothelial dysfunction through ROS production [263-265]. The 
exact role of microparticles in vascular remodeling awaits 
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clarification, but it is possible that they may be more than 
biomarkers of endothelial dysfunction. They interfere with target 
cell responses by transferring chemokines and adhesion molecules 
to endothelial cells leading to monocyte adhesion and hence have 
the potential to directly contribute to vascular injury in 
hypertension. Endothelial dysfunction is also characterized by a 
phenotypic switch and increased adhesiveness for vascular cells 
[169]. In this respect, there are now several studies demonstrating 
the release of adhesion molecules from activated endothelium in 
hypertension. Examples are von Willebrand factor (vWF), 
intercellular adhesion molecule-1 (ICAM-1), vascular cell 
adhesion molecule-1 (VCAM-1) and E-selectin [170]. Among 
them, vWF is probably the most extensively studied endothelial 
product. Pedrinelli et al. demonstrated the presence of increased 
vWF levels in patients with essential hypertension and 
microalbuminuria, suggesting that a dysfunctional glomerular 
endothelium may cause reduced renal function [171], as also 
indicated by the demonstration of the importance of NO in long 
term regulation of renal hemodynamics and renal excretory 
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function [172]. Furthermore, vWF levels correlate well with flow-
mediated dilatation (FMD) and both methods of assessment of 
endothelial function correlate with 10-year cardiovascular risk 
using the Framingham equation [173]. While vWF is an 
established marker of endothelial damage/dysfunction, other 
markers may reflect distinct functions of the endothelium. ICAM-
1, for example, reflects a disruption of the equilibrium between 
pro- and anti-inflammatory mechanisms, and it has been suggested 
that sICAM-1 and FMD are both related to the estimated risk of 
coronary heart disease, independently of each other [174]. Thus, 
biochemical and hemodynamic tests of endothelial function may 
give complementary information on the risk prediction of 
hypertensive patients. Plasma levels of soluble adhesion molecules 
(E-selectin, ICAM-1 and VCAM-1) were also shown to be 
elevated in hypertensive patients in comparison to normotensive 
controls [175-177], and even mild elevation of blood pressure may 
be sufficient to activate their expression [178]. In addition, 
Goonasekera et al. demonstrated that an isolated increase in 
plasma VCAM-1 in hypertensives, associated with raised levels of 
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the endogenous NO inhibitor asymmetric dimethyl arginine 
(ADMA), may signify a selective ‘‘non-inflammatory’’ endothelial 
activation triggered by endothelial NO synthase (NOS) inhibition 
[179]. E-selectin has been also proposed as a surrogate marker of 
endothelial dysfunction as elevated levels can be found in patients 
with hypertension [5]. However, no conclusive data on its 
predictive value are available at present. 
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Chapter II 
The gasotransmitter role of H2S 
The past two decades have seen an increasing interest in the 
biology of endogenous gases. It is becoming clear that nitric oxide 
(NO) is not the only such biologically active gas, and that 
molecules such as carbon monoxide (CO) and hydrogen sulfide 
(H2S), and perhaps others, are also important. Cells are constantly 
enveloped in an atmosphere containing many different gases, and 
it is not surprising that at least some of those gases have evolved 
over the ages into potent regulators of cell function. The latest 
addition to the list of biologically relevant gases is H2S, once 
viewed solely as an environmental pollutant but now seen more 
and more as a biologically significant molecule in its own right. 
Compared with NO and CO, the study of the biology of H2S is still 
in its infancy. Nevertheless, much research has already been 
devoted to a better understanding of the physiological and 
pathophysiological significance of this gas and the way in which it 
interacts with NO and CO. Here, I describe recent advances in the 
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understanding of the biology of H2S, especially its involvement in 
the homeostasis of the cardiovascular system. 
2.1 The concept of “gasotransmitter” 
Signaling molecules come in all sizes and chemical dispositions, 
ranging from relatively large proteins, lipids, and peptides through 
biogenic amines and amino acids, to gaseous molecules. Variations 
in the properties of signaling molecules that depend upon their 
chemical nature are best exemplified among neurotransmitters [1]. 
Amine, amino acid, and peptide neurotransmitters share a number 
of features. All are stored in synaptic vesicles, so that with each 
nerve impulse only a small proportion of the stores is released, 
leaving a large safety net of reserve pools. Release involves 
exocytosis, in which the vesicle fuses with the plasma membrane 
to expel its contents. These neurotransmitters bind to receptor 
proteins on the external surface of adjacent membranes. 
Inactivation occurs by reuptake of neurotransmitters into the 
releasing nerve terminal or adjacent glia, by enzymatic 
degradation, or by simple diffusion away from the synapse.  
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The conventional concepts of intercellular communication has 
been overturned by the discovery small gaseous molecules are 
involved in any signaling process. For instance, a gaseous 
substance is not readily stored in vesicular structures and so must 
be resynthesized as needed. This implies that, rather than supply 
depending on regulation of exocytosis, the biosynthetic enzymes 
must be subject to extraordinarily nuanced regulatory mechanisms. 
Vehicles for intercellular communication are either electrical 
signals via gap junction or chemicals. The conventional doctrine 
about chemical-mediated communication claims that the binding 
of neurotransmitters or humoral factors to receptors located on the 
plasma membrane is the essential triggering event. The ligand–
receptor interaction generates intracellular second messengers that 
relay and direct the extracellular signals to different intracellular 
destinations, resulting in modulated cellular activity. Instead of 
binding to plasma membrane receptors, gasotransmitters diffuse 
into adjacent cells to interact with their targets. 
The Nobel Prize-winning discovery of NO in the 1990s sets the 
stage for recognizing a membrane receptor-independent signaling 
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mechanism, emphasizing the necessity to modify the conventional 
doctrine about cellular signal transduction. The resurgence of CO 
and the discovery of H2S as important endogenous signaling gases 
strengthen and endorse the physiological importance of this group 
of gas molecules. To distinguish NO, CO, and H2S from classical 
neurotransmitters and humoral factors while acknowledging their 
common natures, these endogenous gaseous transmitters have been 
defined as “gasotransmitters,” gauged by the following criteria [2]:  
1. They are small molecules of gas.  
2. They are freely permeable to membranes. As such, their effects 
do not rely on the cognate membrane receptors, and they can 
have endocrine, paracrine, and autocrine effects. 
3. They are endogenously and enzymatically generated and 
regulated.  
4. They have well defined and specific functions at 
physiologically relevant concentrations. 
5. Their cellular effects may or may not be mediated by second 
messengers, but should have specific cellular and molecular 
targets. 
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2.2 Toxicological and chemical features of H2S gas 
molecule 
Hydrogen sulfide (H2S), a colorless gas with a strong odor of 
rotten eggs, was known for many decades only as a toxic 
environmental pollutant [5]. Since the first description of H2S 
toxicity in 1713, most studies about this gas have been devoted to 
its toxic effects with little attention paid to its physiological 
function. In the literature several massive intoxications are 
reported and in the non-scientific literature poisoning by this gas is 
referred to as “sulphurated hydrogen” intoxications. These fatal 
episodes often occurred in sewers and swamps as the main 
biological source is represented by anaerobic bacterial digestion of 
organic substrates [7] but it is also produced through inorganic 
reactions in volcanic gases, natural gas and well waters [8]. 
Chemical and enzymatic transformation of the sulfur compounds 
of foodstuff such as mushrooms, garlic and onions are also 
responsible for H2S production in human gut [9].  
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Early studies in dogs [185] and other mammals [186, 187], and 
more recently anecdotal information from human cases [188] have 
shown that H2S toxicity is closely related with its concentration. 
For example, strong H2S odor can be tolerated at 27 ppm, but eye 
irritation would already occur with 10 ppm H2S. Acute exposure to 
50-100 ppm leads to neurological disorders, skin symptoms, 
behavior changes, general deficits, respiratory symptoms and 
cardiovascular abnormalities. When ambient concentration H2S 
concentration reaches 100-150ppm, the olfactory nerve is 
paralyzed after a few inhalations; furthermore it can leads to 
pulmonary edema with possibility of death up to 320-530ppm of 
H2S. The molecular mechanisms underlying the toxicological 
effects of H2S are mostly attributed to mitochondrial poisoning 
[11, 14]. Cytochrome c oxidase is the terminal enzyme in the 
electron transport chain in mitochondria that catalyzes the 
oxidation of ferrocytochrome c by molecular oxygen. By inhibiting 
cytochrome C oxidase, H2S uncouples oxidative phosphorylation, 
and the production of ATP is subsequently decreased.  
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Chemically, H2S is the sulfur analog to the water molecule and can 
be oxidized in a series of reactions to form sulfur dioxide (SO2), 
sulfates such as sulfuric acid, and elemental sulfur [6]. In water or 
plasma, H2S is a weak acid that dissociates as follows: H2S ↔ HS
- 
+ H
+ ↔ S2- + H+ [5]. In body fluids H2S exists in three free states, 
H2S gas, HS
-
, and a trace of S
2-
. It has been suggested that at pH 
7.4 and at a mammalian body temperature of 37°C, the pKa1 for 
H2S is 6.76 [12]; therefore when either sodium hydrosulfide 
(NaHS, commonly used as an H2S donor since it dissociates to Na
+
 
and HS
–
) or H2S is dissolved in physiological solution (pH 7.4, 
37.8°C), it will form approximately 18.5% H2S and 81.5% 
hydrosulfide anion (HS
-
), as predicted by the Henderson–
Hasselbach equation [12]. There will be only a trace of S
2-
. 
Because pka2 is greater than 12, thus S
2- 
does not occur in vivo at 
substantial amounts [13]. Since all three species of sulfide are 
always present in aqueous solution, it has not been possible to 
determine which of these species is biologically active. Thus, the 
terminology of “the H2S concentration” usually refers to the sum 
of H2S, HS
-
, and S
2-
. 
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One important property of the H2S gas is that it is a highly 
lipophilic molecule (its solubility in lipophilic solvents is fivefold 
greater than in water): it easily partitions into the hydrophobic core 
of the cell membrane similar to O2, CO2, NO and CO, and, thus 
rapidly diffuses into or out of cells [18]. Since the H2S gas is also 
very volatile, it rapidly diffuses out of the blood into the lungs [19] 
or out of organ baths or cell culture media into the air. So, this 
aspect should be kept in mind for performing in vitro experiments. 
Recent interest in H2S as an endogenously-produced biological 
mediator has broadened research in this field considerably beyond 
its toxicology [10]. In fact, as endogenous levels of H2S were 
detected in the rat brain [15] and normal human post-mortem 
tissues at the end of the 1980s [16], a physiologic role for H2S in 
mammalian tissues has been proposed. The physiological 
importance of H2S became recognized in the last one and half 
decades; starting when Abe and Kimura reported in 1996 that 
hydrogen sulfide acts as a novel neuromodulator, by describing for 
the first time H2S production in the hippocampus by an enzyme-
regulated pathway and its ability to influence hippocampal long-
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term potentiation [17]. Since these descriptions, H2S has received 
increasing interest and is now regarded along with CO and NO as 
an endogenous gaseous mediator produced by regulated pathways 
and exerting physiological actions [10]. 
2.3 Endogenous biosynthesis of H2S  
The idea that H2S could be of some physiological importance arose 
when it became clear that it was naturally produced in several 
organisms by constitutively expressed enzymes and that it is 
present in mammalian blood at nanomolar concentration [57]. The 
normal blood level of H2S is reported to be between ∼10 μM in 
Wistar [75] and ∼50 μM in Sprague–Dawley rats [42]; in human, 
10-100 μM H2S in blood was reported [77]. Aside from circulating 
H2S, a significant amount of H2S is produced in various tissues. 
For instance, the physiological concentration of H2S in brain tissue 
has been reported to be 50–160 µM [17, 41] and significant 
amounts of H2S are generated from the vascular system as well 
[42].  Hydrogen sulfide is synthesized in mammalian cells by both 
endogenous enzymes and by non-enzymatic pathways. The latter 
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consists of reduction of elemental sulfur to H2S using reducing 
equivalents obtained from the oxidation of glucose [20] (Fig. 2.1). 
 
Fig. 2.1: Endogenous non-enzymatic production of H2S. 
All essential components of this pathway are present in vivo, 
including the supply of reducible sulfur [2]. However, the non-
enzymatic pathway only accounts for a small portion of H2S 
production [20].  Conversely, most emphasis has been placed on 
the enzymatic formation of H2S. The main substrate for H2S 
biosynthesis is L-cysteine, a sulphidrylated amino acid derived 
from the diet or synthesized from the L-methionine via 
cystathionine by the reverse transsulfuration pathway [22]. This 
pathway is believed to be the solely route for cysteine synthesis in 
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vertebrates and it contributes significantly to the intracellular L-
cysteine pool [30].  L-cysteine may be metabolized to H2S via the 
action of endogenous enzymes found in many of the body’s cells. 
Actually, it has been shown that four separate pathways are 
involved in the enzymatic production of H2S (Fig. 2.2).  
 
Fig. 2.2: Endogenous enzymatic production of H2S. 
In the first pathway, L-cysteine is hydrolyzed by cystathionine β-
synthase (CBS) to produce equimolar amounts of H2S and L-
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serine. This reaction is reversible in the presence of low cysteine 
concentrations or during fetal development, when liver and brain 
CSE activity appears to be low [23]. The most well-known 
reaction catalyzed by CBS is the condensation of homocysteine 
and serine to form cystathionine in an irreversible reaction: 
L-serine + L-homocysteine → L-cystathionine + H2O. 
This is the first step in the biosynthesis of cysteine from 
methionine by reverse transsulfuration. CBS also catalyzes the 
condensation of cysteine with homocysteine to form cystathionine 
and H2S [24].  
In the second pathway, two L-cysteine molecules undergo 
dimerization to form L-cystine, which is transformed into 
thiocysteine, pyruvate and NH3 by cystathionine γ-liase (CSE). 
The thiocysteine can then undergo one of two additional reactions 
to form H2S: thus CSE may catalyze the reaction of thiocysteine 
with other thiol (R-SH) compounds (e.g. glutathione or cysteine) to 
form H2S and CysSR [25, 26] or alternatively, thiocysteine may 
form L-cysteine and H2S, possibly non-enzymatically [27].  
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In the third pathway, cysteine aminotransferase (CAT), in 
conjunction with 3-mercaptopyruvate sulfurtansferase (MST), 
generates H2S. CAT catalyzes the reaction of L-cysteine with a 
ketoacid (e.g. α-ketoglutarate) to form 3-mercaptopyruvate and an 
aminoacid such as L-glutammate. The 3-mercaptopyruvate may 
then be desulphurated by MST to form H2S and pyruvate, or, in the 
presence of sulphite (SO3
2-
), to form thiosulphate and pyruvate 
[29]. In the “thiosulphate cycle”, the thiosulphate reacts with 
reduced glutathione (GSH) to produce H2S, H2SO3 and oxidized 
glutathione (GSSG).  
Recently, also a fourth enzyme, named cysteine lyase (CL), seems 
to be involved in H2S production. It converts L-cysteine and 
sulphite to L-cysteate and H2S. However, less is known about the 
real contribution of this enzyme in H2S biosynthesis. 
CBS, CSE and CAT use the cofactor pyridoxal 5’-phosphate 
(PLP), which is the active form of vitamin B6, conversely to MST 
which activity is zinc-dependent. The expression of these enzymes 
has been detected in a broad variety of cell types, including those 
from the liver, kidney, heart, vasculature, brain, skin, fibroblasts 
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and lymphocytes. In some tissues, such as liver kidney, both CBS 
and CSE contribute to the local generation of H2S, whereas in 
others, one enzyme predominates. For example, CSE is the main 
H2S-generating enzyme in the cardiovascular system [42], 
meanwhile CBS is the predominant H2S synthase in the brain and 
nervous system [17]. MST, along with CAT, contributes to H2S 
formation in both the brain [190] and the vascular endothelium 
[53]. A recent paper has shown that MST and CAT can produce 
H2S only in alkaline conditions and in presence of strong reducing 
agents [191].  Moreover, it has been demonstrated that a specific 
subcellular compartmentalization of these enzymes exists in the 
eukaryotic cells. Indeed, CBS and CSE are located exclusively in 
the cytosol [189], whereas CAT and MST are found both in 
mitochondria and in the cytosol [28]. Interestingly, recently it has 
been showed that CBS and CSE exist also as circulating enzymes. 
In fact, they are secreted by microvascular endothelial cells and 
hepatocytes, circulate as members of the plasma proteome, and 
actively produce hydrogen sulfide from homocysteine in human 
blood [73].  
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2.3.1 CBS and CSE: structure, regulation and tissue 
distribution 
Although four different enzymatic pathways lead to H2S 
biosynthesis, CBS and CSE appear to be responsible for the 
majority of the endogenous production of H2S in mammalian 
tissues [28]. 
CBS is a homotetramer consisting of 63-kDa subunits; each 
subunit comprises 551 amino acid residues [31]. The NH2 terminal 
of CBS contains the binding sites for both PLP and heme. It is not 
clear the functional role of heme domain in the catalytic activity of 
CBS, but it seems that its deletion renders CBS insensitive to 
oxidative stress. As such, a redox sensor role is suggested for this 
heme binding domain [32]. The PLP binding domain is considered 
to be the catalytic domain, and it is deep in the heme domain. The 
COOH-terminus of CBS contains a regulatory domain of ∼140 
residues, playing an autoinhibitory role for the activity of CBS. 
Binding of S-adenosyl-L-methione (AdoMet or SAM, an 
endogenous methyl donor) to this domain markedly activates CBS 
[33]. Deletion of the regulatory domain constitutively activates 
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CBS [30]. This regulatory domain is important for maintaining the 
tetrameric state of the protein. Then calmodulin binding consensus 
sequence (19 aminoacids) has also been identified in CBS at its 
COOH-terminal domain. After calcium-activated calmodulin binds 
to this consensus sequence, the catalytic domain of CBS will be 
opened and the enzyme becomes active [22]. Furthermore, the 
activity of CBS is regulated, presumably at the transcriptional 
level, by glucocorticoid and insulin, which stimulate and inhibit 
gene expression, respectively [34]. Also sex hormones seem to 
regulate brain H2S levels. Since male brains contain much more 
testosterone than female brains at each age, the involvement of 
testosterone in H2S production has been suggested. In agreement 
with this hypothesis, Eto and Kimura reported that the application 
of testosterone to female mice increases H2S and SAM in the 
brain, almost reaching the levels of males [47]. Conversely, 
castration of male mice decreases testosterone and SAM levels as 
well as H2S formation [47]. Binding of NO or CO to the heme 
pocket of CBS also appears to modulate its catalytic activity [35]. 
As mentioned above, CBS is mainly localized in the brain as the 
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primary physiological source of H2S in the central nervous system, 
especially in the hippocampus, cerebellum, cerebral cortex and 
brainstem, and its activity is 30-fold greater than CSE  [17]. Abe 
and Kimura showed that the production of H2S from L-cysteine by 
rat brain homogenates is inhibited in the presence of CBS 
inhibitors such as hydroxylamine or aminooxyacetic acid (AOAA), 
which are reversible and non-selective inhibitors of CBS, because 
they are inhibitors of heme-containing protein and 
aminotransferase respectively [36, 37]. Later, it was showed that 
CBS is preferentially expressed in astrocytes rather than in neurons 
[38].  In other tissues such as cardiovascular and respiratory 
system, testes, adrenal and spleen from rats, mice or human, CBS 
expression is rare or absent. 
CSE is a protein of 405aa and is a tetramer formed by two 
homodimers, both contributing to the active site pocket [74]. CSE 
has been described as an exclusively beta-replacing lyase with a 
strict specificity for the primary substrate L-cysteine and for 
several sulfur-containing cosubstrates [40]. CSE can be regulated 
by several molecules. Among them, it has been shown that NO can 
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affect H2S levels through two mechanisms: increasing CSE 
activity [42]; upregulating CSE expression [192]. CSE can be 
upregulated by bacterial endotoxin [46] and also upon stimulation 
with VEGF [193]. Testosterone is another endogenous CSE 
stimulator. It does not change the expression of CSE but stimulates 
CSE activity [194]. In rat thoracic aorta preparation, testosterone 
increased the production of H2S from L-cysteine, which was 
significantly reduced by PAG and BCA. This would also explain 
testosterone-induced relaxation of rat aortic rings in vitro, which 
again was inhibited by PAG and BCA [194]. The mechanism for 
the transcriptional regulation of CSE is not clear, but there is 
evidence for the involvement of myeloid zinc finger 1 and 
specificity protein 1 (SP1) [46]. Conversely to CBS, CSE 
expression and activity is abundant in mammalian vasculature 
(aorta, mesenteric vessels, portal vein) and respiratory system [41, 
42]. It also appears to be the main H2S-forming enzyme in the 
liver, kidney, uterus, placenta, as well as pancreatic islets [42]. It 
has been showed that CSE is present in relatively large amounts in 
both vascular smooth muscle and endothelial cells [43] as 
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determined by Western blotting and immunohistochemical 
staining. CSE is absent in tissues of mammalian fetuses [44, 45], 
whilst mouse liver CSE activity increases significantly after birth 
and peaks at postnatal day 21 thereafter remaining constant in 
adulthood [46]. This developmental stage-dependent CSE activity 
seems to be related to the age-dependent posttranscriptional 
regulation of this enzyme [195]. Whether a similar age-dependent 
expression of CSE is present in cardiovascular tissues has not yet 
been determined. Animal experiments have identified the 
expression of CSE in portal vein, thoracic aorta [41], mesenteric 
artery, tail artery, and pulmonary arteries of rats [42]. The 
transcriptional expression level of CSE has been quantitated, using 
RNase protection assay, among different vascular tissues. The 
intensity rank of expression levels of CSE mRNA is pulmonary 
artery > aorta > tail artery > mesenteric artery [42]. D, L-
propargylglycine is a specific covalent inhibitor of the cysteine 
desulfhydration, reaction catalyzed by cystathionase. This inhibitor 
considerably reduces hydrogen sulfide production in the rat liver 
and in both mouse and rat aorta [25]. Definitive evidence that CSE 
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is a physiologic source for H2S comes from experiments 
employing CSE knockout mice [78]. H2S levels in aorta and heart 
of homozygous CSE knockout mice are reduced by about 80% 
with a 50% reduction in heterozygous knockouts. Serum H2S 
levels in homozygous and heterozygous CSE knockouts are 
reduced 50% and 20%, respectively. The residual H2S in mutant 
serum may reflect non-enzymatic reduction of elemental sulfur to 
H2S or H2S generated from other tissues by CBS. The studies with 
CSE knockouts establish that H2S is a product of normal 
mammalian physiology. 
2.4 Mechanism of H2S release from cells 
H2S is detectable within blood and many tissues.  In some reports, 
concentrations of up to 160µM in the brain and 100µM in the 
blood are quoted. Although the liver has a high H2S-generating 
capacity and may be responsible for maintaining the concentration 
of H2S in the blood, 100µM H2S would be readily detectable by 
the human nose while, clearly, blood does not normally smell of 
free H2S. There is some uncertainty about the reliability of H2S 
assay methods: total sulfate and sulfite may have been measured in 
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some studies, rather than free H2S, which would account for this 
anomaly. Free (unoxidised) H2S is likely present at lower 
concentrations than estimated initially. Indeed, Kimura and 
colleagues [48] have proposed recently that storage forms of H2S 
such as bound sulfane sulfur may be critical in regulating the H2S 
availability under different intracellular conditions. It means that 
H2S, once produced in mammalian cells, can directly exert its 
biological effects via interaction with different signaling 
molecules, or it can be first stored and released upon a 
physiological signal.  
Two forms of sulfur stores in cells have been identified [48, 49]: 
acid-labile sulfur and bound sulfane sulfur. Acidic conditions 
release H2S from acid-labile sulfur, which occurs mainly in iron 
sulfur enzymes found in mitochondria and plays a critical role in a 
wide range of redox reactions in enzymes of the respiratory chain 
in mitochondria [50]. The critical pH below which H2S is released 
from acid-labile sulfur is 5.4 [21]. As mitochondrial pH is between 
7 and 8, acid-labile sulfur may not release H2S under physiologic 
conditions. The sulfur of H2S can be also incorporated into 
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proteins as bound sulfane sulfur [21, 51], which is divalent sulfur 
bound only to the other sulfur, such as outer sulfur atoms of the 
persulfides (R-S-SH) and inner chain atoms of polysulfides 
(RSnR, R is alkyl or aryl), or thiosulfate (S2O3
2-
), thiosulfonate (R-
S-SO2-R), polythionates (SnO6
2-
), elemental sulfur (S8) and 
disulfides which have an unsaturated carbon adjacent to the C-S 
bond. It seems that the main source of bound sulfane sulfur is MST 
enzyme. It has been showed that cells expressing MST and CAT 
increased the levels of bound sulfane sulfur, while cells expressing 
a defective mutant of MST, which does not produce H2S, maintain 
the levels of bound sulfane sulfur at the control levels [52, 53]. 
Moreover, the bound sulfane sulfur is primarily localized in the 
cytoplasm and releases H2S under the reducing conditions or at pH 
> 8.4 [50]. As it requires an alkaline microenvironment, the 
physiological implication of releasing H2S from this store is 
questioned.  
Interestingly, subcellular compartmentalization of sulfur store may 
facilitate differential H2S release for specialized purposes and may 
have important physiological implications that are worthy of 
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further studies and in depth-research. For example, cross-talk 
between H2S and NO could be highly regulated by their 
compartmentalization, accounting for the differential effects 
observed in different systems. 
2.5 Catabolism of endogenous H2S 
Catabolism of H2S is less recognized and most data were obtained 
by using exogenous H2S; thus these studies have important 
toxicological but not necessarily physiological implications.  
H2S is broken down rapidly in the biological system and its half-
life in mammalian plasma has been estimated at <30 min although 
the mechanism for this has not been identified [54]. Actually, 
several mechanisms have been suggested for H2S degradation in 
the biological system (Fig. 2.3), such as:  
1. expiration and excretion; 
2. oxidation; 
3. methylation; 
4. scavenging. 
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Fig. 2.3: Catabolic routes for H2S metabolism 
H2S, like CO and NO, can be detected in human expired air [55]. 
In fact, a significant amount of exhaled H2S has been measured 
after intravenous administration of sodium sulfide [56]. An 
increased amount of exhaled H2S has also been reported after 
inhibition of endogenous NO synthesis. In healthy individuals, 
very little H2S is lost via the lungs, because metabolic disposal 
keeps the free level of H2S in the blood very low [57]. However, 
mammalian lungs may occasionally provide an escape route for 
H2S, possibly during septic shock, hemorrhagic shock, or 
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pancreatitis when larger than normal amounts of H2S may be 
generated [57]. Given the fact that the endogenous production of 
H2S can be altered in several diseases, it may be useful to evaluate 
the possibility of using exhaled H2S as a diagnostic measurement. 
Endogenous H2S, as a readily diffusible gas, can be rapidly 
metabolized in mitochondria by oxidation to thiosulphate, which is 
further converted to sulfite and sulfate by sulfate oxidase (Fig. 2.4) 
[58].  
 
Fig. 2.4: H2S metabolim (II): oxidation. 
Oxidation of H2S to thiosulfate is probably a non-enzymatic 
process associated with mitochondrial respiratory electron 
transport, although superoxide dismutase may also catalyze this 
reaction [59]. Conversion of thiosulfate to sulfite is catalyzed by 
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thiosulfate: cyanide sulfurtransferase (TST, rhodanase) which 
transfers sulfur from thiosulfate to cyanide or other acceptors [60]. 
The sulfite, which originates in this reaction, is rapidly oxidized to 
sulfate. Thus, under physiological conditions sulfate is a major 
end-product of H2S catabolism. Although thiosulfate is also 
excreted in urine, its concentration is less than 1% of sulfate [61]. 
However, sulphate in body fluids cannot be used as a ‘bio-marker’ 
of endogenous H2S production (in the same way that NOx is used 
as a marker of NO) since it is also derived from the direct 
oxidation of cysteine by cysteine dioxygenase (CDO). So, urinary 
thiosulfate seems to be the best biological indicator of whole-body 
H2S production [62]. Mitochondria are very effective in oxidizing 
sulfides, however, if the supply of sulfide exceeds the ability of the 
mitochondrial enzymes to oxidize all of it, H2S can poison 
enzymes [63]. 
Methylation is an additional, but perhaps quantitatively less 
important, metabolic pathway to degrade cellular H2S. Conversely 
to oxidation, the methylation takes place in the cytosol. It consists 
of the methylation of sulfides by thiol S-methyltransferase (TSMT) 
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to methanethiol and dymethilsulfide, a non-toxic compound (Fig. 
2.5) [58].  
 
Fig. 2.5: H2S metabolism (III): methylation. 
TSMT is an ubiquitous enzyme with the highest activity in the 
colonic and cecal mucosa [64], but its activity has also been 
reported in the liver, lung and kidney.  
Finally, H2S can be scavenged by methemglobin to form 
sulfhemoglobin [65]. At this regard, Yang et al. reported that 
pretreating wild-type HEK-293 cells with methemoglobin for 1h 
prior to adding 100µM H2S significantly abolished the 
antiproliferative effect of H2S [66]. Since hemoglobin can 
scavenge NO and CO too, it may act as a common “sink” for all 
three gasotransmitters and these gas can compete with oxygen for 
binding, thus contributing to their toxicity on high exposure [67]. 
H2S can also be scavenged by metallo- or disulfide-containing 
molecules such as horseradish peroxidase, catalase and oxidized 
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glutathione (GSH) [68]. Finally, H2S is a reducing agent and could 
also be consumed by endogenous antioxidant species in the 
vasculature such as peroxynitrite [69], hypochlorite [70] 
superoxide [71] or hydrogen peroxide [72].  
2.6 The biological function and signaling mechanism of 
H2S in the vascular system  
To date, much research into H2S has centered upon its effects on 
individual body systems. Although many such systems have come 
under the spotlight, the effect of this gas on the cardiovascular 
system has attracted the most attention. Many other possible roles 
for endogenous H2S have been postulated (Fig. 2.6), for example, 
in the peripheral and central nervous systems, pain appreciation 
and neurodegeneration, control of gastrointestinal and urogenital 
function, and endocrinology, respiratory system regulation and 
inflammatory response [28, 79-83].  
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Fig 2.6: Biological roles for H2S in body systems. 
The biological effects of H2S have been studied in a range of body 
systems including individual cells, intact and homogenized tissues, 
intact animals (both mammalian and no-mammalian) and also in 
man [28]. Its function has been investigated using mainly two 
approaches: 1) by inhibiting endogenous H2S; 2) by administering 
exogenous H2S mainly using NaHS as donor. 
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The modern era of H2S research in the vasculature most likely 
started with the finding that H2S dilates blood vessels. It was first 
demonstrated by Hosoki et al. in 1997 that arteries and veins 
express CSE and generate H2S in vitro [41]. NaHS at 
concentrations above 100 µM may induce the relaxation of 
phenylephrine-precontracted isolated rat artery [41, 42, 84], but 
when it is used at concentration below 100µM may induce further 
contraction of precontracted isolated vessels [84-86]. The 
mechanisms underlying this vasoconstrictor effector are not fully 
understood, but the dilation is the most prominent effect in the 
vessels. Bucci et al. showed that the administration of L-cysteine 
elicited to vasodilation in isolated aorta rings of rat e, which was 
significantly blocked by both PAG and BCA, CSE-inhibitors 
[125]. Importantly, perfusion of the rat mesenteric arterial bed with 
the H2S precursor, 1mM L-Cys, increased endogenous release of 
H2S and relaxed the arterial bed, which are peripheral resistance 
vessels more significant for the regulation of vascular resistance 
and blood pressure than large conduit arteries [76]. Over the years 
H2S has been reported to relax a long list of different blood 
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vessels, other than aorta and mesenteric vessels, such as gastric 
artery and portal vein [41, 84, 87] and dilate hepatic [88, 89] but 
not coronary [90] vascular beds. H2S also relaxes the corpus 
cavernosum of rabbits [91] and men [92] and in this way may play 
a part, alongside NO, in control of erectile function [93, 92]. H2S 
also relaxes the human internal mammary artery or other arteries in 
the organ bath [94]. The response of blood vessels to H2S varies 
according to different several factors, such as: the preparation of 
H2S; the precontraction agent used; the type of vessel; the 
condition of endothelium. The potency of vasorelaxant effect of 
H2S is affected by the preparations of H2S [101]. At the same 
concentration level, H2S-gassed solution has much stronger 
vasorelaxant effects than NaHS solution does. The stimulus used 
to precontract vascular tissues also significantly affects the effect 
of H2S. While H2S relaxed phenylephrine-precontracted aortic 
tissues, high concentration of KCl (> 60mM)-induced vascular 
contraction was essentially not affected by H2S. Different vascular 
tissues manifest different sensitivities to H2S. Although rat aortic 
and mesenteric artery tissues produce similar levels of hydrogen 
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sulfide, H2S is nearly six-fold more potent in relaxing rat 
mesenteric beds than relaxing rat aortic tissues. The higher 
sensitivity of mesenteric arteries, which are resistance vessels, to 
H2S stands for the importance of this gas in regulating peripheral 
resistance as well as blood pressure [76]. The mechanisms for 
differential vasorelaxant effects of H2S are not clear yet, but 
several possibilities exist. One explanation is the tissue-type 
specific distribution of the molecular targets of H2S or it could be 
that the sensitivities of contractile proteins to H2S may vary 
between conduit and resistance arteries [76]. Also different types 
of blood vessels face different shear stress levels, possess different 
cellular components (smooth muscle cells, endothelial cells, and 
connective tissues, etc.), and have different stiffness. In addition, 
oxygen-dependent sensitivity of blood vessels to H2S should also 
be considered. It has been reported that H2S induced 
vasorelaxation at physiological O2 levels, and this vasorelaxation 
occurred much faster at below physiological O2 levels. With higher 
than physiological O2 levels, H2S has the tendency to induce 
vasoconstriction [102]. This could result from the product of H2S 
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oxidation, which may mediate vasoconstriction. Blood in small 
peripheral vessels has lower oxygen partial pressure, and these 
small vessels consume oxygen at higher rate due to high content of 
smooth muscle cells and low collagen. The situation is just 
opposite in large conduit arteries. The difference in tissue oxygen 
level may explain different vascular effects of H2S. Finally, the 
condition of the endothelium can affect the H2S-vasorelaxant 
action too. Initial studies demonstrated that neither endothelial 
denudation nor vascular denervation affected H2S induced 
vasorelaxation, suggesting the direct effect on smooth muscle cells 
[42]. However, subsequent more detailed study revealed that NOS 
inhibitors or endothelial removal attenuated the relaxation of rat 
aortic tissues induced by H2S and shifted H2S concentration–
response curve to the right with EC50 changed from 136 to 273 µM 
[101]. Although this observation did not address whether H2S is 
endothelium derived or not, it shows that the presence of an intact 
endothelium does affect H2S-induced vasorelaxation. The 
endothelium dependence of H2S effect was again more pronounced 
in isolated and perfused rat mesenteric artery bed [76]. The 
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removal of the functional endothelium significantly reduced H2S-
induced relaxation of rat mesenteric artery bed by about sevenfold 
with EC50 of H2S changed from 25 to 161 µM. As this tissue type-
selective endothelium-dependent effect of H2S is similar to that of 
endothelium-derived hyperpolarizing factor (EDHF), it has been 
considered that H2S itself  is a possible candidate for EDHF or that 
H2S releases EDHF from endothelium. Both assumptions seem to 
be true. Indeed, Zhao and colleagues has shown that the co-
application of apamin and charybdotoxin (Ca
2+
-dependent K
+
 
channel, KCa) significantly weakened H2S-induced relaxation of 
endothelium-intact rat aortic tissues [42]. Moreover, d’Emmanuele 
Di Villa Bianca et al. observed that H2S could activate 
phospholipase A2 (PLA2), which in turn releases arachidonic acid 
leading, initially, to vasoconstriction followed by vasodilation 
mediated by cytochrome P450-derived metabolites. Because 
EDHF has been presumed to be a cytochrome P450 derivative of 
the arachidonic acid, their results suggest that H2S acts through 
EDHF release [100]. 
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In vivo studies confirmed such as vasorelxing effect of H2S. In 
fact, in whole animals, intravenous injection (i.v.) of  L-cysteine 
(endogenous source of H2S [42])  and either ‘fast’ (e.g. NaHS [84, 
42]) or ‘slow’ (e.g. GYY4137 [95]) H2S-releasing donors all elicit 
dose-related falls in mean arterial blood pressure again indicative 
of a dilator effect on blood vessels. Interestingly some reports 
suggest a central component to the vasodilator effect of H2S 
perhaps mediated by an action in hypothalamus [97, 98] or on 
baroreceptors [99]. In either case, the net effect of H2S is to cause 
blood vessel dilation in vivo. The EC50 of H2S in inducing 
vasorelaxation is quite close to the reported endogenous level of 
H2S in plasma, which suggests that under physiological in vivo 
conditions the vascular tone of resistance arteries is likely 
regulated by endogenous H2S.  
The defining evidence for the role of endogenous H2S in regulating 
vascular tone emerged after the CSE gene was knocked out from 
genetically engineered mice [43]. The endothelium-dependent 
relaxation of mesenteric arteries induced by methacholine, 
muscarinic receptor agonist, is virtually diminished in CSE 
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knockout mice. These results suggest that, similar to NO, acute 
production of H2S from vascular endothelial cells is triggered by 
muscarinic activation. In agreement with this finding, Bucci et al. 
also showed that endothelium-dependent relaxations triggered by 
acetylcholine (Ach) were attenuated by CSE inhibition in rat aorta 
[125]. Methacholine increased H2S levels in cultured endothelial 
cells by more than twofold. Atropine, a cholinergic antagonist, 
abolished methacholine effect. In the presence of the calcium 
ionophore A23187, endothelial production of H2S is significantly 
increased. Chelating of intracellular-free calcium with BAPTA 
abolished the effect of A23187 on H2S production as well as 
lowering the basal level of H2S in endothelial cells. Furthermore, 
co-immunoprecipitation study demonstrated the binding of 
calmodulin to recombinant CSE in vitro. This binding is 
contingent on the presence of calcium, and abolished by 
calmodulin antagonist W7. These results demonstrated that a 
calcium–calmodulin system is the prerequisite for muscarinic 
activation of CSE in endothelial cells. Once CSE is knocked down 
from endothelial cells, the effects of methacholine and A23187 on 
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H2S production were abolished, indicating that CSE, like eNOS, is 
activated by a calcium/calmodulin dependent mechanism [43]. 
Therefore, this could be a proof that, within the vascular wall, 
these 2 pathways coexist and serve a similar function.  
Moreover, the fact that the lack of CSE from knocking down mice 
leads to age-dependent hypertension, similarly to NO synthase 
knockout mice, it underlies the important role of H2S in the 
homeostasis of cardiovascular system, especially in the regulation 
of blood pressure; in addition, it indicates that H2S is a 
vasoregulator of potency comparable to that of NO. Taken 
together, these findings strongly suggests that NO and H2S either 
cooperate dynamically to maintain vessel homeostasis or serve as 
each other’s backup system under pathological conditions.  
2.7 A mechanism for H2S regulation: H2S-NO cross-
talk 
H2S may provide a tonic influence on vascular tone under different 
conditions. It may also be acutely released upon the arrival of a 
specific stimulus. In either case, the production of H2S needs to be 
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regulated should this gasotransmitter fulfill important 
physiological functions. We for the first time showed that NO is an 
endogenous regulator for the production of H2S in vascular tissues 
[42]. The NO-stimulated H2S production takes place following two 
schemes. Acutely, NO increases CSE activity in vascular tissues. 
Incubating the homogenized rat vascular tissues with different 
concentrations of SNP increased the accumulated H2S production 
during a 90-min period. Putatively, NO increases the activity of 
cGMP-dependent protein kinases, which in turn stimulates CSE. 
This mechanism is supported by the finding that the blockade of 
PKG abolished the NO-induced increase in H2S level in vascular 
tissues [120]. It is also possible that NO acts directly on CSE 
protein. Rat mesenteric artery CSE protein contains 12 cysteines 
that are the potential substrate of S-nitrosylation. Currently, the 
three-dimensional structure of CSE is unknown, and which 
cysteine contains a free –SH group cannot be assured yet. 
However, the nitrosylation of a certain free –SH group of CSE in 
the presence of NO does represent a possibility [121]. Chronically, 
NO up-regulates the expression of CSE [42]. NO has been shown 
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to regulate protein expression and synthesis, including growth 
factors [122], leukocyte adhesive proteins [123], and extracellular 
matrix proteins [124]. Wang et al. showed that, incubating the 
cultured vascular SMCs with SNAP, another NO donor, for 6 h 
significantly increased the transcriptional level of CSE. In rats, the 
NOS inhibitor L-NAME produced a time-dependent elevation in 
systolic blood pressure associated with inhibition of CSE gene 
expression and H2S production whereas exogenous H2S 
administration prevented the development of hypertension induced 
by L-NAME, highlighting the physiological significance of NO in 
the regulation of H2S production in the cardiovascular system [13]. 
The mechanism, by which NO increased CSE transcription, is not 
clear yet. Published data have shown that pre-treating rat aortic 
tissues with 60 µM H2S inhibited the vasorelaxant effect of SNP, 
an NO donor. Incubation of NaHS with a range of NO donors or 
NO gas in vitro was reported to form a nitrosothiol molecule. In 
this way, H2S acts similar to an NO scavenger [116]. The 
formation of this nitrosothiol molecule inhibited the vasorelaxant 
effect of NO both in vitro and in vivo. NaHS also inhibited the 
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conversion of [
3
H]-arginine into [
3
H]-citrulline by recombinant 
eNOS [117]. In another study on isolated rat aortas and cultured 
human umbilical vein endothelial cells, NaHS incubation reduced 
eNOS activity, eNOS transcript abundance, and L-arginine 
transport in a concentration-dependent manner. H2S treatment 
reduced protein expression of eNOS, but not of nNOS and iNOS. 
The downregulation of the vascular L-arginine/eNOS/NO pathway 
was observed after intraperitoneal injection of NaHS (14 µmol/kg) 
into rats [118]. In contrast, H2S by itself had no effect on NO 
production from the rat vascular SMCs, but it augmented 
interleukin β-induced NO production and this effect was associated 
with increased expression of iNOS [119]. Whether H2S and NO at 
low concentrations have a synergistic effect on vascular relaxation 
has been controversial. However, Hosoki et al. reported the 
additive effect of SNP and NaHS (30µM) in relaxing rat aortic 
tissues [41]. This discrepancy may be partially explained by the 
experimental conditions of these studies, including differences in 
tissue preparations and tension development before the application 
of H2S. Although H2S or NO alone relaxes vascular tissues, the 
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integrated vascular effects of the two gasotransmitters are more 
complicated than a simple algebraic summation of individual 
actions. In fact, it is clear that there is an interaction of 
physiological significance between H2S and NO, which produce its 
effect in the cardiovascular system, however the precise 
relationships between H2S, NO and NOSs are still far from clear. 
2.8 Mechanisms of H2S-induced vasorelaxation 
The arising findings on the biological properties stimulated several 
groups toward the research on the mechanism of action of H2S. 
Given that H2S is a strong reducing agent and it may easily interact 
with other oxidative species, it has been suggested that some of its 
effects may be mediated by protection of protein thiol groups from 
oxidation. However, all studies performed to date indicate that 
effects of H2S applied at physiological concentration are not 
reproduced or only partially mimicked by thiol-protecting agents, 
suggesting that this is not a major mechanism of H2S action [17]. 
Furthermore, previous studies have shown that both superoxide 
dismutase (SOD) and catalase did not change H2S-induced 
vasorelaxation of rat vascular tissues [42, 101]. These observations 
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suggest that the vascular contractility change induced by H2S may 
not be linked to a changed redox status of vascular tissues. 
Other than antioxidant effect, several signaling mechanism have 
been supposed to be triggered by H2S with respect to vasorelaxing 
action, including opening of the ATP-sensitive K
+
 channel (KATP) 
[42], inhibition of voltage-operated Ca
2+
 channels [114], effects on 
ATP generation (i.e. metabolic inhibition) [113], changes in 
vascular smooth muscle intracellular pH [115] and increasing in 
cGMP levels through inhibition of phosphodiesterase (PDE) [125]. 
Among them the activation of KATP channel and the inhibition of 
PDE seem to be the most relevant targets that mediated H2S effect 
within the vasculature.  
2.8.1 H2S as a KATP channels opener 
The first and most recognized molecular target of H2S in smooth 
muscle cells (SMCs) is the ATP-sensitive K
+
 channel (KATP 
channel) [42]. H2S directly stimulates KATP channels and leads to 
consequent membrane hyperpolarization. The closure of voltage-
dependent calcium channels by membrane hyperpolarization 
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results in smooth muscle relaxation. The KATP channel is an inward 
rectifying channel composed of two types of subunits. The smaller 
pore-forming subunits are the inwardly rectifying potassium 
channel subunits (Kir6.1 or Kir6.2), while the larger regulatory 
subunits are the sulfonylurea receptors (SUR1, SUR2A, and 
SUR2B), so-called because of its sensitivity to high-affinity 
sulfonylurea inhibition and offering the site of action for MgADP 
and K
+
 channel. The KATP channel isoforms come from differing 
combinations of subunits. For example, Kir6.1/SUR2B is found in 
vascular smooth muscle cells (VSMCs), whereas Kir6.2/SUR2B is 
found in nonvascular SMCs [103]. The KATP channels exist in the 
sarcolemmal, mitochondrial, and nuclear membranes of various 
tissues [104], and are characterized by their inhibition by 
micromolar concentrations of intracellular ATP [105]. Hence, an 
increase in intracellular ATP closes these channels, leading to cell 
depolarization. The KATP channels participate in the control of 
membrane potentials and the regulation of cellular activities such 
as energy metabolism, apoptosis, and gene expression. Zhao et al. 
first reported that glibenclamide, a KATP channel antagonist, 
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significantly attenuated the vasodilatatory effect of H2S, whereas 
pinacidil, a KATP opener, mimicked the effect of H2S in a 
concentration-dependent fashion [42]. In smooth muscle cells 
isolated from the rat mesenteric artery, H2S increased the open-
probability of KATP channels without altering their conductance 
[106]. Interestingly, CSE inhibitors reduced KATP channel current 
indicating that endogenous H2S continuously stimulated the 
channel under baseline conditions [42]. Unlike direct effect on 
smooth muscle cells, the endothelium-dependent component of 
H2S-induced vasorelaxation is independent of KATP channels [76]. 
In order to gain insight on the molecular mechanism for an 
interaction between H2S and KATP channel proteins, Jiang et al. 
studied the effect of H2S in HEK-293 cells expressing different 
KATP channel subunits, rvKir6.1 and rvSUR1, heterologously. 
They found that H2S stimulated coexpressed rvKir6.1/rvSUR1 
KATP channels, but had no effect on KATP currents generated by 
rvKir6.1 expression alone [107]. This strongly indicates that H2S 
acts on SUR1 but not Kir6.1 subunit of KATP channel complex to 
cause the channel to open. Alternatively, the structural coupling 
105 
 
between Kir6.x and SUR.x subunits might have been altered by 
H2S so that the channel complex changes its configuration more 
favorably for opening [107]. It was reported that expressions of 
SUR2B were higher in the aorta than in the pulmonary artery, 
suggesting that the greater KATP channel density in the aorta may 
underlie its greater extent of relaxation than that in pulmonary 
arteries [108]. It was further demonstrated that sulfhydryl group(s) 
located on the extracellular surface of the SUR subunit is the likely 
target of H2S. Mutagenic studies confirmed that H2S failed to 
affect KATP channel currents after one of the two cysteine residues 
(C6S and C26S) in the extracellular loop of rvSUR1 subunits was 
point-mutated. Hence, extracellular cysteine residues Cys6 and 
Cys26 of rvSUR1 are most likely the targets of H2S actions [107]. 
In the most recent report published by the same group, the 
researchers found evidence that H2S covalently sulfhydrylates 
cysteine-43 on Kir 6.1 to bring about the hyperpolarization which 
underlies H2S-induced vasorelaxation [109]. S-sulfhydration is a 
covalent modification of a cysteine residue in which a sulfhydryl 
group is transferred to the cysteine residue of a protein, yielding to 
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hydropersulfide (-SSH) group, which result in increased reactivity 
of L-cysteine [110]. Importantly, the enhanced chemical reactivity 
of these modified cysteines may also be reflected in enhanced 
biological activity. 
Furthermore, H2S has been shown as enhancing the binding of 
phosphatidylinositol-4,5-trisphosphate to Kir 6.1 to elicit KATP 
activation [109] (Fig. 2.7). 
 
Fig. 2.7: Mechanism of H2S-induced relaxation (I): H2S as a KATP opener. 
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Indirect evidence also suggests that H2S may act on small to 
medium conductance KCa channels in endothelial cells, as such 
fulfilling the role of an endothelium-derived hyperpolarizing factor 
(EDHF) [111]. The earliest speculation that H2S may be an EDHF 
was derived from an observation that the co-application of 
charybdotoxin and apamin to endothelium-intact vascular tissues 
reduced the H2S-induced vasorelaxation [42, 76, 100]. The 
endothelium dependent amplification of the vasorelaxant effect of 
H2S is even more pronounced in peripheral resistance arteries than 
in large conduit arteries [76]. It is known that the contribution of 
EDHF to endothelium dependent vasorelaxation is much greater in 
smaller arteries, including mesenteric artery and coronary artery 
[111]. The involvement of voltage-dependent K
+
 (KV) channels in 
the vascular function of H2S has been deduced as well. Cheang et 
al. recently investigated the effect of H2S on membrane potentials 
of isolated rat coronary artery tissues. Using a membrane potential-
sensitive fluorescent dye, the investigators found that addition of 
NaHS caused smooth muscle hyperpolarization. This effect was 
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inhibited by 4-aminopyridine (4-AP), but not by the KATP channel 
blocker glibenclamide [112]. 
Despite numerous reports and the widely accepted notion that the 
KATP channel is the main underlying mediator of most H2S-induced 
vascular responses, H2S-induced vascular relaxation is only often 
partially inhibited by glibenclamide and, in some cases, no 
inhibition can be achieved [94, 112, 113].  
2.8.2 H2S as an inhibitor of PDEs 
It is well-known that cyclic guanosine monophosphate 
(cGMP)/PKG facilitates the dephosphorylation of MLC, 
preventing the association of myosin with actin and consequently 
leading to vessel relaxation. The cellular cGMP level is reached by 
a balance of cGMP production and degradation, which is regulated 
by the activation of guanylyl cyclases (sGC) and 
phosphodiesterase (PDE) isoenzymes respectively [126, 127]. 
Although H2S, similarly to NO and CO, binds with high affinity to 
heme [128], it does not appear to activate soluble guanylate 
cyclase [129]. In fact, it has been shown that, conversely to NO 
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and CO, H2S does not stimulate soluble guanilate ciclase (sGC), 
and its vasorelaxing effect is not inhibited by ODQ [1H-[1,2,4] 
oxadiazolo-[4,3-a] chinossalin-1-one], a sGC inhibitor [42]. 
Nevertheless, H2S can affect cGMP levels within the vasculature. 
Indeed, Bucci et al. showed that the incubation of cultured rat 
aortic SMC with exogenous NaHS (10-200µM) increased cGMP 
levels in a concentration dependent-manner. More importantly, 
CSE overexpression (by CSE cDNA transfection) and CSE gene 
silencing (using small interfering RNA [siRNA] approach) greatly 
enhanced and attenuated cGMP levels, respectively, suggesting an 
endogenous role of H2S in regulating cGMP levels [125]. The 
ability of H2S to enhance cGMP levels was greatly reduced by the 
nonselective phosphodiesterase inhibitor 3-isobutyl-1- 
methylxanthine (IBMX), suggesting that H2S and IBMX share a 
common target. By using a cell-free assay, they definitely showed 
that H2S elevates cGMP levels by inhibiting PDE activity [125] 
(Fig. 2.8). 
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Fig. 2.8: Mechanism of hydrogen sulfide-induced vasorelaxation (II)- H2S as 
an endogenous inhibitor of PDEs. 
On the basis of the above, the mechanism through which H2S 
promotes vasorelaxation would likely depend on the relative 
expression of KATP channels, the PDE isoform expressed, and the 
amount of H2S present in the microenvironment. For example, 
tissues expressing KATP channels and no or low PDE levels would 
be expected to dilate in a glibenclamide-inhibitable manner. It 
could be possible that tissues expressing high PDE5 levels and 
abundant amounts of PKG, but no KATP channels, would dilate in a 
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cGMP-dependent manner. Another important observation that 
needs to be kept in mind is that PKG activates K
+
 channels, 
leading to hyperpolarization and relaxation [130, 131]. This latter 
finding allows to the author to speculate that in cells and tissues in 
which H2S responses are mediated by K channels, there might be 
both a cGMP-independent and a cGMP/PKG-dependent 
component. There is a need, therefore, to re-evaluate the 
conventional view that H2S has no effect on cGMP levels [42, 101, 
106], and to clarify the inconsistence of these observation. 
2.9 Role of H2S in cardiovascular disease: involvement 
in the pathogenesis of hypertension 
Recently, an increasing number of diseases have been related to an 
imbalance of endogenous H2S production [4]. The endogenous 
release of H2S from mammalian tissues is likely to occur in a slow 
and constant rate and it appears to be involved in several processes 
such as neuromodulation [17], hypertension [132], inflammation 
[133, 134], hemorrhagic shock [135] and edema [136, 137]. 
112 
 
The primary role of CSE in disparate cell and organ functions 
makes it likely that deficient generation of the product of its 
activity, H2S, could be involved in human diseases. H2S deficiency 
is a feature of rats with experimentally induced hypoxic pulmonary 
hypertension [138]. Reduced NO synthesis is the major factor 
underlying pulmonary hypertension in humans [139]. Given the 
functional parallelism and complementarity of H2S and NO 
systems, a role of H2S deficiency in this disease seems likely.  
The vasorelaxant property of H2S gives this gasotransmitter a role 
for regulating peripheral resistance and blood pressure. Reduced 
endogenous H2S level, especially in blood vessel wall, would be in 
favor of hypertension development, logically. This was indicated 
in an early study in which it was found that the administration of 
PAG (37.5mg/Kg), an irreversible/suicide inhibitor of CSE, to rats 
for 5 weeks significantly elevated BP and increased the media 
cross-sectional aorta wall, indicating significant aortic structural 
remodeling [140]. A better alternative than using CSE inhibitors in 
animal experiments would be the use of genetically modified 
animals. CSE-KO mice were reported to exhibit pronounced BP 
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elevations compared with their wild-type counterparts [43], 
suggesting that the physiological production of H2S may be critical 
for the regulation of basal BP. The elevated blood pressure in 
CSE-KO mice was not related to the contractile status of 
peripheral blood vessels since phenylephrine-induced constriction 
of isolated mesenteric arteries was not different between WT and 
CSE-KO mice [43]. On the other hand, endothelium-dependent 
vasorelaxation, triggered by the activation of muscarinic 
cholinergic receptors on the endothelium, was severely abolished 
in CSE-KO mice. Therefore, it was concluded that hypertension in 
CSE-KO mice is caused by the elimination of CSE expression in 
vascular tissues, especially in the endothelium, and the loss of H2S 
as a critical EDRF in regulating peripheral resistance. 
The role of H2S in the pathogenesis of spontaneously hypertensive 
rats (SHR) was also examined. SHR develop hypertension 
spontaneously, coincident with decreased H2S production and CSE 
mRNA expression in aortic tissues and lowered plasma level of 
H2S compared to control Wystar-Kyoto (WKY) rats [140, 141]. 
These findings suggest that the hypertension in SHR involves a 
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reduction in the production and function of H2S [140]. This is 
supported by the observation that chronic daily administration of 
NaHS (56µmol/kg/day/i.p.) for 5 weeks significantly reduced the 
SBP by 25 mmHg and inhibited aortic structural remodeling in the 
SHR but it had no effect in normotensive strain [140]. 
Consistently, Shi et al. reported significantly reduced SBP, 
diastolic blood pressure (DBP), and MAP of SHR to similar 
extents after NaHS (30 o 90µmol/kg/day, i.p.) for 3 months. A 
lower dose (10µmol/kg/day, i.p.) also reduced MAP, but the 
decrease in SBP was not statistically significant [142]. In addition, 
chronic treatment with GYY4137 also significantly reduced the 
SBP in SHR from day 2 after treatment [95]. Therefore, H2S has a 
profound antihypertensive effect in SHR. Administration of CSE 
inhibitor, PAG, decreased plasma H2S concentration and aortic 
H2S production and elevated blood pressure in normotensive rats 
but not in SHR, indicating that vascular H2S is involved in the 
regulation of vascular tone under baseline conditions, and that H2S 
generating system is suppressed in the hypertensive strain [13]. 
Several mechanisms seem to underlie the antihypertensive effect 
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of H2S. For example, H2S inhibits renin-angiotensin system at 
different step of the enzymatic cascade. Lu et al. found that H2S 
decreased plasma renin activity (PRA) in renin-dependent 2K1C 
rats, but had no significant effect on PRA in normotensive or 
renin-indipendent 1K1C rats [143]. H2S suppressed renin 
degranulation and release was further shown to be mediated by the 
attenuation of AC activity and lowered cAMP production [144]. 
The same author also reported that neither acute nor chronic 
treatment with H2S significantly affected the angiotensin 
converting enzymes (ACE) activity in normal (basal ACE activity) 
or hypertensive (elevated ACE activity) rat aortic tissues [143]. 
Conversely, Laggner et al. found that H2S (60µM) inhibited ACE 
activity, but not its mRNA expression, on the surface of cultured 
HUVEC monolayers [145]. The inconsistent H2S effect on ACE 
could be attributed to the different type of blood vessel used. 
Nevertheless, H2S inhibition of renin or ACE would lead to 
significantly attenuated Ang II [143, 145].   
On the other hand, CSE induction and excessive H2S generation 
play a role in hypotension in septic shock [146] in the rat and, 
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again by analogy with NO, this gas may be a player in the 
corresponding human disease. A significant decrease in plasma 
H2S has been reported in children with hyperlipidaemia and in 
patients with coronary heart disease [146]. 
In conclusion, it is clear that H2S has a physiological importance in 
mammalian tissues and acts as an important mediator on the stage 
of the vascular homeostasis. 
2.10 Physiologic regulation of blood pressure: role of 
renin-angiotensin system (RAS) 
The mean arterial BP level is determined by the product of cardiac 
output (CO) and total peripheral resistance (TPR). These two 
principal determinants are importantly inﬂuenced by many 
physiologic factors. Cardiac output, for example, depends 
primarily on heart rate and stroke volume. Heart rate is governed 
by beta-1 and cholinergic receptors under the control of 
sympathetic and parasympathetic stimulation, respectively. The 
stroke volume is determined by the ventricular force of contraction 
(also under autonomic stimulation) and the ﬁlling pressure which 
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is in turn determined by the intravascular ﬂuid volume status and 
the venous capacitance. Similarly, the systemic vascular resistance 
is inﬂuenced by multiple vasoactive mechanisms under the control 
of local, regional, and systemic neural, humoral, and renal factors. 
Importantly, all of these physiologic determinants of ﬂow and 
resistance are interdependently governed by rapid-, intermediate-, 
and late-acting mechanisms that maintain the arterial BP within the 
normal range despite signiﬁcant variations in the individual 
parameters [293, 294]. The complex systems and mechanisms that 
constitute the feedback and reﬂex control of BP have been 
extensively studied and characterized. Rapid responses and 
reﬂexes, for example, occurring within seconds after an acute rise 
in BP include the baroreceptor system, vagus nerve, and the central 
vasomotor center of the brainstem. In response to the rise in BP, a 
reﬂex decrease is noted in the sympathetic trafﬁc to the arterioles 
and veins resulting in a decrease in peripheral resistance and 
cardiac ﬁlling pressure, respectively. In addition, slowing of the 
heart rate and reduced myocardial contractility occur as a result of 
simultaneous increases in parasympathetic outﬂow and decreased 
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sympathetic tone to the heart. Chemoreceptors acting at the 
vasomotor center also play a role in response to acute changes in 
BP level but, in addition, respond to changes in blood oxygen 
tension and carbon dioxide tension. Thus, the rapid-acting reﬂex 
and feedback mechanisms in response to acute changes in BP are 
almost entirely mediated by changes in activity of the autonomic 
nervous system [295]. Intermediate-acting responses that occur 
over minutes and hours involve the renin-angiotensin-aldosterone 
system, antidiuretic hormone, and the renal juxtaglomerular 
apparatus. Both local and circulating RAS play important roles in 
this feedback mechanism. In the systemic RAS, a drop in BP 
stimulates renin release via afferent arteriole baroreceptor 
mechanism and increased activity of the renal sympathetic nerves. 
A macula densa mechanism of renin release also exists [296-299]. 
In addition to these intermediate-acting responses, the RAS has a 
role in the long-term regulation of blood pressure. Late-acting 
mechanisms operate in days to weeks and are very important 
because of their long-term efﬁciency in BP regulation. 
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The Renin-Angiotensin-System (RAS) is the most carefully 
studied mechanism of blood pressure (BP) and volume regulation, 
and development of pharmacological antagonists to its various 
components has proved useful in the treatment of hypertension and 
related target organ disease (TOD) [148]. 
The traditional view of RAS is of a typical endocrine system. It 
consists of an enzymatic cascade that starts with the cleavage of 
angiotensinogen by renin to form the inactive decapeptide 
angiotensin I (Ang I). Thereafter, Ang I is converted by 
angiotensin-converting enzyme (ACE) to form angiotensin II (Ang 
II) (Fig. 2.9). 
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Fig. 2.9: The renin-angiotensin system (RAS). 
Renin is an aspartyl protease that is synthesized as an inactive 
precursor, prorenin, primarly in the juxtaglomenrular cells 
surrounding the afferent arteriole of the glomerulus. Renin is 
activated by proteolytic cleveage of an N-terminal peptide while 
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still in the kidney. Both prorenin and activated renin are stored in 
granules in the juxtaglomerular apparatus and are released in a 
regulated fashion in response to a variety of stimuli, including 
decreases in BP or renal interstitial pressure via intrinsic 
juxtaglomerular baroreceptors, SNS activation of the renal nerves, 
and/or macula densa stimulation by decreased distal tubular 
sodium delivery. Importantly, the primary mechanism by which 
the RAS contributes to the acute changes in BP and volume 
homeostasis is by regulating renin release into the circulation. 
Renin acts on circulating angiotensinogen of hepatic origin to 
produce the biologically inactive decapeptide, Ang I, within the 
plasma. Ang I is cleaved to the octapeptide Ang II by ACE, 
present on the luminal surface of endothelial cells throughout the 
vasculature. In addition to this classical endocrine system, non-
renin enzymes, including tonin and cathepsin, exist and can 
generate Ang II directly from angiotensinogen. ACE, or kininase, 
is a bivalent dipeptide carboxyl metallopeptidase present as a 
membrane-bound form in endothelial, epithelial, or neuroepithelial 
cells, including the heart, kidney, and brain, and as a soluble form 
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in blood and numerous body fluids [149]. ACE cleaves the C-
terminal dipeptide from Ang I and bradykinin, by generating the 
vasoconstrictor agent Ang II and inactivating the vasorelaxant 
mediator bradykinin respectively. ACE strategically regulates the 
balance between the RAS and the kallikrein-kinin system [150]. 
Ang II acts on two major receptors known as AT1 and AT2 [151]. 
Both the AT1 and the AT2 receptors belong to the superfamily of 
G-protein-coupled receptors that contain 7 transmembrane regions 
[152]. Their amino acid sequence seems to be highly conserved 
across species and across tissues within a species. AT1 and AT2 
receptors have distinct signal transduction pathways. AT1 receptor 
is distributed ubiquitously and abundantly in adult tissues, 
including blood vessels, heart, kidney, adrenal gland, liver, brain 
and lung. Activation of the AT1 receptor stimulates a variety of 
tyrosine kinases, which in turn phosphorylate the tyrosine residues 
in a number of proteins, leading to constriction of resistance 
vessels, cell growth and proliferation. Moreover, it induces 
aldosterone release, central sympathetic activation, renal salt and 
water retention, and other functions that tend to elevate BP and 
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cause hypertrophy or hyperplasia of target cells. NO can down-
regulate AT1 receptors in vascular tissues [153] and the adrenal 
gland [154] and mitigate the action of Ang II. 
The AT2 receptor was discovered more recently, and much less is 
known about its functions and signal transduction pathways than 
for the AT1 receptor. In fetal tissues, the AT2 receptor is highly and 
ubiquitously expressed, but expression in many organs is 
dramatically reduced after birth [155, 156]. However, expression 
levels are maintained in the adult adrenal gland, brain, uterus and 
ovary, and the receptor is also expressed by endothelial cells [157]. 
The physiologic role of the AT2 receptor in adult humans is 
unclear, but it is thought to function under stress conditions (e.g. 
vascular injury, ischemia or reperfusion). Observation of increased 
AT2 receptor expression in myocardial infarction [158] and skin 
wounds [159], as well as its much higher level of expression in 
fetal compared to normal adult tissues, have led to speculation as 
to a possible role for the AT2 receptor in cell growth, development, 
and/or differentiation. Activation of the AT2 receptor subtype 
stimulates a phosphatase that inactivates mitogen-activated protein 
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kinase (MAPK), a key enzyme involved in transducing signals 
from the AT1 receptor. Thus, activation of the AT2 receptor 
opposes the biologic effects of AT1 receptor activation. In fact, 
conversely to AT1 receptor, its activation leds to the synthesis 
and/or the release of both prostaglandins and NO and have been 
shown to exert antiproliferative effects [160]. 
The circulating RAS participates in short-term regulation of the 
cardiovascular system, which becomes activated in acute 
conditions including hypertension, hypovolemia and hemorrhage. 
In the case of chronic condition, including hypertension and 
chronic heart failure, activation of the RAS cause long-term 
regulation of cardiovascular homeostasis via sustained activation 
of local angiotensin and degradation of bradykinin, resulting in 
permanent structural changes [150]. 
The RAS induces vascular disease by multiple mechanisms 
including directly and indirectly (via aldosterone): stimulating 
vascular smooth muscle cell migration, proliferation, and 
extracellular matrix production; increasing the release of 
plasminogen activator inhibitor type 1 and enhancing the 
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expression of monocyte chemoattractant protein 1; augmenting the 
expression of adhesion proteins (e.g ICAM-1, integrins, and 
osteopontin) in vascular cells; and stimulating the production of 
inflammatory chemokines and cytokynes that enhance the 
migration of inflammatory cells [304]. 
2.11 Arterial hypertension: pathogenesis and 
pharmacological therapies 
Arterial hypertension represents one of the most common 
conditions associated with increased cardiovascular risk, including 
stroke, renal failure, myocardial infarction and heart failure. 
The term hypertension applies to any adult with a blood pressure 
persistently at or above 140mmHg systolic and at or above 
90mmHg diastolic. It is distinguished: in primary (essential) or 
idiopathic hypertension and secondary hypertension. 
Primary or idiopathic hypertension accounts for the majority 
(>90%) of cases of human hypertension and the causes are 
unkonwn [161].  Conversely, secondary hypertension has 
identifiable causes, such as tumors which produce epinephrine or 
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other vasoconstrictor hormones, primary aldosteronism, 
renovascular diseases which cause fluid retention, thyroid or 
parathyroid gland disorders, aortic coarctation and others. This list 
is much longer and more complicated when one tries to consider 
the possible causes in the remaining 90% of the hypertensive 
patients. The genesis of essential hypertension is a complex 
interplay of various pathophysiologic factors that include, but are 
not limited to, increased sympathetic nervous system (SNS) 
activity; heightened exposure or response to psychosocial stress; 
overproduction of sodium-retaining hormones and 
vasoconstrictors; long-term sodium intake; inadequate dietary 
intake of potassium and calcium; increased or inappropriate renin 
secretion with resultant increased production of angiotensin II 
(Ang II) and aldosterone; deficiencies of vasodilators, such as 
prostacyclin, nitric oxide (NO), the natriuretic peptides and a 
variety of other vasodilator peptides, including the angiotensin 1-7 
peptide, calcitonin gene-related peptide (CGRP), substance P and 
adrenomedullin; alterations in expression of the kallikrein-kinin 
system that affect vascular tone and renal salt handling; 
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abnormalities of resistance vessels, including selective lesions in 
the renal microvasculature; diabete mellitus (DM); insulin 
resistance; obesity and the production of vasoactive 
adipocytokines; increased activity of vascular growth factors, 
alterations in adrenergic receptors that influence heart rate, 
inotropic properties of the heart, and vascular tone; and altered 
cellular ion transport. These factors interact with genetic, 
demographic and environmental influences, explaining the 
heterogeneity of the hypertensive population. In addition, 
increased vascular stiffness, endothelial dysfunction, inflammation 
and increased oxidative stress play a role in increasing BP and 
cardiovascular (CV) risk and offer potential therapeutic targets 
with benefits that may go beyond lowering BP. Analyses of BP 
patterns in families suggest that genetic factors account for 40% to 
50% of BP variance, whereas shared environment accounts for 
10% to 30% [148]. However, single gene mutations play a minor 
role, accounting for <1% of cases of hypertension. DNA variants 
in multiple so-called candidate genes (those having relevance to 
disease development or progression) with subtle effects on gene 
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expression or function, when taken cumulatively, may have major 
impact in raising BP. Improved techniques of genetic analysis, 
especially genome-wide linkage analysis, have enabled a search 
for complex sets of genes that may contribute to the development 
of primary hypertension in the population. 
The unifying aspect of hypertension is that two pathological 
processes are manifest. Hypertension will cause pathological 
changes to: (1) the muscle of the heart and (2) the arteries. The 
muscle cells enlarge, with increased extracellular proteins. During 
the established phase of hypertension, total peripheral resistance 
occurs and may be due to a decrease density of diameter of smaller 
vessels, structural changes causing decreased compliance, or a 
change in activity or sensitive of the vessels to hormonal stimuli. 
In later stages of hypertension there is an increase in connective 
tissue with an associated decrease in vascular compliance. 
Hypertension is frequently associated with atherosclerotic plaques 
and it is likely that hypertension may increase some of the 
endothelial denuding, damaged endothelial cells causes or permits 
an injury repair response, the response causes infiltration of 
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macrophages, this infiltration continues to produce foam cells, and 
the atherosclerotic plaque cycle continues.  
Pharmacological treatment of patients with hypertension decreases 
morbidity and mortality from cardiovascular disease. Effective 
antihypertensive therapy markedly reduces the risk of strokes, 
cardiac failure, and renal insufficiency due to hypertension. 
Currently therapies for hypertension can act on peripheral 
resistance, cardiac output or both. Drugs may decrease the cardiac 
output by inhibiting myocardial contractility or by decreasing 
ventricular filling pressure. On the other hand, drugs can decrease 
peripheral resistance by acting on smooth muscle to cause 
relaxation of resistance vessels or by interfering with the activity 
of systems that produce constriction of resistance vessels (e.g. the 
sympathetic nervous system, the RAS). 
Antihypertensive drugs can be classified according to their sites or 
mechanisms of action as resumed in the following table (Tab.2.1): 
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Pharmacological Therapy of Hypertension 
Diuretics 
1. Thiazides and related agents (hydrochlorothiazide, chlorthalidone, 
chlorothiazide, indapamide, methylclothiazide, metolazone). 
2. Loop diuretics (furosemide, bumetanide, torsemide, ethacrynic acid). 
3. K+-sparing diuretics (amiloride, triamterene, spironolactone). 
Sympatholytic drugs 
1. β receptor antagonists (metoprolol, atenolol, betaxolol, bisoprolol, 
carteolol, esmolol, nadolol, nebivolol, penbutolol, pindolol, propranolol, 
timolol). 
2. α receptor antagonists (prazosin, terazosin, doxazosin, phenoxybenzamine, 
phentolamine). 
3. Mixed α-β receptor antagonists (labetalol, carvedilol). 
4. Centrally acting adrenergic agents (methyldopa, clonidine, guanabenz, 
guanfacine). 
5. Adrenergic neuron blocking agents (guanadrel, reserpine). 
Ca
2+
 channel blockers (verapamil, diltiazem, nisoldipine, felodipine, nicardipine, 
isradipine, amlodipine, clevidipine, nifedipine). 
Angiotensin-converting enzyme inhibitors (captopril, enalapril, lisinopril, 
quinapril, ramipril, benazepril, fosinopril, moexipril, perindopril, trandolapril). 
Ang II receptor antagonists (losartan, candesartan, irbesartan, valsartan, 
telmisartan, eprosartan, olmesartan). 
Direct Renin Inhibitor (aliskiren). 
Vasodilators 
1. Arterial (hydralazine, minoxidil, diazoxide, fenoldopam). 
2. Arterial and venous (nitroprusside).  
Tab. 2.1: Classification of antihypertensive drugs by their primary site or 
mechanism of action. 
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 2.12 ACE-inhibitors 
ACE-inhibitors (ACEi) are widely used in controlling blood 
pressure in hypertensive patients. They act on the RAS by 
inhibiting the conversion of Ang I to the active Ang II. Inhibiton of 
Ang II production lowers blood pressure and enhances natriuresis. 
ACE is an enzyme with many substrates, and its inhibition may 
also induce effects unrelated to reducing the levels of Ang II. 
ACEi increase bradykinin levels and bradykinin stimulates 
prostaglandin biosynthesis; both may contribute to the 
pharmacological effects of ACE inhibitors. It has been 
demonstrated that ACE inhibitors enhance mediator release (eg, 
NO, prostaglandins or endothelium-derived hyperpolarizing factor) 
[312, 313] not only by protecting BK from degradation, but also by 
affecting bradykinin 1 and 2 receptor (BR1 and BR2) differently 
[311]. Several studies showed that ACE inhibitors are indirect 
allosteric enhancer of B2R signaling as interaction between B2R 
and ACE takes place on the cell surface. It seems that ACE 
inhibitors induce a conformational change in ACE that is 
transmitted to the B2R owing to their close contact, resulting in 
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increased mediator release [314–322]. On the other hand, ACE 
inhibitors are direct activators of B1Rs at an allosteric site that 
differs from the orthosteric site of peptide ligands. The 
consequence is a prolonged high-output NO production by iNOS 
in human endothelial cells [323-325]. Apart of BK-mediated 
beneficial properties, ACE-i may suppress oxidative stress by 
decreasing the activities of the NAD(P)H oxidase, PKC and 
MAPK [326] and by decreasing the expression of oxidative 
stresslectin-like oxidized LDL receptor-1 (LOX-1) [327]. 
Furthermore, ACE-i decrease tissue factor (TF) and MCP-1 after 
1-month therapy in patients with MI and downregulated TF 
synthesis in vitro by inhibition of endotoxin-induced nuclear 
factor-kappaB translocation to the promoter region of the gene 
encoding for TF [328]. ACEi increase by 5-fold the circulating 
levels of the natural stem cell regulator N-acetyl-seryl-aspartyl-
lysyl-proline, which may contribute to the cardioprotective effects 
of ACE-inhibitors [306]. In addition, ACEi increase renin release 
and the rate of formation of Ang I by interfering with both short- 
and long-loop negative feedbacks on renin release. Accumulating 
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Ang I is directed down alternative metabolic routes, resulting in 
the increased production of vasodilator peptides such as Ang (1-7). 
ACEi can be classified into three broad groups based on chemical 
structure:  
1) sufhydryl-containing ACE-inhibitors structurally related to 
captopril, such as alacepril and zofenopril; 
2) dicarboxyl-containing ACE-inhibitors structurally related to 
enalapril (e.g. lisinopril, benazepril, quinapril, moexipril, 
ramipril, trandolapril, perindopril); 
3) phosphorus-containing ACE-inhibitors structurally related to 
fosinopril, as ceronapril. 
Many ACEi are ester-containing prodrugs that are 100-1000 times 
less potent but have a better oral bioavailability than the active 
molecules. They differ with regard to potency, whether ACE 
inhibition is primarily a direct effect of the drug itself or the effect 
of an active metabolite, and pharmacokinetics. 
The main effect of ACE inhibition is the long-term fall of systemic 
blood pressure accompanied by a reduction in total peripheral 
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resistance. Cardiac function in patients with uncomplicated 
hypertension generally is little changed, although stroke volume 
and cardiac output may increase slightly with sustained treatment. 
Baroreceptor function and cardiovascular reflexes are not 
compromised, and responses to postural changes and exercise are 
little impaired. Other than antihypertensive action, several large, 
randomized, placebo-controlled clinical studies demonstrate that 
inhibition of ACE in patients with systolic dysfunction prevents or 
delay the progression of heart failure, decreases the incidence of 
sudden death and myocardial infarction, decreases hospitalization, 
and improves quality of life. Thus, ACE-inhibitors show additional 
protective effects in the cardiovascular system. Indeed, different 
studies have showed that ACEi induced many beneficial effects on 
endothelial function in both animal models of hypertension [307], 
diabete [308] and atherosclerosis [309, 310]. Interestingly, these 
beneficial effects seem to involve different mechanisms which are 
unrelated to Ang II inhibition. Moreover, recent findings reported 
the existence of significant differences between ACE inhibitors, as 
far as protection vs ischemic injury is concerned [329]. Early 
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studies, focused on the comparison between sulphydryl-containing 
ACEi captopril and dicarboxyl-containing ACEi enalapril, led to 
the hypothesis that the presence of a thiol group may be critical for 
cardioprotection [330-332]. With respect to the role of –SH group 
in the beneficial effect, more recently much attention has been paid 
to another sulphydrylated ACEi, e.g. zofenopril, which exerts 
protective action in the vasculature to a greater extent than 
captopril. 
2.13 The sulphydrylated ACEi zofenopril 
Zofenopril, [1(S), 4(S)]-1(3-mercapto-2methyl-1-oxopropyl) 4-
phenyl-thio-L-proline-S-benzoylester, is the latest ACE inhibitor to 
reach European market in 1999. As the most part of ACEi, 
zofenopril is a prodrug, which is desterified in vivo to the active 
water-soluble inhibitor, the sulphydryl group containing 
compound, zofenoprilat (Fig. 2.10). 
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Fig. 2.10: Molecular structure of (A) zofenopril and (B) its active metabolite 
zofenoprilat. 
Zofenopril is notably lipophilic and this feature allows it to 
undergo extensive and prolonged tissue penetration, which 
enhances ACE inhibition in tissues, more than other ACE 
inhibitors. Importantly, concentrations of zofenopril in the heart 
and aortic wall have been found to be greater than plasma 
concentrations, and penetration of cardiac tissue by zofenopril is 
particularly efficient [333]. Zofenopril, along with captopril, has 
sulphydryl moiety which was related to the cardiprotective effect 
of these drugs both in vitro and in vivo. In vitro studies showed 
that captopril (36-1080µM) and zofenopril (3.6-36µM) 
significantly increased coronary flow after 5 minutes of perfusion 
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in a concentration-dependent manner in isolated rat hearts, 
although the pharmacological efficacy as well as the relative 
potency of zofenopril was definitely higher. This effect was not 
accompanied by an increase in 6-keto PGF1α overflow in the 
coronary effluent. On the other hand, ramiprilat induced coronary 
vasodilation after 20 minutes of perfusion and was associated with 
an increase in 6-keto PGF1α outflow [334], suggesting a different 
mode of action for ACEi with and without –SH group. In another 
study, zofenoprilat and captopril, but not enalaprilat, potentiated 
the vasodilatator effect of bradykinin on coronary vessels in 
isolated rat hearts [334-336]. ACEi are likely to cause vasodilation 
by a bradykinin-mediated release of NO, which can be enhanced in 
presence of free –SH groups. Sulphydrylated ACEi may therefore 
potentiate nitrates and reverse tolerance to their therapeutic effects, 
as suggested by previous preclinical trials [337]. Several studies 
have investigated the cardioprotevtive effects of zofenopril in 
experimental model of global ischemia/reperfusion as well. The 
characteristic of reperfusion is the release of big amounts of lactate 
dehydrogenase (LDH, an indicator of cell viability), decreased 
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cardiac function, and increased end-diastolic pressure (EDP, an 
indicator of severe damage). It has been demonstrated that both 
zofenoprilat at 3 and 10µM and captopril 400µM improved 
contractile force and reduced EDP and LDH in a concentration-
dependent fashion. Conversely, enalaprilat or ramiprilat, at 
concentrations up to 400µM and 100µM respectively did not show 
any cardioprotective effects [338]. In another model of cardiac 
ischaemia and reperfusion, it was compared the effect of 
zofenopril, captopril and fosinopril at the same dose of 50µM with 
respect to some typical parameter of ischaemia/reperfusion, such 
as reduction of left ventricular (LV) pressure and coronary flow, as 
well as increased release of creatine kinase (CK, a sensitive 
indicator of membrane injury). Treatment with zofenopril and 
captopril, but not fosinopril improved post-ischaemic LV function, 
increased coronary flow and reduced CK release. Moreover 
zofenopril, but not captopril, attenuated oxidative stress during 
reperfusion [339]. More recently, it has been found that zofenopril 
reduced infarct size in isolated rat hearts, which was partially 
reduced by BR2 antagonist, HOE-140 [340]. Moreover, the 
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cardioprotection afforded by zofenoprilat was also associated with 
better preservation of protein thiols at the end of the ischaemia. 
These findings reinforce the concept that zofenopril has a specific 
cardioprotective effect, which might be related either to 
interference with bradykinin metabolism and/or to preservation of 
protein SH groups. The ability of zofenopril to prevent ischemic 
myocardial damage was evaluated also in vivo in a chronic closed-
chest pig model [342]. Zofenopril decreased the pressure-rate 
product and reduced the peak efflux of chatecolamines in coronary 
venous effluent during reperfusion in pigs pre-treated with 
zofenopril 2 days prior to ischaemia. The effects of zofenopril on 
the myocardial changes induced by sustained arterial hypertension 
or cardiac ischaemia have been studied in several trials. It has been 
showed that renal hypertension induced by aortic banding and 
constriction of the right renal artery was consistently reduced by 
oral administration of 6mg/Kg zofenopril daily for 8 weeks [343]. 
Studies performed with SHRs, zofenopril was given daily in food 
for 6 months and it was effective to reduce the mean arterial 
pressure from 106 to 84 mmHg. Its effect was similar to that of 
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hydralazine, but zofenopril also significantly reduced the LV 
systolic force–time integral (a measure of total ventricular load) 
and the LV weight to body weight ratio [344]. Because free radical 
damage of vascular etiology could be an important mechanism of 
myocardial ischemia-reperfusion injury [350], it has been 
suggested that the effect could be due to the free radical 
scavenging ability of the sulphydryl moiety of the agent. The 
protective effects of zofenorpil and other SH-containing ACEi 
from free radical-induced cell damage have been assessed in 
cultured endothelial cells exposed to a superoxide anion and 
hydroxyl radicals generating system [351]. Preincubation of the 
cells with captopril, epicaptopril (the stereoisomer of captopril 
which is devoid of ACE inhibitory properties), or zofenopril 
produced a concentration-dependent (10-200µM) inhibition of 
malonyldialdehyde formation. Both loss of cell viability and 
membrane blebbing were reduced by SH-ACEi at concentrations 
as low as 10µM, although zofenopril was 5 times more potent. In 
contrast, non-sulphydrylated ACEi were ineffective up to 200µM. 
Furthermore, it has been proposed that zofenopril can be 
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cardioprotective via modulation of KATP channels, because KATP 
openers were found to protect ischemic myocardium in various 
experimental models [352-355]. Sargent et al. showed that the 
effects of zofenopril were reversed by two structurally different 
blockers of the KATP channels: glyburide and 5-hydroxydecanoate. 
Isobolographic analysis demonstrated that treatment with a 
combination of zofenopril and cromakalim (a KATP opener) 
resulted in superadditive response in the ischemic myocardium, 
and KB analysis demonstrated that glyburide is a noncompetitive 
antagonist in the presence of zofenopril and a competitive 
antagonist in the presence of cromakalim. The results suggest a 
link between the cardioprotective effects of zofenopril and the 
KATP channel. This activity appears to be a receptor-mediated 
event, involving a mechanism different from that of the classical 
KATP openers, such as cromakalim [356]. 
In other recent studies, zofenoprilat was shown to protect 
endothelial function in different experimental models [345]. It 
abolished the proapoptotic effects of doxorubicin, promoted 
mitosis of bovin coronary venular endothelial cells (CVEC) [346], 
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enhanced concentration-dependently cell survival, and improved 
vascular-endothelial-growth-factor–induced proliferation of 
CVECs [347]. Experimental evidences suggest also that zofenopril 
reduced stimulated and un-stimulated release of ET-1 secretion 
and concomitantly increased of nitric oxide production in 
HUVECs [348, 349]. Zofenoprilat improve the vascular reactivity 
and ameliorates endothelial dysfunction in non-obese diabetic 
(NOD) mice, animal model of type I diabete. It seems that it 
increases NO bioavaibility through by regulating the expression of 
Caveolin-1, which inhibits eNOS activity, conversely to the 
enalapril. Moreover zofenopril, but not enalapril ameliorates 
diabete oucome in diabete mice in terms of reduced polyuria and 
glycosuria [308]. 
Zofenopril inhibits LDL oxidation and attenuate atherosclerosis in 
different experimental model of atherosclerosis such as in 
apolipoprotein E deficient mice [309] or Watanabe Heritable 
Hyperlipidimic (WHHL) rabbits [310]. Cominacini et al. showed 
that zofenoprilat, but not enalaprilat, significantly and dose-
dependently reduced the formation of intracellular ROS and 
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superoxide induced by oxidized low density lipoprotein (ox-LDL) 
and tumour necrosis factor-α (TNF- α) in human endothelial cells 
[357]. Zofenoprilat but not enalaprilat also decreased the 
consumption of intracellular glutathione induced by ox-LDL and 
TNF-α. While zofenoprilat significantly and dose-dependently 
reduced the expression of VCAM-1, ICAM-1 and E-selectin 
induced by ox-LDL and TNF-α in human umbilical vein 
endothelial cells (HUVECs), enalaprilat did not. In addition, pre-
incubation of HUVECs with zofenoprilat dose-dependently 
reduced the increased activation of nuclear factor-κB (NF-κB) by 
ox-LDL and TNF-α [357]. It is known that the migration of 
circulating monocytes and ox-LDL into the subendothelial space is 
one of the key events in atherosclerosis [358] and is mediated by 
the occurrence and expression of adhesion molecules on 
endothelial cells. NF-κB, a redox-sensitive element, is a 
transduction factor in the molecular gene induction of adhesion 
molecules. Thus SH-containing ACE inhibitors, in addition to 
controlling blood pressure, may be useful in inhibiting 
atherosclerotic plaque progression, which slows the development 
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of atherosclerosis. Finally, the impact of zofenopril in nitric oxide 
production and cGMP concentrations was evaluated in bovine 
aortic endothelial cells (BAEC). Zofenopril enhance NO 
production which is associated to an increase in NO bioactivity, as 
demonstrated by the significant increase in endothelial cell cGMP 
accumulation. This effect was again notable only for zofenoprilat 
over the range of concentrations used (10-30-60µM); captopril also 
had an effect on cGMP, but only at the highest concentration 
tested. In contrast, enalaprilat was not significantly effective at the 
different tested doses. F2-isoprostanes were reduced, with the 
reduction correlating with the increases in nitrite/nitrate and cGMP 
produced by zofenoprilat, suggesting that the benefit of 
zofenoprilat is, in part, a consequence of reduced oxidant stress in 
the endothelial cell leading to improved bioacvtive nitric oxide 
production [359]. 
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2.14 Objectives of the project 
Hydrogen sulfide (H2S) has been shown to exhibit a variety of 
biological effects in the cardiovascular system. It has been viewed 
especially as a vasorelaxing agent with antihypertensive properties. 
Indeed, both pharmacological inhibition and genetic disruption of 
CSE locus leads to an increase of blood pressure [78]. Thus, the 
interest in the biology of H2S is growing up and a number of 
researches are devoting to the investigation of mechanism of action 
of H2S and as well as to the development of drugs that can 
modulate H2S release or biosyntheis in targeted tissues. Therefore, 
the thesis proposes two aims: 
I) Examine the molecular target of H2S which triggers 
vasodilation. Several mechanisms have been proposed to 
contribute to the effects of H2S on vessel tone. Initially, H2S 
was shown to enhance vasorelaxation by promoting KATP 
channel opening [42]. However, additional pathways 
contribute to vasorelaxation in response to H2S, as KATP 
channel blockers fail to inhibit or do not completely abolish 
H2S-induced relaxations in some tissues [360]. These 
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additional vasodilatory pathways might include other ion 
channels, as well as cGMP nucleotide regulated pathways. 
With respect to the latter, our group has recently observed 
that H2S increases cGMP levels in smooth muscle cells 
[125]. Unlike nitric oxide that enhances cGMP synthesis by 
activating soluble guanylyl cyclase, elevations in cGMP in 
response to H2S result from phosphodiesterase (PDE) 
inhibition [125]. By virtue of H2S ability in inhibiting PDE, 
and thus to interact with L-arginine/NO/cGMP pathway, our 
purpose is to further analyze the role of cGMP in H2S-
induced vasorelaxation and to determine the contribution of 
cGMP-dependent protein kinase (PKG) in H2S response. 
II) Investigate the role of sulphydrylated molecules, such as 
zofenopril, in the vascular function with respect to H2S 
pathway. Given that H2S is involved in the pathogenesis of 
hypertension [140], it can be addressed as an additional 
therapeutic target for the management of this disease. 
Actually, ACE inhibitors are widely used in controlling 
blood pressure in hypertensive patients and they represent 
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first line treatment in different cardiovascular diseases, since 
they also show additional beneficial effects unrelated to 
ACE inhibition [309]. In particular, therapeutic use of 
zofenopril, a sulphydrylated ACE inhibitor, has raised 
hypothesis over a potential role of thiol group in such 
beneficial effects, other than antioxidant activity [357, 359]. 
Therefore, our aim is to investigate the link between the 
benefits of sulphydrylated ACEi zofenopril in therapies with 
respect to H2S pathway activation. 
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Chapter 3 
MATERIALS and METHODS I 
3.1 Ethics statement 
All animal procedures were in compliance with the European 
Community guidelines for the use of experimental animals and 
approved by the Committee Centro Servizi Veterinari of the 
University of Naples ‘‘Federico II’’; institutional regulations do not 
require the use of animal protocol numbers for approved protocols. 
3.2 Animals 
Male and female mice CD-1 6 to 8 weeks old and 129/Sv were 
purchased from Harlan Laboratories (Italy). Mice carrying a null 
mutation of the gene encoding PKG-I (PKG-I
-/- 
mice, also termed 
cGKI
L-/L- 
mice) and CSE
-/-
 mice were generated as previously 
described [19,46]. PKG-I
-/-
 mice were on a 129/Sv genetic 
background and analyzed at an age of 10 to 16 weeks. Animals were 
housed in our animal facility having free access to water and food. 
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3.3 Reagents 
Cell culture media and serum were obtained from Life Technologies 
GIBCO-BRL (Paisley, UK). All cell culture plastic ware was 
purchased from Corning-Costar Inc. (Corning, NY). West Pico 
chemiluminescent substrate was purchased from Pierce 
Biotechnology (Rockford, Illinois); DC Protein assay kit, Tween 20 
and other immunoblotting reagents were obtained from Bio-Rad 
Laboratories (Hercules, CA); penicillin and streptomycin were 
purchased from Applichem (Darmstadt, Germany). GYY4137, DT-2 
and TAT were purchased from Cayman Chemical (Ann Arbor, 
Michigan), Biolog (Bremen, Germany) and Genscript (Piscataway, 
USA), respectively. The GAPDH, pVASP and secondary Abs were 
purchased from Cell Signaling Technologies (Beverly, MA), while 
the CSE antibody was obtained from Abnova Novus Biologicals 
(Littelton, CO). The PKG-I Ab used has been generated as previously 
described [47]. The anti-von Willebrand factor was obtained from 
Dako (Glostrup, Denmark), and the secondary anti-mouse and anti-
rabbit antibodies used for the immunofluorescence studies were 
obtained from Life Technologies (Darmstadt, Germany). The cGMP 
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EIA kit was obtained from Assay Designs (Ann Arbor, MI). 
Sildenafil, sodium hydrosulfide (NaHS), L-cysteine (L-cys), S-
nitroso-N-acetylpenicillamine (SNAP), phenylephrine, 
protease/phosphatase inhibitors and all other chemicals used in 
solutions and buffers were purchased from Sigma Chemical Co 
(Milan, Italy). All drugs were dissolved in distilled water. 
3.4 Ex vivo studies 
Animals were sacrificed with CO2 and thoracic aortas were rapidly 
harvested, dissected, and cleaned of adherent connective and fat 
tissue. Rings of about 1 mm length were denuded of the endothelium, 
cut and placed in organ baths (2.5 ml) filled with oxygenated (95% O2 
-5% CO2) Krebs solution maintained at 37°C. The rings were 
connected to an isometric transducer (type 7006, Ugo Basile, 
Comerio, Italy) and changes in tension were recorded continuously 
with a computerized system (Data Capsule 17400, Ugo Basile, 
Comerio, Italy). Exclusively in the set of experiments performed on 
aortic rings harvested from PKG
-/-
 and their respective background 
129/Sv the endothelium was preserved. The composition of the Krebs 
solution was as follow (mM): NaCl 118, KCl 4.7, MgCl2 1.2, KH2PO4 
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1.2, CaCl2 2.5, NaHCO3 25, and glucose 10.1. The rings were 
stretched until a resting tension of 1.5 g was reached and allowed to 
equilibrate for at least 45 min, during which time tension was 
adjusted, as necessary, to 1.5 g and bathing solution was periodically 
changed. In each experiment, rings were first challenged with PE (1 
mM) until the responses were reproducible. The rings were then 
washed and contracted with PE (1 mM) and, once a plateau was 
reached, a cumulative concentration-response curve of the following 
drugs was performed: SNAP (100 pM–3 mM); NaHS (1 mM–300 
mM); L-cys (1 mM–300 mM); GYY4137 (1 mM–300 mM). Rings 
were treated with the PKG inhibitor DT-2 or its control peptide TAT 
(1–3 mM; 20 minutes), or with PDE5 inhibitor sildenafil (1 nM; 15 
minutes). After incubation time, cumulative concentrationresponse 
curve to SNAP; NaHS; L-cys; GYY4137 were performed. A 
preliminary study on the optimal incubation time and concentration of 
the drug treatments was carried out (data not shown). In another set of 
experiments, a cumulative concentrationresponse of NaHS and L-cys 
were carried out on aortic rings from PKG-I
-/-
 and 129/Sv strains. 
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3.5 Conscious systemic blood pressure measurement 
Systolic blood pressure (SBP) was measured in conscious mice using 
the pneumatic tail-cuff method (W+W Blood pressurereporter, model 
8006, Ugo Basile). Before the measurement, animals were preheated 
in a room at 30°C for 30 min, then they were placed in a plastic 
chamber. A cuff with a pneumatic pulse sensor was attached to the 
tail. This procedure was performed every day for 1 week before 
starting the experiments in order to habituate the animals to this 
procedure. During the entire measurement period, the temperature 
was maintained at 30°C. Two consecutive measurements were always 
recorded. SBP was measured and, once basal SBP was assessed, 
intraperitoneal injection of (D)-DT2 (100 nmoles) was performed. A 
more stable form of DT-2 [(D)-DT-2] that is composed of D-
aminoacids was chosen for the in vivo experiments. SBP was then 
evaluated twice every 5 minutes. Fifteen minutes after the (D)-DT2 
injection, NaHS (1µmol/kg) was administered subcutaneously. SBP 
was then monitored every 5 minutes for three times. (D)-DT2 volume 
injected was 50µl i.p. NaHS volume injected was 30µl s.c. Both drugs 
were dissolved in saline. 
153 
 
3.6 Cell culture 
Rat aortic smooth muscle cells (RASMCs) were isolated from 12- to 
14-wk-old male Wistar rats, five rats per isolation, as previously 
described [412]. Animals were anesthetized with pentobarbital 
sodium (40 mg/kg ip). Once fully anesthetized as judged by the lack 
of reaction to a noxious stimulus, animals were exsanguinated; 
thoracic aortas were then removed. More than 95% of cells isolated 
stained positive for smooth muscle a-actin. Cells between passages 2 
and 5 were used for all experiments. RASMCs were routinely cultured 
in DMEM containing 4.5 g/l glucose and supplemented with 10% 
FBS and antibiotics.  
3.7 Western Blotting 
Aortic tissues of CD-1 and 129/Sv were homogenized in modified 
RIPA buffer (Tris HCl 50 mM, pH 7.4, TritonX-100 1%, Sodium-
deoxycholate 0.25%, NaCl 150mM, EDTA 1mM, 
phenylmethanesulphonylfluoride 1 mM, aprotinin 10 mg/ml, 
leupeptin 20 mM, NaF 50 mM) using a polytron homogenizer (two 
cycles of 10 s at maximum speed). In experiments performed to 
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determine the expression of CSE in wild-type and PKG-I
-/-
 animals, 
aortas from three animals were pooled and then homogenized. After 
centrifugation of homogenates at 12000 r.p.m for 15 min, protein 
concentration was determined by Bradford assay using BSA as 
standard. 40 mg of the denatured proteins were separated on 10% 
SDS/PAGE and transferred to a PVDF membrane. Membranes were 
blocked in PBS-Tween 20 (0.1%, v/v) containing 3% non fat dry milk 
for 1 hour at room temperature, and then incubated with the primary 
antibody overnight at 4°C. The filters were washed with PBS-tween 
20 (0.1%, v/v) extensively for 30 min, before incubation, for 2 hours 
at 4°C, with the secondary antibody (1:5000) conjugated with 
horseradish peroxidase anti-mouse IgG. The membranes were then 
washed and immunoreactive bands were visualized using a 
chemiluminescence substrate. 
3.8 cGMP measurements 
Rat aortic smooth muscle cells were incubated for 5 min with the 
indicated concentration of the H2S donors. After the treatment, cells 
were washed with Hanks’ balanced salt solution and cGMP was 
extracted using 0.1N HCl. cGMP content was measured in the 
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extracts using a commercially available enzyme immunoassay kit 
following the manufacturer’s instructions. For cGMP measurements 
in tissue and plasma of CSE knockout mice (CSE
-/-
), eight-week male 
CSE
-/-
 and wild-type mice (CSE
+/+
) were used in this experiments. 
Animals were anesthetized with pentobarbital sodium (40 mg/kg ip) 
and exsanguinated. Blood plasma was prepared by spinning a tube of 
fresh blood containing EDTA (1500xg for 15 min at 4°C). The aorta 
and mesenteric artery tissues were dissected and cleaned for 
immediate cGMP measurement. First, aortic rings were placed in 
Krebs solution at 37°C and incubated for 30 min. After that, rings 
were stimulated with sodium nitroprusside (10mM) for 2 min and 
then tissues were rapidly blotted weighted and quick frozen in liquid 
nitrogen. Tissues were snap frozen and homogenized in 1–3 volumes 
of buffer (containing 5% trichloroacetic acid) per gram of tissue and 
centrifuged at 1,500xg for 10 min. The supernatant was carefully 
removed and used in the next step. Residual TCA acid was removed 
by extraction into five volumes of watersaturated diethyl ether 
(repeated twice for a total of 3 extractions). Any residual ether was 
removed by warming the samples at 70°C for 5 min. The samples 
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were then processed according to the instructions provided with 
commercially available enzyme immunoassay kit following the 
manufacture’s instruction. Blood plasma was prepared by spinning a 
tube of fresh blood containing EDTA (1500xg for 15 min at 4°C). The 
aorta and mesenteric artery tissues were dissected and cleaned for 
immediate cGMP measurement. First, aortic rings were placed in 
Krebs solution at 37°C and incubated for 30 min. After that, rings 
were stimulated with sodium nitroprusside (10 mM) for 2 min and 
then tissues were rapidly blotted weighted and quick frozen in liquid 
nitrogen. Tissues were snap frozen and homogenized in 1–3 volumes 
of buffer (containing 5% trichloroacetic acid) per gram of tissue and 
centrifuged at 1,500xg for 10 min. The supernatant was carefully 
removed and used in the next step. Residual TCA acid was removed 
by extraction into five volumes of watersaturated diethyl ether 
(repeated twice for a total of 3 extractions). Any residual ether was 
removed by warming the samples at 70°C for 5 min. The samples 
were then processed according to the instructions provided with 
commercially available enzyme immunoassay kit following the 
manufacture’s instruction.  
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3.9  Statistical analysis 
Data were expressed as mean ± s.e.m. Statistical analysis was 
determined by using one or two way ANOVA and Dunnett’s or 
Bonferroni as a post-test or t-test analysis when appropriate. 
Differences were considered statistically significant when P-value was 
less than 0.05. GraphPad Prism software (version 4.02, GraphPad 
Software, San Diego, CA) was used for all the statistical analysis. 
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Chapter 4 
RESULTS I 
4.1 PDE regulates H2S-induced relaxation 
It has been demonstrated that exposure of smooth muscle cells to 
NaHS increases cGMP by inhibiting PDE [125]. To test whether our 
biochemical observations are functionally relevant, we pre-incubated 
rat aortic rings with a low concentration of the PDE5 inhibitor 
sildenafil (1 nM) and then contracted them with phenylephrine. Such 
pre-treatment did not have a significant effect on the ability of 
phenylephrine to cause tissue contraction, but differentially affected 
NO-induced vs H2S-induced vasorelaxation. Incubation of rings with 
sildenafil led to a potentiation of NO-induced relaxation as evidenced 
by the leftward shift of the SNAP dose-response curve (6x10
-7
 M vs. 
1.4x10
-7
 M vehicle vs sildenafil, p<0.001; Fig. 4.1A). In contrast to 
the findings with the NO donor, pre-treatment with sildenafil 
attenuated the relaxing effect of NaHS in rat aorta (Fig. 4.1B). The 
observed rightward shift of the NaHS dose-response in the presence 
of sildenafil (2.8x10
-4
 M vs. 8.5x10
-5
 M vehicle vs sildenafil p<0.001) 
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is consistent with the notion that NaHS-stimulated vasodilation is at 
least in part mediated by PDE5 inhibition. 
 
Fig. 4.1: The PDE5 inhibitor sildenafil differentially affects NO and H2S-
regulated vascular tone. (A) Incubation of isolated aortic rings with sildenafil (1 
nM) significantly inhibited NaHS-induced vasodilatation. (B) Incubation of 
isolated aortic rings with sildenafil (1 nM) significantly enhanced SNAP-induced 
vasodilatation. *** p<0.001 vs vehicle (dH2O), n = 6 for each group. 
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To provide proof that endogenously produced H2S acts as a PDE 
inhibitor, we measured cGMP levels in the plasma and vascular 
tissues of CSE
-/- 
mice. In these experiments we observed cGMP levels 
in the plasma (9.81±0.75 pmole/ml), aorta (9.55±0.80 pmole/mg 
protein), and mesenteric artery (0.42±0.04 pmole/mg protein) from 
CSE
-/- 
mice were significantly lower than those in the plasma 
(20.74±1.97 pmole/ml), aorta (23.40±1.44 pmole/mg protein) and 
mesenteric artery (1.57±0.05 pmole/mg protein) from CSE
+/+
 mice 
(Fig. 4.2). In addition, stimulation of vascular tissues with sodium 
nitroprusside increased cGMP levels in a statistically significant 
manner only in the vessels of wild-type, but not in the vessels of CSE
-
/-
 animals. The above observations taken together are consistent with 
the idea that H2S is an inhibitor of PDE activity in vascular tissues. 
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Fig 4.2: CSE deficiency reduces cGMP levels. cGMP levels in the aorta (A), 
mesenteric artery (B) and plasma (C) of CSE
-/-
 mice were significantly lower than 
those from CSE
+/+
 mice. Sodium nitroprusside (SNP, 10 mM) significantly 
increased cGMP levels in aorta (B) and mesenteric artery (C) from CSE
+/+
 mice 
but not CSE
-/-
 mice; * p,0.05 vs CSE
+/+
 mice, #p<0.05 basal, n = 5 for each 
group. 
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4.2 H2S activates PKG in vascular tissues 
To elucidate the downstream signalling pathways activated in 
response to increased intracellular cGMP, we evaluated the ability of 
NaHS to stimulate cGMP-dependent protein kinase. To this end, we 
determined VASP phosphorylation on Ser239, as an index of PKG 
activation [24]. Indeed, exposure of aortic tissue to NaHS enhanced 
vasodilator stimulated phosphoprotein (VASP) phosphorylation in a 
time-dependent manner (Fig. 4.3A). Moreover, incubation of rings 
with DT-2, a PKG-I inhibitor, attenuated NaHS-induced 
vasorelaxation, while TAT (control peptide) had no effect (Fig. 4.3B); 
these findings provide evidence that PKG-I participates in H2S-
stimulated dilatation. To study the role of PKG-I in the hypotensive 
effect of H2S in vivo, mice we pre-treated with DT-2 prior to being 
treated with the NaHS (Fig. 4.3C). DT-2 administration led to an 
increase in systolic blood pressure (SBP). Subcutaneous injection of 
NaHS resulted in a fall in SBP that reached a trough, 5 min after the 
injection, with a complete recovery within 15 minutes. In contrast, 
NaHS did not alter SBP in mice treated with the PKG-I inhibitor. 
  
163 
 
  
 
164 
 
 
 
 
Fig. 4.3: H2S activates PKG and triggers vasodilatation. (A) Mouse aorta was 
incubated with NaHS (50 mM) for the indicated time and VASP phosphorylation on 
Ser239 was determined. Up: rapresentative blot; down: quantification of scanned 
autoradiograms, *p<0.05 vs vehicle, n = 3. (B) Incubation of aortic rings with the 
selective inhibitor of PKG, DT-2 (1, 3 mM) significantly inhibited NaHS-induced 
vasodilatation. TAT peptide (3 mM) was used as a control; *** p<0.001 vs. vehicle 
(dH2O), n = 6 for each group. (C) Mice were injected with vehicle or DT-2 (100 
nmoles, ip); after 15 min NaHS (1 mmol/kg) was administered subcutaneously. 
Systolic blood pressure (SBP) was monitored in conscious mice; *** p<0.001 vs 
vehicle, n = 4 for each group. 
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In a different set of experiments we utilized GYY4137, a slow releasing 
H2S donor. It should be noted that incubation of aortic smooth muscle 
cells with GYY4137, unlike NaHS, resulted in only minor increases in 
cGMP content (Fig. 4.4A&B). In agreement to what has been published, 
relaxation in response to GYY4137 took longer to manifest compared to 
the fast relaxations brought about by NaHS [95]. Moreover, GYY4137-
stimulated relaxations were PKG-independent, as DT-2 failed to block 
the effects of this H2S donor. 
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Fig. 4.4: GYY4137-induced relaxation is independent of PKG. Aortic smooth 
muscle cells were exposed to the indicated concentration of NaHS (A) or 
GYY4137 (B) and cGMP levels were determined after 5 min. *p<0.05 control, n 
= 4 for each group. (C) Incubation of isolated aortic rings with PKG selective 
inhibitor DT-2 (3 mM) did not affect GYY4137-induced vasodilatation; n = 6 for 
each group. 
A
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4.3 Genetic evidence for the role of PKG-I in H2S-induced 
vasorelaxation 
Although DT-2 is the most selective PKG-I inhibitor available, 
questions regarding its specificity have surfaced [413]. To confirm 
that H2S uses PKG-I-regulated pathways to reduce vascular tone, we 
utilized blood vessels from PKG-I
-/-
 mice. In these experiments we 
found that relaxations to NaHS were significantly hampered in PKG-I 
-/-
 vessels (Fig. 4.5A); however a significant residual response was 
observed, suggesting that complementary vasodilator pathways do 
exist. Importantly, glibanclamide, a KATP channel inhibitor, blocked 
NaHS-induced dilation in vessels from wild-type, but not PKG-I 
-/-
 
mice, suggesting that both PKG-I and KATP work on the same effector 
pathway to trigger vasodilation. To study whether PKG-I is important 
for the dilatation in response to endogenously produced H2S, rings 
were exposed to Lcysteine, the substrate for H2S generation, and 
reduction in vessel tone was measured. L-cysteine promoted 
vasorelaxation in the vessels of wild-type mice; this response was 
greatly reduced in PKG-I
-/-
 vessels (Fig. 4.5B). The diminished 
relaxation to L-cysteine observed in the PKG-I
-/-
 mice was not due to 
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lower levels of the H2S producing enzyme CSE in PKG-I 
-/-
 aortic 
tissue (Fig. 4.5D). It should be noted that relaxations in response to L-
cysteine were of smaller magnitude in the 129/Sv mice (wt mice) 
compared to those observed in CD1 used in the first series of our 
experiments (max relaxation 30±4.89 vs. 23±2.14 in CD1 and 129/Sv 
respectively). This difference can be attributed to the lower levels of 
CSE expression in the aortas of 129/Sv mice (Fig. 4.5C). 
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Fig. 4.5: PKG contributes to the relaxing effect of exogenous and endogenous 
H2S. (A) Mouse aortas from wild-type or PKG-I
-/-
 animals were pre-treated with 
vehicle or glibenclamide (10 mM, 30 min) and then incubated with the indicated 
concentration of NaHS (n = 6 rings harvested from 3–4 animals); dashed lines 
are used for wild-type animals, while solid lines are used for knockouts. (B) L-
cysteine-induced vasodilatation of aortic rings pre-contracted with phenylephrine 
from wild-type and PKG-I
-/-
 mice. Note that cumulative concentration-response 
curves to L-cysteine were significantly different among the different strains of 
mice used CD1 vs 129/Sv (WT); °°° p<0.001 vs. CD1, *** p<0.001 vs WT, n = 8 
rings harvested from 3–4 animals for each group (C) Representative blot and 
quantitation depicting aortic CSE expression in 129/Sv vs CD-1; n = 3 for each 
group, *p<0.05. (D) Representative blot showing expression of CSE in aortic 
homogenates in wild-type and PKG-I
-/-
 mice. Experiments were performed twice 
with similar results. 
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4.4 H2S stimulates relaxations in both endothelium intact 
and denuded aortic rings 
To test the relative contribution of each cell type (endothelium vs smooth 
muscle) to the relaxing effect of H2S, endothelium intact or endothelium 
denuded mouse (CD 1) vessels were exposed to either a H2S donor or a 
H2S substrate (L-cysteine). While the vasodilatory response to NaHS was 
identical irrespective of whether endothelium was present or not (Fig. 
4.6B), responses to L-cysteine were reduced in endothelium-denuded 
vessels (Fig. 4.6A). Staining of aortic tissue with an antibody against 
CSE revealed that although small amounts of the enzyme are present in 
the endothelium, the majority of CSE is expressed in the smooth muscle 
layer (Fig. 4.6C). 
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Fig. 4.6: Role of endothelium in H2S induced-vasodilatation. (A) L-cysteine-
induced vasodilatation was significantly impaired in aortic rings without endothelium 
(–end). (B) NaHS-induced vasodilatation is not affected by endothelium removal; *** 
p<0.001 vs –end, n = 6 for each group. (C) Representative photomicrographs of 
aortas stained with a CSE antibody and counter-stained for von-Willebrant factor, 
smooth muscle α-actin (SMA) and DAPI, showing localization of CSE. 
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Chapter 5 
DISCUSSION I 
Relaxation to H2S is reported to occur through KATP channel activation 
[42], leading to the hypothesis that H2S is an endothelium-derived 
hyperpolarizing factor [109, 111]. The effect of H2S on these channels 
has been proposed to result from sulfhydration of Cys 43 of the pore-
forming Kir6.1 subunit and/or interactions with Cys6 and Cys26 of the 
regulatory subunit SUR1 [107, 109]. Despite the large number of 
publications proving KATP channel involvement in the dilatory responses 
to H2S, H2S-induced vascular relaxation is only partially inhibited by 
glibenclamide [28, 42, 76, 414]. There are also instances where KATP 
channel inhibition does not attenuate H2S-induced vasorelaxation [112, 
117]. Based on the ability of H2S to increase cGMP levels in vascular 
tissues, herein we investigated the role of this cyclic nucleotide in H2S-
induced vasorelaxation and the interaction between cGMP-regulated 
pathways and KATP channels in mediating the effects of H2S. As we have 
previously shown that H2S inhibits PDE activity [125], initially, we 
sought to determine whether H2S-triggered relaxation is mediated by 
inhibition of PDE. Inhibition of PDE5 by sildenafil blocks cGMP 
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breakdown and leads to a reduction in vascular tone [415]. PDE5 
blockade has been shown to potentiate the vasodilatory action of NO 
donors in the aorta [415]. In our experimental setup we confirmed that 
pre-treatment of mouse aortic rings with sildenafil potentiated the 
dilatory response to SNAP. In contrast, pre-incubation with sildenafil 
lead to a rightward shift and reduced the maximal response to NaHS, 
suggesting that H2S, at least in part, relaxes vascular tissue by inhibiting 
PDE5. To obtain additional evidence that H2S regulates cGMP levels we 
used tissues from CSE
-/-
 mice. Under basal conditions cGMP levels in the 
aorta and mesenteric artery were lower in CSE
-/-
 compared to wild-type 
controls. In addition, although a significant increase in cGMP levels was 
observed after exposure to a NO donor in vessels from wt animals, no 
such increase was seen in CSE
-/-
 Taken together this data suggest that 
H2S relaxes blood vessels by modulating cGMP levels. We next sought 
to determine the signalling pathways downstream of cGMP that become 
activated after H2S exposure and lead to vasodilation. cGMP is known to 
activate cGMP-dependent protein kinases and to modulate the activity of 
cGMP-gated ion channels and phosphodiesterases [416]. To evaluate the 
ability of NaHS to activate PKG we used VASP phosphorylation on 
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Ser239, a site that is preferentially phosphorylated by PKG. 
Phosphorylation of this VASP residue in vascular extracts is widely used 
as an index of NO/cGMP pathway activity [417]. Exposure of aortic 
rings to NaHS resulted in a time-dependent phosphorylation [416]. In 
agreement with our findings, relaxation in response to H2S in the mouse 
gastric fundus is partially blocked by a MLCP inhibitor [418]. So far, 
studies designed to evaluate the role of cGMP in H2S-induced relaxation 
have reported mostly negative results. In many cases authors were unable 
to inhibit NaHS-stimulated relaxation by inhibiting soluble guanylyl 
cyclase activity (sGC) [42, 101, 112, 419]. cGMP levels might still rise 
in response to H2S donors in ODQ-treated tissues, as PDE rather than 
sGC is the target for H2S; cGMP in vascular tissues incubated with ODQ 
can be synthesized by the basal sGC activity (ODQ does not inhibit basal 
sGC activity [420]), as well as through natriuretic peptide receptors. In 
our next series of experiments we utilized GYY4137, a slow releasing 
H2S donor and determined the contribution of cGMP/PKG pathway to 
vasorelaxation. In line with previous findings, GYY4137 relaxed pre-
contracted aortic rings [95], but elicited a smaller dilatory response with 
slower kinetics; maximal relaxation to GYY4137 was 46% and took 90–
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120 min to occur, while NaHS relaxed aortic rings >80% within 30 min. 
Another striking difference between the two donors was their differential 
sensitivity to PKG inhibition. Unlike what was observed with NaHS, 
GYY4137-induced relaxation was not inhibited by DT-2. Also, exposure 
of smooth muscle cells to GYY4137 at concentrations below 0.3 mM 
failed to enhance cGMP levels in smooth muscle cells. The difference in 
the rate of H2S release and thus the concentrations of H2S achieved after 
administration of a given dose of each H2S donor could explain the 
difference in their ability to inhibit PDE and enhance cGMP levels in 
cells. Although it is frequently claimed and intuitively makes sense that 
slow H2S release from donors is more physiologically relevant, 
endogenous H2S production has never been compared to the rate of H2S 
release from this slow H2S donor, neither has the half-life of GYY4137 
been determined in any biological system, in vitro or in vivo. The time 
required for GYY4137 to elicit vasorelaxation, compared to the fast 
responses triggered by L-cysteine, indicates that it might require 
bioactivation or that GYY4137 releases H2S at a much slower rate than 
that produced endogenously. In line with the minimal amounts of H2S 
liberated from this donor, when high GYY4137 concentrations are used, 
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PDE inhibition becomes apparent. Thus, one might hypothesize that 
lower GYY4137 concentrations that trigger sub-maximal vasodilation 
occur through cGMP-independent pathways (this would represent the 
50% residual dilation seen in PKG-I
-/-
 animals after NaHS), while at 
higher H2S concentrations cGMP pathways become important. In 
addition to the herein presented finding that the fast H2S donor NaHS 
increases cGMP levels in smooth muscle cells, we have demonstrated 
that slow releasing H2S donors (thioglycine, thiovaline) are also capable 
of increasing cGMP in this cell type [421]. Taken together our findings 
suggest that researchers utilizing different H2S donors with varying half-
lives and modes of H2S release, should not assume the participation of 
cGMP/PKG pathways in the observed responses, but should rather 
determine cGMP levels and PKG activation after application of the donor 
in their system. DT-2 is a peptide inhibitor that was originally described 
as being highly selective for the PKG isoform expressed in vessels, PKG-
I [422]. It is 1000-foldmore selective for PKG vs. PKA and exhibits a 
100-fold selectivity for PKG-I vs. PKG-II. However, questions regarding 
the behaviour and specificity of this inhibitor in intact cells have emerged 
[423]. Gambaryan et al., reported that DT-2 modulated the activity of 
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ERK, p38, PKB and PKC. To prove the involvement of PKG-I in H2S-
induced vasodilation we used a genetic model. Mice with targeted 
disruption of the PKG-I locus exhibited a reduced maximal relaxing 
response to NaHS. To test if endogenously produced H2S also reduces 
vessel tone through PKG-I activation, vessels were exposed to L-cysteine 
and vascular tone determined. Similarly to what was observed with 
NaHS, relaxations to L-cysteine were reduced in the PKG-I
-/-
 animals, 
providing genetic evidence that relaxation in response to both 
exogenously applied H2S (NaHS) and endogenously produced H2S are 
mediated in part through PKG-I. Moreover, inhibition of KATP channels 
with glibenclamide led to an inhibition of NaHS-induced vasorelaxation 
in rings from wildtype mice, that was of similar magnitude to that 
observed in PKGI
-/-
 animals. It should be emphasized that glibenclamide 
did not exhibit an additional inhibitory effect on NaHS dilations in PKG-
I
-/-
 mice, suggesting that KATP and PKG-I work in tandem to promote 
vasorelaxation. Evidence that PKG activates KATP channels in the 
cardiovascular system has been previously reported [424-427]. It should 
however be noted that a substantial relaxation (approximately 50%) was 
still observed in the vessels of PKG
-/-
 mice, providing proof that 
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additional pathways become activated by NaHS and allow H2S to reduce 
vessel tone. The KATP-insensitive dilatory response to NaHS might occur 
through voltage-dependent K
+
 channels [414], and intracellular 
acidification through activation of Cl
-
/HCO3
-
 [428]. The relative 
contribution of cGMP/PKG pathways vs alternative pathways in H2S 
vasorelaxation are expected to vary with the vascular bed and species 
studied. In addition to the relaxing effect of NaHS on pre-contracted 
rings, we also observed that NaHS administration in vivo reduced systolic 
blood pressure in a DT-2 sensitive manner. However, since the 
requirement for PKG-I in the drop in blood pressure elicited by NaHS 
was only shown using a pharmacological inhibitor for which concerns 
have been raised [423], ultimate proof that PKG-I mediates the reduction 
in mean arterial blood pressure triggered by H2S will have to await 
conformation by a genetic model. In the course of our experiments we 
noticed that L-cysteine exerted a somewhat smaller effect in the aortic 
rings of the control mice (WT) compared to the dilation we routinely get 
in response to this H2S synthesis substrate. As the PKG-I-/- mice have 
been generated on a 129/Sv genetic background, we compared L-
cysteine-induced relaxation in CD-1 and 129/Sv mice. Indeed, we 
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observed that L-cysteine-induced relaxations were attenuated in 129/Sv 
mice compared to CD-1 and this reduced response correlated with a 
lower expression of CSE in the vessels of 129/Sv animals. It should also 
be noted that relaxation of aortic rings from C57BL/6J mice are even 
smaller (approximately 15%, data not shown). These observations taken 
together confirm that strain differences in H2S responses do exist, adding 
another level of complexity when comparing data from different studies. 
Zhao et al [42] have previously shown that CSE, but not CBS, is 
expressed in the endothelium-free rat pulmonary artery, mesenteric 
artery, tail artery and aorta; they also proposed that CSE localizes to the 
smooth muscle cell layer of blood vessels. It later became apparent that 
cultured endothelial cells, as well as the endothelium in native vessels 
express CSE [43, 193, 429]. To determine the relative functional 
importance of each layer in H2S dilation, we tested the ability of 
endothelium-intact and endothelium-denuded aortic rings to relax to L-
cysteine. Removal of the endothelium resulted in a significant decrease 
of L-cysteine stimulated relaxation without affecting that ability of NaHS 
to dilate the vessels. On the other hand, we observed that in the mouse 
aorta, CSE is primarily expressed in the smooth muscle cell layer; 
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however, lower CSE levels are present in the endothelium. The 
significant effect of endothelial denudation in L-cysteine dilation could 
be attributed to the fact that removal of the endothelial lining results in 
loss of NO production. Lack of NO is expected to inhibit H2S responses 
as the action of the two gasotransmitters on vascular tone and 
angiogenesis has been shown to be interdependent [430]. In summary, 
we have provided pharmacological and genetic evidence for the existence 
of a cGMP/PKG pathway downstream of H2S that regulates vascular 
tone. The two vasodilatory gasotransmitters, H2S and NO, regulate 
contractility by acting on the degradation and synthesis of cGMP, 
respectively. Convergence of the two pathways on the same effector 
(PKG) in the vessel wall, would allow for the fine-tuning of vascular 
tone, but also provide the redundancy needed to maintain vascular 
homeostasis and prevent disease development. 
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Chapter 6 
MATERIALS AND METHODS II 
6.1 Animals and systolic blood pressure measurements 
Male spontaneously hypertensive rats (SHR) and control Wistar 
Kyoto (WKY) rats 8 weeks old were purchased from Charles River 
and kept in animal care facility under controlled temperature, 
humidity and light/dark cycle and with food and water ad libitum. Rat 
systolic blood pressure (SBP) was monitored in conscious animals 
twice a week by using BP Recorder 58500 (Ugo Basile, Milano, Italy) 
in an ad hoc pre-warmed room within the animal care facility. All 
animal procedures were performed according to the Declaration of 
Helsinki (European Union guidelines on use of animals in scientific 
experiments) ARRIVE guidelines and authorised by Centro Servizi 
Veterinari Università degli Studi di Napoli “Federico II”. 
6.2 Drugs and reagents 
All reagents for Krebs buffer solution preparation were purchased 
from Carlo Erba Reagents (Milano, Italy). Phenylephrine (PE), 
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Acetylcholine (Ach) and L-cys were instead purchased from Sigma-
Aldrich (Milano, Italy). Experiments were performed by using 
zofenopril or its water-soluble metabolite zofenoprilat. In particular 
we used S-zofenopril calcium salt, the diasteiroisomers S-zofenoprilat 
sodium and R-zofenoprilat sodium salt. Enalapril and its active 
metabolite enalaprilat were used as a non-sulphydrylated ACE 
inhibitor control. All ACE inhibitors were supplied by Menarini 
Research group (Firenze, Italy).  
6.3 Experimental design: in vivo study 
SHR and WKY rats of 8 weeks of age have been employed. Systolic 
blood pressure (SBP) was monitored for 4-6 weeks until hypertension 
was developed in SHR and a statistical difference (p<0.05) in pressure 
values was reached between SHR and WKY strains. Rats were 
divided in six different treatment groups (n=10 for each group) and 
organized as follows:  
 -SHR: vehicle, zofenopril and enalapril. 
-WKY: vehicle, zofenopril and enalapril 
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 Drug treatment was carried out on a daily basis for two weeks by 
using either 10mg/kg of zofenopril or 6mg/kg of enalapril, in 0.2% 
carboxymethylcellulose, per gavage. SBP was monitored during the 
treatment. After two weeks, animals were sacrificed. Carotid and 
aorta were harvested and ex vivo vascular reactivity assessed. 
Vascular tissues obtained were also used for western blot analysis and 
H2S determination. Blood samples were also collected in order to 
measure H2S levels. Zofenopril is a mixture of diasteroisomers and 
the active diasteiroisomer normally employed in therapy is the S 
isoform. Indeed, R-zofenoprilat has an ACE IC50 of 1700nM while the 
S isoform IC50 is 10.9 nM [437]. In another set of experiments, we 
evaluated blood pressure changes following treatment in vivo with S-
zofenopril water soluble metabolites S-zofenoprilat or its inactive 
diastereoisomer R-zofenoprilat, at a dose that does not inhibit ACE 
[437]. Similarly to above, an ex vivo analysis of the aorta and carotid 
reactivity was performed.  
6.4 Experimental design: ex vivo study 
Rings from aortic and carotid arteries were mounted in an isolated 
organ bath system filled with Krebs’ buffer solution (mmol/L: 115.3 
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NaCl, 4.9 KCl, 1.46 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 25.0 NaHCO3 
and 11.1 glucose) at 37°C and gassed with O2/CO2 mixture 
(95%/5%). Organ baths were equipped with force transducer 
(FORT10, Ugo Basile, Milano, Italy) connected to the acquisition 
data system PowerLab (ADInstruments, Colorado Springs, CO, US) 
with a computerized system where changes in tension were 
continuously measured. The rings were stretched until a resting 
tension of 1.5 g (for carotid) or 0.5 g (for aorta) was reached and 
allowed to equilibrate for at least 45 min, during which time tension 
was adjusted, as necessary, to the resting tension and bathing solution 
was periodically changed. In each experiment, rings were first 
challenged with PE (1 µM) until the responses were reproducible. The 
rings were then washed and contracted with PE (1 µM) and, once a 
plateau was reached, a cumulative concentration-response curve of 
Ach (0.1nmol/L-30µmol/L) or L-cys (0.1µmol/L-10mmol/L). 
6.5 Western blot analysis 
Aortic and carotid tissues were homogenized in modified RIPA buffer 
(50mmol/L Tris-HCl, pH 7.4, 1% v/v Triton, 0.25% w/v sodium 
deoxycholate, 150mmol/L sodium chloride, 1mmol/L EDTA, 
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1mmol/L phenylmethanesulphonylfluoride, 10mg/ml aprotinin, 
20mmol/L leupeptin and 50mmol/L sodium fluoride). The denatured 
proteins (40 µg) were separated on 10% sodium dodecyl sulphate 
polyacrylamide gels and transferred to a polyvinylidene fluoride 
membrane (PVDF).  Membranes were blocked in phosphate buffered 
saline containing 0.1% v/v Tween 20 (PBST) and 3% w/v non-fat dry 
milk for 30 minutes, followed by overnight incubation at 4°C with 
rabbit polyclonal CBS (1:1000) or mouse monoclonal CSE (1:500) 
antibody (Santa Cruz Biotechnology Inc, Hidelberg, Germany). 
Mouse anti-ACE antibody has also been tested (1:500, Santa Cruz 
Biotechnology Inc, Heidelberg, Germany). Membranes were 
extensively washed in PBST prior incubation with horseradish 
peroxidase conjugated secondary antibody for 2h. After incubation, 
membranes were washed and developed using Image Quant 400 (GE 
Healthcare, US). Mouse anti-β-actin antibody has been used as 
loading control (1:5000, Sigma-Aldrich, Milano, Italy). 
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6.6 H2S quantification assays 
6.6.1 Methylene blue assay-Tissue CSE/CBS activity assay 
Tissue H2S production rate was measured by using Stipanuk and Beck 
based assay with modifications [25, 194, 419]. Briefly, aorta and 
carotid vessels were homogenized in lysis buffer containing 
potassium phosphate buffer 100mmol/L pH 7.4, 10mM sodium 
orthovanadate and proteases inhibitors. Protein concentration was 
determined by using Bradford assay (Bio-Rad Laboratories, Milano, 
Italy). Homogenates were added to a reaction mixture (total volume 
500µL) containing pyridoxal-5’-phosphate (2mmol/L, 20µL), L-cys 
(10mmol/L, 20µL) and saline (30µL). The reaction was performed in 
sealed eppendorf tubes and initiated by transferring tubes from ice to a 
water bath at 37°C. After 40 min incubation, zinc acetate (1% w/v, 
250µL) was added followed by trichloroacetic acid (10% w/v, 
250µL). Subsequently, N,N-dimethylphenylendiamine sulphate 
(20mmol/L, 133µL) in 7.2mol/L HCl and FeCl3 (30mmol/L, 133µL) 
in 1.2mol/L HCl were added and solution optical absorbance was 
measured after 20 min at a wavelength of 650 nm. All samples were 
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assayed in duplicate and H2S concentration was calculated against a 
calibration curve of NaHS (3.12–250µmol/L).  
6.6.2 Methylene blue assay-Plasmatic levels of H2S measurement 
Plasmatic levels of H2S were determined in absence of L-cys in the 
reaction mixture. Results were expressed as µM concentration. H2S 
determination in plasma samples was performed as follows: each 
sample (100µL) was added into eppendorf tubes containing 
trichloroacetic acid (10% w/v, 300µL), in order to allow protein 
precipitation. Supernatant was collected after centrifugation and  zinc 
acetate (1% w/v 150µL) was then added. Subsequently, N,N-
dimethylphenylendiamine sulphate (20mmol/L, 100µL) in 7.2mol/L 
HCl and FeCl3 (30mmol/L, 133µL) in 1.2mol/L HCl was added to 
each tube and absorbance measured after 20 min at a wavelength of 
650 nm. All samples were assayed in duplicate and H2S concentration 
was calculated against a calibration curve of NaHS (3.12–
250µmol/L). All chemicals used in this assay were purchased at 
Sigma-Aldrich (Milano, Italy). 
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6.6.3 Fluorimetric assay 
The fluorimetric determination of H2S released by zofenoprilat was 
performed according to a method previously described [439] with 
modifications. Briefly, vehicle or the indicated concentration of 
zofenoprilat was placed in a black 96-well microplate. Hank's 
Balanced Salt Solution (HBSS, Cat. No. 14025, Invitrogen, at pH 7.4) 
containing dibromobimane (250 μM) was then added into the well and 
fluorescence was measured immediately in a plate reader at 360/465 
nm excitation/emission (GENios, Tecan) every 1 min over a 30 min 
period. The amount of H2S (measured as thiobimane) was expressed 
as relative fluorescence unit (RFU). In experiments designed to 
quench H2S, hemoglobin (10μΜ) was mixed with zofenoprilat before 
adding dibromobinane. All reactions were performed in triplicate. 
6.6.4 Amperometric assay 
The amperometric assay was performed by an Apollo-4000 Free 
Radical Analyzer (WPI) detector and 2mm H2S-selective 
minielectrodes [95]. Following the manifacturer’s instructions, a PBS 
buffer 10x was prepared (NaH2PO4xH2O 1.28 g, Na2HPO4 x12H2O 
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5.97 g, NaCl 43.88 g in 500ml H2O) and stocked at 4°C. Immediately 
before the experiment, the PBS buffer 10x was diluted in distilled 
water (1:10), to obtain the assay buffer; pH was adjusted to 7.4. The 
H2S-selective minielectrode was equilibrated in 10ml of the assay 
buffer, until recovery of a stable baseline was achieved. Then 100µL 
of an aqueous solution of Zofenoprilat were added, at the final 
concentration of 1 mM. The H2S generation was monitored for 20min. 
When required by the experimental protocol, L-cys (4 mM) was 
added, before the zofenoprilat. The correct relationship between the 
amperometric currents (recorded in nA) and the corresponding 
concentrations of H2S were determined by opportune calibration 
curves, which were previously obtained by the use of increasing 
concentrations of NaHS (1µM, 3µM, 5µM, 10µM) at pH 4.0. 
6.7 Statistical analysis 
All data were expressed as mean±SEM. Statistical analysis was 
performed by using one-way ANOVA and Dunnet as post-test, or 
two-way ANOVA and Bonferroni as post-test where required 
(GraphPad software, San Diego, CA, US). Differences were 
considered statistically significant with a P value less than 0.05. 
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Chapter 7 
RESULTS II 
7.1 Blood pressure changes following ACE inhibition 
Animals received daily drug treatment by oral gavage administration 
and SBP was monitored as described. SHR rats treated with vehicle 
showed a significant increase in SBP compared to WKY (fig. 7.1A, 
P<0.001). Both S-zofenopril and enalapril significantly lowered SBP 
in SHR rats compared to vehicle group (fig. 7.1A, P<0.001). S-
zofenopril showed a greater response when compared to enalapril 
(167.5±2.5 vs 178.8±4.6 mmHg, P<0.05, n=10). Both drugs reverted 
the increase in tissue ACE expression in aorta (fig. 7.1B), but only S-
zofenopril was effective on ACE expression in carotid homogenates 
harvested from hypertensive animals (Fig. 7.1B and 7.1C).  
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Fig 7.1: Blood pressure measurements in vivo. A) Blood pressure values (SBP, 
mmHg) following two weeks treatment with S-zofenopril (ZOF) or enalapril 
(ENA) in SHR and WKY rats. Data are expressed as mean±SEM for n=10. * vs 
WKY vehicle, P<0.001; # vs SHR vehicle, P<0.001; ° vs SHR ENA, P<0.05. B) 
Expression of ACE in aortic tissue harvested from WKY or SHR rats, following 
ACE inhibitors treatment. * vs WKY vehicle, P<0.01; # vs SHR vehicle, P<0.01. 
C) Expression of ACE in carotid tissue harvested from WKY or SHR rats, 
following ACE inhibitors treatment. * vs WKY vehicle, P<0.01; # vs SHR vehicle, 
P<0.05. 40µg of total protein was loaded per each lane and β-actin has been 
used as loading control. Blots are representative of 3 different experiments. 
Optical density is expressed as arbitrary units (mean±SEM) and normalized to β-
actin expression levels as housekeeping gene. 
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7.2 Zofenopril treatment rescues endothelial dysfunction 
in hypertensive rats  
Aorta and carotid arteries were harvested from rats treated with either 
enalapril or S-zofenopril and their response to Ach assessed in vitro. 
Ach-induced relaxation was significantly impaired in SHR compared 
to WKY rats in both aorta, (fig. 7.2A P<0.001) and carotid (fig. 7.2C, 
P<0.001). S-zofenopril treatment restored the Ach-induced 
vasodilatation in both aorta (fig. 7.2B, P<0.001) and carotid (fig. 
7.2D, P<0.001).  Enalapril did not significanly modify the vascular 
response to Ach in both vessel types (fig. 7.2B, P<0.001).   
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Fig. 7.2: S-zofenopril treatment ameliorates vascular reactivity in SHR. 
Functional reactivity in vascular tissue harvested from WKY rats treated with 
vehicle ( , dashed line) and SHR rats treated with vehicle (▼), zofenopril ( , 
ZOF) or enalapril (▲, ENA). A) Ach-induced vasorelaxation in aortic rings is 
reduced in SHR rats compared to WKY, P<0.001. B) Ach-induced vasorelaxation 
is restored after S-zofenopril, but not enalapril, treatment, P<0.001. C) Ach-
induced vasorelaxation in carotid rings is reduced in SHR rats compared to 
WKY, P<0.001. D) Ach-induced vasorelaxation is restored after S-zofenopril, but 
not enalapril, treatment, P<0.001. Ach induced response is expressed as % of 
relaxation (mean±SEM for n=6). * vs WKY vehicle; # vs SHR vehicle. 
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7.3 H2S pathway is modulated following in vivo S-
zofenopril treatment 
Reduction in hydrogen sulphide levels has been associated with the 
development of hypertension in this rat strain, as reported by several 
studies [140, 431]. Therefore, we questioned whether or not 
prolonged ACE inhibition with enalapril or S-zofenopril could affect 
the H2S pathway. We first assessed CSE expression by western blot 
analysis in aorta and carotid samples harvested from treated animals. 
We found, as already reported in literature [140, 431], that expression 
of CSE in aorta samples was significantly lower in SHR compared to 
WKY rats, in naive animals (Fig. 7.3A, P<0.05). Treatment with S-
zofenopril, but not enalapril, restored CSE expression in SHR rats to 
WKY level (Fig. 7.3A, P<0.05). Interestingly, CSE expression in 
carotid arteries of SHR was significantly higher than expression in 
WKY. Neither zofenopril nor enalapril did significantly modify CSE 
expression (Fig. 7.3B, P<0.05). CBS expression was not modified 
either in the carotid or in the aorta of SHR rats when compared to 
WKY (data not shown). 
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.  
Fig. 7.3: S-zofenopril chronic treatment increases CSE expression in vascular 
tissues A) Expression of CSE protein levels in aorta lysates. B) Expression of 
CSE protein levels in carotid lysates. 40µg of total protein was loaded per each 
lane and β-actin has been used as loading control. Blots are representative of 3 
different experiments. Optical density as expressed in arbitrary units 
(mean±SEM) and normalized to β-actin expression levels as housekeeping gene. * 
vs WKY vehicle, P<0.05; # vs SHR vehicle, P<0.05. 
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7.4 S-zofenopril treatment restores tissue and plasma H2S levels 
and contributes to L-cysteine-induced vasodilatation 
H2S levels were measured both in aorta and carotid. As already 
shown, H2S levels within the aorta (fig. 7.4A) and the carotid (fig. 
7.4B) of SHR animals were significantly lower than WKY [140, 431]. 
S-zofenopril restored H2S values to WKY levels in the aorta (fig. 
7.4A, P<0.01), as opposite to enalapril (fig. 7.4A). In the carotid there 
was no significant reduction of H2S levels between WKY and SHR. 
However, H2S levels were significantly enhanced in carotid harvested 
from SHR rat treated with S-zofenopril (fig. 7.4B).  Treatment with 
either S-zofenopril or enalapril did not affect H2S production in WKY 
rats. Plasma H2S values observed were significantly lower in SHR rats 
compared to WKY (fig. 7.4C, P<0.05). S-zofenopril treatment 
restored H2S plasma concentration to WKY levels (fig. 7.4C, 
P<0.05), while enalapril did not modify H2S plasma levels (fig. 7.4C). 
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Fig. 7.4: Tissue and plasmatic levels of H2S are restored by S-
zofenopril  chronic administration in vivo. A) H2S production rate in 
aorta harvested from WKY and SHR rats treated with vehicle, S-zofenopril or 
enalapril, after 40 minutes incubation in presence of L-cysteine as substrate. B) 
H2S production rate in carotid harvested from WKY and SHR rats treated with 
vehicle, S-zofenopril or enalapril, after 40 minutes incubation in presence of L-
cysteine as substrate. C) H2S levels determination in plasma samples. Data are 
expressed as mean±SEM for n=6. * vs WKY vehicle, P<0.05; # vs SHR vehicle, 
P<0.05. 
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In another set of experiments, concentration-response curves of L-cys 
were performed in vitro. The vasorelaxant effect induced by L-cys on 
either aorta (Fig. 7.5A), or carotid (Fig. 7.5C) harvested from SHR 
rats was not significantly different from the response obtained in 
WKY. However, S-zofenopril, but not enalapril treatment, enhanced 
L-cys- induced vasodilatation in aorta (Fig. 7.5B; P<0.05) and carotid 
rings (Fig. 7.5D; P<0.01) from SHR strain. 
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Fig. 7.5: L—cys-stimulated vasorelaxation is enhanced following zofenopril 
treatment. L-cys-induced vasorelaxation in aortic rings from WKY rats treated 
with vehicle ( , dashed line) and SHR rats treated with vehicle (▼), zofenopril (
, ZOF) or enalapril (▲, ENA). A) L-cys-induced vasorelaxation in aortic rings 
is slightly, though not significantly, reduced in SHR rats compared to WKY. B) L-
cys-induced vasorelaxation is significantly enhanced in aorta of S-zofenopril 
treated animals, P<0.05. C) L-cys vasodilation does not significantly change 
between carotid rings harvested from SHR compared to WKY rats. D) S-
zofenopril treatment significantly increases vasorelaxation induced by L-cys 
administration in carotid rings, compared to vehicle treated animals, P<0.01. 
Data are expressed as mean±SEM for n=6. # vs SHR vehicle. 
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7.5 S-zofenopril acts as an H2S donor  
In order to evaluate if S-zofenopril can act as an H2S donor we 
measured the H2S release in vitro by using S-zofenoprilat, the active 
metabolite bearing the free thiol. The evaluation was performed by 
using two different analytical approaches, a fluorimetric and an 
amperometric assay in order to overcome the bias due to the coloured 
S-zofenoprilat solution. The amperometric assay showed that S-
zofenoprilat spontaneously released H2S in solution and that H2S 
release can be triggered by addition of a nucleophilic substance, such 
as L-cys (Fig. 7.6C). In order to further confirm these data we 
performed measurements in a fluorimetric assay. Also in this case 
zofenoprilat caused a time-dependent H2S release. The fluorescent 
signal is significantly inhibited by haemoglobin (Hg), a H2S 
scavenger (Fig. 7.6A). As expected, zofenopril, the prodrug, did not 
release H2S. In parallel, we also assessed that H2S is released by S-
zofenoprilat in a concentration-dependent manner (Fig. 7.6B). These 
findings were further supported by amperometric assay, confirming 
that H2S is released by S-zofenoprilat, especially in presence of L-cys, 
used in this case as a nucleophilic trigger (Fig. 7.6C).  
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Fig. 7.6: S-zofenoprilat releases H2S.  Free H2S release determination. A) Time-
dependent release of H2S by S-zofenoprilat 
dibromobinane (0.25 mM) and fluorescence was measured every 2 min, P<0.001. 
S-zofenopril (♦, ZOF, 0.1mM) shows no H2S release and haemoglobin ( , Hg, 
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10µM) reduces the amount of H2S detected from S-zofenoprilat (ZAT), P<0.01. 
Data are presented as means+SEM for n=4. * vs vehicle (○, CTR); # vs ZAT. B) 
H2S release from different concentration of S-zofenoprilat in DMEM, quantified 
again by using dibromobimane fluorimetric determination. C) Amperometric 
measurement vs time of H2S release in aqueous buffer, P<0.05. *vs S-
zofenoprilat. D) Vasorelaxant effect of S-zofenoprilat ( , ZAT) vs enalprilat (▲, 
ENAT) in rat isolated aortic rings. Data are expressed as mean±SEM for n=6. * 
vs ENA). 
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7.6 ACE is involved in H2S pathway activation 
In order to further define the role of the thiol group we treated SHR 
rats in vivo with either the inactive form of zofenoprilat on ACE 
activity, namely R-zofenoprilat vs the active metabolite S-
zofenoprilat. As expected, S-zofenoprilat significantly lowered blood 
pressure, while R-zofenoprilat did not (Fig. 7.7A). R-zofenoprilat, 
despite the lack of effect on blood pressure, was as active as S-
zofenoprilat in restoring the vascular response to Ach in both aorta 
(Fig. 7.7B) and carotid (Fig. 7.7C). The treatment with either R-
zofenoprilat or S-zofenoprilat, restored H2S levels in aorta (Fig. 
7.8A), carotid (Fig. 7.8B), as well as in plasma samples (Fig. 7.8C).  
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Fig. 7.7: R-zofenoprilat treatment  does not affect blood pressure, but improves 
Ach-induced vasorelaxation A) Blood pressure values (SBP, mmHg) following two 
weeks treatment with S-zofenopril (ZOF), S-zofenoprilat (S-ZAT) or R-zofenoprilat 
(R-ZAT) in SHR rats. Data are expressed as mean±SEM for n=10. * vs WKY vehicle, 
P<0.001; # vs SHR vehicle, P<0.001; ° vs SHR ENA, P<0.05. B) Functional 
reactivity in vascular tissues harvested from SHR rats treated with vehicle ( , dashed 
line), S-zofenopril ( , ZOF), S-zofenoprilat (●,S-ZAT) or R-zofenoprilat (♦, R-ZAT) . 
Ach-induced vasorelaxation in aortic rings is reduced in SHR rats compared to WKY, 
P<0.001, but it is restored following, S-zofenopril, S-zofenoprilat or R-zofenoprilat, 
but not enalapril, treatment, P<0.001. C) Ach-induced vasorelaxation in carotid 
rings is reduced in SHR rats compared to WKY, P<0.001, while it is restored after S-
zofenopril, S-zofenoprilat or R-zofenoprilat, but not enalapril, treatment, P<0.001. 
Ach induced response is expressed as % of relaxation (mean±SEM for n=6). # vs 
SHR vehicle. 
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Figure 7.8: Both S-zofenoprilat and R-sofenoprilat restores plasmatic and tissue 
levels of H2S. A) H2S production rate in aorta harvested from WKY and SHR rats 
treated with vehicle, S-zofenopril, S-zofenoprilat or R-zofenoprilat, after 40 minutes 
incubation in presence of L-cysteine as substrate. B) H2S production rate in carotid 
harvested from WKY and SHR rats treated with vehicle, S-zofenopril, S-zofenoprilat 
or R-zofenoprilat, after 40 minutes incubation in presence of L-cysteine as substrate. 
C) H2S levels determination in plasma samples. Data are expressed as mean±SEM 
for n=6. * vs WKY vehicle, P<0.05; # vs SHR vehicle, P<0.05. 
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Chapter 8 
DISCUSSION II 
Clinical evidences have accumulated demonstrating that sulfhydrylated 
ACE inhibitors have some additional beneficial effects not related to 
ACE inhibition [340, 432-434]. Zofenopril is a highly lipophilic ACE 
inhibitor characterised by long-lasting tissue penetration that has 
cardioprotective properties and attenuates ventricular remodelling in 
animal models of myocardial injury. In particular the additional 
beneficial effects of zofenopril have been ascribed to the presence of the 
thiol group. Our working hypothesis was that the active metabolite of 
zofenopril e.g. zofenoprilat, bearing a free thiol, could act in vivo through 
modulation of the H2S pathway accounting for the beneficial effect 
generically ascribed, in the current literature, to antioxidant activity. The 
study has been performed in vivo by comparing zofenopril to a non 
sulphydrylated ACE inhibitor belonging to the carboxylic class widely 
used in clinic, e.g. enalapril. Both enalapril and zofenopril are pro-drugs 
that are metabolized in vivo to their respective active form enalaprilat 
and zofenoprilat. In order to define which was the contribution of H2S in 
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zofenopril action, we used SHR rats as model of hypertension. SHR rats 
and their matched control WKY were treated with S-zofenopril and 
enalapril at doses already known to cause a maximal reduction in blood 
pressure in this preclinical animal model [435]. As expected, both ACE 
inhibitors reduced blood pressure as well as ACE expression in both rat 
aorta and carotid in SHR rats. However, zofenopril was significantly 
more effective than enalapril in lowering blood pressure in vivo. The in 
vitro study demonstrated that Ach-induced vasorelaxation was 
significantly reduced in both isolated aorta and carotid harvested from 
SHR rats when compared to WKY as already described. S-zofenopril 
treatment rescued vascular responsiveness to Ach to WKY levels. 
Conversely, enalapril did not significantly modify such a response. This 
result strongly implied that the vascular effect exerted by zofenopril 
treatment was not to be ascribed solely to ACE inhibition but it involves 
additional mechanism(s). The most widely known additional mechanism 
through which ACE inhibitors works involves the inhibition of the 
degradation of bradykinin thereby promoting the generation of nitric 
oxide within the endothelium. The importance of this mechanism in 
driving the extra effect of ACE has been also clinically demonstrated in 
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patients by blocking the bradykinin receptor [436]. However, since in our 
condition both enalapril and zofenopril do inhibit ACE, it is clear that 
zofenopril possesses an additive effect over enalapril, the non-
sulphydrylated ACE. Expression of CSE, as well as H2S plasma levels, 
has been shown to be reduced in SHR rats [140, 431]. In line with these 
data S-zofenopril, but not enalapril, restored CSE expression in analysed 
vascular tissues as well as plasma and tissue H2S levels. These data 
implies that following in vivo administration of S-zofenopril there is an 
amelioration or, in other words, a re-assessment of the L-cysteine/H2S 
pathway within the vessels that restores Ach response. This hypothesis is 
sustained by the finding that L-cysteine-induced vasorelaxation, 
evaluated on both types of isolated vessels, was significantly enhanced 
exclusively following in vivo S-zofenopril treatment. In summary the  in 
vivo treatment with S-zofenopril, as opposed to enalapril, in both vessels 
types analysed (resistance-carotid and capacitance-aorta)  restores  i)  the 
Ach-induced relaxation; ii) the tissue and plasma H2S levels iii)  CSE 
expression coupled to an enhancement of the response to L-cysteine.  
These findings strongly support our hypothesis that S-zofenopril, once 
converted into S-zofenoprilat, up-regulates H2S pathways within the 
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vessel wall. We next asked whether S-zofenoprilat could itself release 
H2S in addition to up regulating its endogenous production. In order to 
answer to this question, and to further demonstrate that zofenopril 
additional effects do involve H2S, we run two different in vitro cell free 
assays to test whether S-zofenoprilat can release H2S. The widely used 
methylene blue based colorimetric assay could not be employed since 
zofenoprilat colours the solution and interferes with the assay. Therefore 
we utilized two different approaches by using a fluorimetric and an 
amperometric based assays. Both assays clearly demonstrated that S-
zofenoprilat can release H2S. In the assay performed with the fluorescent 
probe zofenoprilat, but not zofenopril, released H2S and the fluorescent 
signal could be significantly inhibited by haemoglobin. The 
amperometric assay confirmed that zofenoprilat can slowly release H2S 
in solution and that this can be further increased by adding L-cysteine. 
The use of L-cysteine in the assay did not only stem from the idea that 
H2S release from zofenoprilat is facilitated by  nucleophilic substances, 
but was also based on the observation  that the metabolism of 
zofenoprilat involves cysteine conjugation, as demonstrated by using 
radiolabelled zofenopril. The ability to release in vitro H2S was also 
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confirmed by the finding that s-zofenoprilat, but not enalprilat, relaxes in 
a concentration dependent manner the isolated rat aorta. These findings 
imply that following in vivo treatment with zofenopril, S-zofenoprilat 
could supply a tonic pulse of H2S by slowly releasing it within the 
cellular environment, where the ACE resides, leading to the beneficial 
vascular effects above described. In other words following the binding of 
zofenoprilat to endothelial ACE, H2S is delivered locally. The vascular 
effect observed is also in line with the finding that S-zofenopril exerts a 
preferential inhibition on ACE expressed within the tissue, where it is 
metabolized to S-zofenoprilat, rather than on the plasma isoform. This 
effect is evident only when vascular homeostasis is disrupted since 
changes in H2S do not play a role in physiological conditions as 
demonstrated by the parallel experiments performed on tissues harvested 
by WKY rats.   
Zofenopril is a mixture of diasteroisomers and the active diasteiroisomer, 
as ACE inhibitor, is the S form. R-zofenoprilat has an IC50 of 1700nM 
while the S isoform IC50 is 10.9 nM [437].  In order to further strengthen 
our findings regarding the role of H2S in the action of Zofenopril, we 
dosed SHR rats with either the R- or S- diastereoisomer of zofenoprilat . 
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R-zofenoprilat treatment did not reduce blood pressure in SHR rats in 
contrast to S-zofenoprilat. As expected, due to the first pass metabolism, 
the active metabolite S-zofenoprilat was less active in lowering blood 
pressure, compared to zofenopril. However, the Ach-induced 
vasorelaxation in both carotid and aorta from SHR rats were rescued by 
both isoforms of zofenoprilat. Furthermore, H2S levels found in tissues 
and plasma of R-zofenoprilat treated animals were identical to the ones 
observed in S-zofenoprilat treated group. These data further confirm that 
the modulation of the H2S pathway by zofenopril represents an additional 
mechanism that is unrelated to ACE inhibition.  
In conclusion, we show here that sulfhydrylated ACE inhibitor zofenopril 
represents a unique molecule that up regulates the activity of the H2S 
pathway in vivo. In line with this hypothesis it has been demonstrated 
that zofenopril, but not rampipril or atenolol, ameliorates flow-mediated 
dilation in hypertensive patients [438]. Overall these findings confirm 
that H2S plays an important role in cardiovascular homeostasis and 
provide proof of concept for the development of H2S-releasing 
therapeutic agents in cardiovascular disease therapy.  
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Chapter 9 
INTRODUCTION 
9.1 Reticulon 4B/Nogo-B: from ER structural protein to 
vascular function 
Nogo-B belongs to the family of reticulon proteins (RTN), which are 
a large, ubiquitously expressed group of eukaryotic proteins ranging 
in size from 200 to 1200 amino acids. They are characterized by 
compartimentalization to the endoplasmic reticulum (ER) membrane. 
ER is an eukaryotic organelle with the most architecturally shape. It is 
composed of a nuclear envelope, sheet-like cisternae interrupted by 
nuclear pores and stabilized by connections to the underlying lamina, 
and a polygonal array of tubules connected by three-way junctions 
extended throughout the periphery of the cell [300-303] (Fig. 9.1). 
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Fig. 9.1: ER structure. It consists of two different shaped domains: the nuclear 
envelope (NE) and the peripheral ER. The NE consists of two continuous sheets of 
membranes, connected to one another at nuclear pores. The peripheral ER 
consists of a network of membrane tubules connected by three-way junctions. 
All these structural regions exist within the continuous membrane 
bilayer and therefore must be maintained by proteins that partition as 
they generate these ER domains [301]. ER sheets are flat, extended 
surfaces with little membrane curvature. ER tubules are long and 
cylindrical with high membrane curvature and intersect to form an 
elaborate network that pervades the cytoplasm [303]. The thickness of 
sheets and diameter of tubules varies depending on the cell type, but 
tipically is around 60-100nm suggesting that both domains are being 
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shaped actively [301]. These distinct morphological ER domains have 
drawn the attention of researchers not only because of their 
morphology, but also because of their critical functions. ER sheets are 
often characterized by the presence of membrane bound ribosomes 
(rough ER, RER) and perform all functions associated with the 
biosynthesis of membrane and secreted proteins, including the control 
of their proper folding and modification. Conversely, ER tubules are 
mainly formed of smooth ribosom-free ER (SER) and possibly 
involved in lipid biosynthesis, delivery as well as Ca
2+
 signaling. 
Defects in ER morphology, particularly the loss of tubular ER, can 
cause retarded growth in budding yeast and decreased embryonic 
survival in Caenorhabditis elegans [363, 364], as well as a 
neurodegenerative disease known as hereditary spastic paraplegia 
(HSP) in humans [365]. These facts strongly suggest that vital 
functions of the ER rely on its morphological integrity. The ER is an 
extremely dynamic organelle, which continuously undergoes 
significant rearrangement of its structure. The outgrowth and the 
retraction of tubules depend on the close association between the ER 
and the microtubules (MTs) cytoskeleton. There are two distinct 
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mechanisms whereby ER tubules move along MTs. One mechanism 
is defined as tip attachment complex (TAC) dynamics and involves 
the attachment of the tip of the ER tubule to the tip of a dynamic MT. 
During TAC dynamics, the ER tubule grows and retracts in concert 
with the dynamic of its MT partner [367]. The second mechanism is 
defined as sliding, and it is faster and much more common than TAC. 
During ER sliding events, tubules are pulled out of the ER membrane 
by the motor proteins kinesin-1 and cytoplasmic dynein along MTs 
that are marked by acetylation [368, 369]. However, although the 
cytoskeleton is required for the extension of the ER network, the 
alignment of membrane tubules with the cytoskeleton is not perfect, 
and the network does not rapidly collapse upon depolymerization of 
microtubules or actin filaments [370]. In addition, ER networks can 
be formed in vitro from small vesicles where an intact microtubule or 
actin network is not required [371]. Thus, the cytoskeleton is most 
likely unnecessary for determining or maintaining the shape of ER 
tubules. The most plausible models for shaping ER tubules are based 
on mechanisms generating or stabilizing high curvature in 
membranes. Although several different mechanisms can be 
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envisioned, recent results demonstrate that Rtn and DP1/Yop1 protein 
families are responsible for generating and maintaining ER tubules 
[364]. Deletion of these proteins in yeast or their depletion in 
mammalian cells reduce the tubulation of ER, indicating that they are 
required for tubule formation [363, 364]. The overexpression of 
reticulons or DP1/Yop1p lead to long tubules, which become resistant 
to the collapse that normally follows the depolymerization of 
microtubules, indicating that these proteins can stabilize ER tubules 
[373]. The RTNs and DP1/Yop1p might stabilize the high curvature 
of ER tubules by utilizing two cooperative mechanisms: hydrophobic 
insertion (wedging) and scaffolding [303]. The hydrophobic insertion 
mechanism is based on the two hydrophobic hairpins in these 
proteins, which are proposed to form a wedge-like structure that 
displaces the lipids preferentially in the outer leaflet of the lipid 
bilayer, thus causing local curvature. Recent studies have shown that 
both mammalian and plant reticulons suffer mislocalization and 
dysfunction when the hydrophobic segments are manipulated to 
disrupt potential hairpins [397-399]. The hairpin may be a common 
feature of integral membrane proteins that preferentially localize to 
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curved membranes. Examples of such proteins include atlastin (ATL), 
spastin, a microtubule-seveing ATPase on the ER, and caveolin-1, one 
of the major structural components of the caveoli [365, 401-404]. The 
scaffolding mechanism assumes that the reticulons and DP1/Yop1p 
form arc-like oligomers that mold the lipid bilayer into tubules. Arc-
like scaffolds, rather than rings or spirals that wrap around tubules, are 
consistent with the observation that the reticulons also localize to 
sheet edge [372]. Because arcs are not entirely encircling a tubule, 
they would not block the long-distance diffusion of other membrane 
proteins. The reticulons and DP1/Yop1p conceivably combine the 
“wedge insertion” and “scaffolding” mechanisms to shape ER tubules 
(Fig. 9.2). 
 
 
 
 
220 
 
 
Fig. 9.2: Mechanisms for shaping ER tubules. The reticulons and DP1/Yop1p 
induce and stabilize high curvature in ER tubules by inserting into the membrane 
as a “wedge” and forming an arc-like “scaffold”. 
All RTN family members contain a conserved C-terminal domain (the 
reticulon homology domain, RHD), consisting of two hydrophobic 
regions, each 28-36 amino acids long, flanking a hydrophilic loop of 
60-70 amino acids, followed by a C-terminal tail of approximately 50 
amino acids [374, 375]. In contrast to the RHD domains, the N-
termini of reticulons are completely divergent. The RHD hydrophobic 
regions are unusually long for transmembrane domains: each spans 
approximately 30-35 amino acids, whereas most transmembrane 
domains are about 20 amino acids in length. The topology of these 
hydrophobic regions within membranes is so far only partially 
221 
 
defined. The RHD loop region has been detected both on the surface 
of cells and intracellularly, and it has been suggested that the RHD 
hydrophobic regions might either span the ER membrane or plasma 
membrane completely or might double back on themselves to form a 
hairpin (Fig. 9.2). 
 
Fig. 9.3: Possible membrane topologies of Nogo. (I) The topology proposed by 
GrandPre et al. [381] placed both the N- and C-terminus facing the cytoplasm 
and the Nogo-66 domain exposed extracellularly. (II) This topology shows that 
the N-terminus of Nogo is oriented extracellularly [365] and is also supported by 
studies on Nogo-B by Acevedo et al. [392]. (III) This topology has been recently 
proposed by Voeltz et al [364]. In this model, reticulon homology domain (RHD) 
does not span the membrane, but rather form hairpin loops. 
All reticulon genes contain multiple introns and exons, and most are 
alternatively spliced into multiple isoforms [374].  In mammals, there 
are four reticulon genes encoding reticulon proteins 1-4 (RTN1-4). The 
expression patterns of different reticulons and their splice isoforms 
can be variable, even within the same organism [376-378]. Thus, there 
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is a complex array of RTN variants that are present in different 
combinations in a cell- or tissue-specific manner. An example of this 
variable pattern of expression is seen in Nogo/RTN4 expression. 
Nogo/RTN4 can give rise to 10 splice variants, of which the major 
isoforms are 3 (Fig. 9.4): Nogo-A, which is localized mainly in the 
central nervous system, whereas its splice variant RTN4B/Nogo-B is 
found in a variety of tissues, included non-neural ones [379]. The 
third splice variant RTN4C/Nogo-C was found in the CNS, but is 
particularly enriched in skeletal muscle.  
 
Fig. 9.4: The three main transcripts of mammalian RTN4/Nogo genes. They 
are characterized by conserved C-terminal RHD, but they differ in length and 
tissue distribution. 
The regulatory processes underlying these variable patterns of 
expression remain undefined. Most of the information regarding the 
function of reticulons comes from studies of RTN4A/Nogo-A as a 
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myelin-derived inhibitor of neurite outgrowth [380-382]. Its potential 
to inhibit nerve growth is shown by the fact that peripheral nerves 
regenerate well after a lesion, whereas ectopic expression of Nogo-A 
in Schwann cells leads to delayed recovery of the crushed sciatic 
nerve [405]. Analysis of the regions of Nogo-A responsible for this 
inhibition identified the RHD-localized 66-amino acid hydrophilic 
loop (Nogo-66) as a potent inhibitor of neurite outgrowth. Following 
soon thereafter, a cell surface receptor for Nogo-66 was discovered 
and named Nogo Receptor (NgR) [383]. Another region, located 
within the N-terminus of Nogo-A, was also shown to have inhibitory 
activity and has been termed A20 [383, 384]. This region inhibits 
outgrowth in NgR-independent manner, yet a receptor associated with 
binding of this region remains unknown. Interestingly, the RHD from 
any Nogo/RTN isoform member is sufficient to delay nerve 
regeneration after nerve crush injury [385]. A number of in vivo 
studies have confirmed the role of Nogo-A as a mediator of inhibition 
of neural regeneration. These studies have relied upon genetic and 
pharmacological neutralization of Nogo-A, and conclude that its 
inhibition promotes axon growth and functional recovery following 
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spinal cord injury [386-390]. In contrast to these important advances 
made in understanding the physiological significance of reticulon 
protein function, little attention has been paid to the intracellular role 
of reticulons [391]. A number of studies of Nogo localization have 
shown that only a minor proportion of Nogo (2-5%) is localized to the 
cell surface [381, 392, 393], and topology analyses suggest that Nogo-
66 is primarily arranged in a cytosolic orientation [364].                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
These data suggest that in addition to the neurite inhibitory function of 
Nogo-A, much remains to be studied regarding what is likely to be  
the major, intracellular function of Nogo-A. 
Given the notable importance of the understanding of Nogo-mediated 
processes in the CNS, little attention has been paid to the role of Nogo 
isoforms in the non-neural tissues, especially in the vasculature. Using 
a proteomics-based approach to identify novel caveolae and lipid raft-
enriched proteins in endothelial cells, Acevedo and colleagues 
demonstrated that the reticulon protein RTN4B/Nogo-B is higly 
localized in caveolin-1 enriched microdomains (CEM) and lipid rafts 
(LR), with its N-terminus oriented extracellularly [392]. They also 
indentified Nogo-B in both endothelial and vascular smooth muscle 
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cells of the vessel wall. For the first time they described that the N-
terminus of Nogo-B (AmNgB) is a stimulant of adhesion of ECs and 
VSMCs and acts as a chemoattractant for ECs, conversely it inhibits 
PDGF-induced VSMC migration [392]. These results were shown to 
be physiologically relevant, as genetic loss of Nogo-B results in 
exaggerated neointimal proliferation, suggesting that endogenous 
Nogo-B regulates vascular remodeling especially in injured vessels 
[392]. Therapeutic delivery of Nogo-B in both murine and porcine 
models of acute vascular injury reduces the extent of vascular growth 
and neointima formation [406]. In humans, Nogo-B levels are reduced 
in atherosclerotic tissue and aortic aneurysms, and this reduction may 
contribute to plaque formation, destabilization, and vascular 
abnormalities [394, 407]. A negative role for Nogo-B was assessed 
also in lung inflammation, where its reduction contributes to the 
pathogenesis of asthma by enhancing the magnitude of Th2-driven 
allergic inflammation. However, in models of wound healing and 
tissue ischemia, endogenous Nogo-B participates in the extent of 
recovery, largely via regulation of macrophage motility and gene 
expression [408]. Furthermore, it plays a critical role in hepatic 
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fibrosis as hepatic Nogo-B levels are significantly elevated in 
cirrhosis, whereas the absence of Nogo-B ameliorates liver fibrosis 
and portal hypertension [409]. Finally, it has been shown that 
endothelial Nogo-B is a novel regulator of acute inflammatory 
response in vivo, controls ICAM-1–dependent leukocyte TEM in vitro 
[410]. Thus, it appears that Nogo isoforms exert diverse actions in 
multiple cell types, and the differences in function are likely 
attributable to the intracellular role of the RTN domain versus the 
biologically active fragments generated upon tissue damage. 
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9.2 Purpose of the study 
Recent literature has supported the considerable importance of Nogo-
B in the vasculature since it has been demonstrated to be abundantly 
expressed in both endothelial and vascular smooth muscle cells and to 
regulate vascular remodeling in vivo as its loss is associated with 
abnormal vascular function and stenotic atherosclerotic lesions in 
humans [392, 394]. However, all these studies were performed in 
injured vessels from both WT and Nogo-A/B
-/- 
mice and they are still 
far from address to Nogo-B some mechanisms through which it 
regulates vascular homeostasis in physiological conditions. Therefore, 
the purpose of this focused project is to study the role of Nogo-B 
within the vasculature, in particular in resistance arteries such as the 
mesenteric artery from WT and Nogo-A/B
-/-
 mice and to evaluate 
their vascular function by using the pressure myograph. 
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Chapter 10 
MATERIALS AND METHODS 
10.1 Animals  
Nogo-A/B-deficient mice were generated as described by Kim et al. 
[400]. Age-matched male, 14 to 16 week-old Nogo-A/B
-/-
 mice and 
their wild type (WT) littermates were used. All animal experiments 
were approved by the Weill Cornell Institutional Animal Care and 
Use Committee. 
10.2 Reagents 
Phenylephrine (Phe), Acetilcholine (Ach) and all reagents for Krebs 
buffer solution preparation were purchased from Sigma (St. Louis).  
10.3 Blood pressure measurements in conscious mice 
Systolic, diastolic and mean blood pressure (SBP, DBP and MBP 
respectively) was measured in conscious mice using the pneumatic 
tail-cuff method (MRBP System, Life Science). The mice, left in a 
room at 30°C for 30 min in order to acclimate, were placed in a plastic 
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restrainer and a cuff with a pneumatic pulse sensor was attached to the 
tail. The restrainer was placed in the warm section of the system and 
the temperature was set at 34°C.This procedure was performed every 
day for 5 consecutive days according to the following protocol:  
 Day 1 and 2: animal training. In order to acclimate the animals 
to this procedure, they were trained before to start the 
experiments. 
 Day 3 to 5: blood pressure measurements. Three consecutive 
measurements were performed per each mouse every day and 
then the blood pressure values were obtained from averaged 
measurements. 
  During the entire measurement period, the temperature was 
maintained at 34°C. 
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10.4 Preparation of vessel segments 
Animals were sacrificed with CO2. The intestine with mesentery 
attached was rapidly removed and placed in cold (4°C) Krebs 
solution, composed as follow (mM): NaCl 118, KCl 4.7, MgCl2 1.2, 
KH2PO4 1.2, CaCl2 2.5, NaHCO3 25, and glucose 10.1. Second-
generation mesenteric arteries were carefully cleaned from adhering 
tissue under a dissecting microscope (Zeiss, Discovery.V8). 
10.5 Pressure myograph recordings 
To measure acute changes in diameter in response to pharmacological 
agents and mechanical stimuli, in particular the stretch, the arteries 
with intact endothelium were mounted on glass micropipettes in a 
pressure myograph chamber (Danish MyoTechnology, Aarhus, 
Denmark), by keeping the orientation of the vessel in relation to the 
flow in vivo and were secured with silk sutures. The micropipettes 
were connected to a pressure interface which regulated intraluminal 
pressure and flow. The vessel diameter was monitored live using a 
microscope connected to a digital video camera (IC Capture) and 
computer software with edge detection capability. The edge chosen by 
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the software were examined critically in all experiments. The vessel 
was superfused with warmed (37°C) and oxygenated (95% O2 and 5% 
CO2) Krebs. 
10.6 Experimental protocol 
Before experimentation, intraluminal pressure was gradually 
increased to 95mmHg. At this pressure, the vessels were stretched 
manually in the longitudinal direction to 115% of its unstretched 
length. Preparations were subsewuently equilibrated at 37°C for 30 
min at 45mmHg.  
In each experiment, vessels were first challenged with PE (1 µM) 
until the responses were reproducible. The vessels were then washed 
and contracted with PE (1 mM) and, once a plateau was reached, a 
cumulative concentration-response curve of Ach (1nM-30µM) was 
performed to evaluate endothelium integrity. Vessels showing less 
than 70% of endothelium were discarded. 
After the vessels were washed and stabilized for 15 min, cumulative 
dose-response curve of Phe (1nM-30µM) and AngII (0.1nM-3µM) 
were performed. 
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After washing, the pressure was brought to 20mmHg and left for 5min 
in way to stabilize the vessel at the new reached diameter value. 
Myogenic tone was provoked by raising intraluminal pressure from 20 
to 120mmHg in 25-mmHg steps. Each pressure level was maintained 
for 5 min, and the vessel diameter was then measured. At the end of 
each experiment, the vessel was fully relaxed by using-Ca
2+
-free 
Krebs supplemented with 2mM EGTA. Myogenic tone was expressed 
as [(D1-D2)/D1]x100, where D1 is the passive diameter in Ca
2+
-free 
buffer and D2 is the active diameter. 
10.7 Vessel morphometry 
Three secondary-branches of mesenteric arteries per mouse were 
harvested and freed from surrounding fat tissue. Following full 
relaxation with Ach 1µM, they were fixed with 4% paraformaldehyde 
(PFA) and left overnight at 4°C. Fixed specimen was washed with 
PBS and then paraffin-embedded. 5µm cross-sections were obtained 
and VVG (Verhoeff’s Van Gieson) staining was performed to identify 
the elastic elamina. Wall thickness, area and radius were determined 
by using a computerized image-analysis system (Image-Pro). At least 
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three sections per vessel from each mouse were analysed. Wall 
thickness was obtained from three averaged measurements. 
10.8 Statistical analysis  
Data were expressed as mean ± SEM. Statistical analysis was 
determined by using Student’s t-test analysis for unpaired data, or, in 
the case of multiple comparison, two way ANOVA and Bonferroni as 
a post-test. Differences were considered statistically significant when 
p<0.05. GraphPad Prism software (version 5.0, GraphPad Software, 
San Diego, CA) was used for all the statistical analysis. 
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Chapter XI 
RESULTS 
11.1 Vascular Nogo-B is involved in blood pressure 
homeostasis 
To investigate the Nogo-B in vascular homeostasis, we measured the 
blood pressure in Nogo-A/B
-/-
 and WT mice by using tail cuff system, 
which allow us to perform measurements in non-anesthetized mice. 
We found that systolic (fig. 11.1A), diastolic (fig. 11.1B) and mean 
(fig. 11.1C) blood pressure were significantly lower in Nogo-A/B-/- 
mice compared to matched WT (systolic 123.2±4.3mmHg and 
90.7±3.3mmHg; diastolic 97±4.6mmHg and 62.9±2.3mmHg; mean 
106±4.7mmHg and 72±2.6mmHg, WT and Nogo-A/B
-/-
 respectively).  
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Fig. 11.1: Vascular Nogo B can regulate blood pressure in vivo. Nogo-A/B
-/- 
mice displayed a reduced (A) systolic, (B) diastolic and (C) mean blood pressure. 
(*** P<0.001 n=7 for each group). 
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11.2 Loss of Nogo-B leads to arterial wall remodeling 
It is well-known that increased or decreased pressure itself is 
responsible for the initiation of vascular remodeling. To assess 
vascular structure quantitatively, cross-sections of mesenteric artery 
were stained for elastic elamina (VVG staining) following 
morphometric analysis. The data indicated a reduction in both media 
wall thickness (4.4±0.26µm vs 3.7±0.24µm WT and Nogo-A/B
-/-
 
respectively) and media thickness-radius ratio (0.044±0.003µm and 
0.034±0.001µm, WT and Nogo-A/B
-/-
 respectively) (fig. 11.2). 
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Fig. 11.2: Nogo-A/B
-/-
 mice showed both media thickness and media 
thickness:radius ratio reduction compared to WT mice. (A) VVG staining of 
mesenteric vessel sections from WT and Nogo-A/B
-/-
 mice, respectively. (B) 
summarized analysis of morphometry (* P<0.05. n=10 per group). 
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11.3 The lack of Nogo-B impairs the myogenic tone, but 
not the pharmacological response to Ach and Phe in 
mesenteric arteries 
Since the lack of Nogo-B causes hypotension in mice, we evaluated 
the vascular reactivity of mesenteric artery from both WT and Nogo-
A/B
-/-
 mice. In particular we evaluated the pharmacological response 
and the myogenic tone by using the pressure myograph. 
First we performed cumulative Ach dose-response curve and we 
found that vasodilation triggered by activation of cholinergic receptor 
is not affected in Nogo-A/B
-/-
 mice compared to WT mice (Emax 
87.5±4.2% vs 86.6±2.7% WT and Nogo-A/B
-/-
 respectively) (fig. 
11.3A). Then, we evaluated whether adrenergic system was affected 
by the loss of NogoB. As shown in fig 11.3B, Phe-induced 
vasoconstriction was not modified in Nogo-A/B
-/-
 mice (Emax WT 
52.3±1.8% vs KO 54.4±2.6%). This suggested that both cholinergic 
and adrenergic tone were not influenced by the loss of vascular Nogo-
B. 
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In another set of experiments, pressure was increased in steps from 20 
to 120mmHg to induce myogenic response. Active lumen diameter 
was significantly increased in Nogo-A/B
-/-
 compared to WT mice 
(Emax 265.2±13.8µm and 301.2±13.7µm, WT vs Nogo-A/B
-/-
(fig. 
11.3C). 
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Fig. 11.3: Myogenic tone, but not cholinergic and adrenergic response is 
impaired in Nogo-A/B
-/-
 mice (A) Ach-induced vasorelaxation and (B) Phe-
induced vasoconstriction are not influenced by the lack of Nogo-B. Conversely 
(C) myogenic tone is impaired in Nogo-A-B-/- mesenteric artery (** P<0.01, n= 
10).  
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Chapter 12 
DISCUSSION 
Nogo is a novel member of the RTN family of proteins named after 
the main subcellular localization of RTN-1 in the endoplasmic 
reticulum [302]. These proteins share a conserved 188 amino acid 
residues long C-terminal reticulon homology domain with two large 
hydrophobic regions of unknown function [381, 393]. The N-terminal 
sequences share some physicochemical properties but differ among 
the RTN family members. Of the three majorisoforms of Nogo, Nogo-
A and Nogo-C are highly expressed in the central nervous system, 
with Nogo-C being additionally found in skeletal muscle, while 
Nogo-B is found in a ubiquitous pattern, such as the central and 
peripheral nervous systems, vessel wall, heart, spleen, skeletal muscle 
and testis [439, 440]. Previous works have focused on the biology of 
Nogo-A, Nogo-A receptors and Nogo-A co-receptors as negative 
regulators of axonal regeneration in the central nervous system [376, 
385, 390]. However, it is still unknown the biological function of 
Nogo-B in the peripheral system. Acevedo et al [392] investigated the 
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expression and the role of Nogo-B in peripheral blood vessels and 
reported that Nogo-B was highly expressed in endothelial and smooth 
muscle cells of vessel wall, and that it was a regulator of cell 
migration in vitro and vascular remodeling in vivo. Although they 
suggested that Nogo-B participates in vessel injury and vascular 
remodeling, the physiological importance of Nogo-B in vascular 
homeostasis, remains still undefined. Given the abundance of Nogo-B 
in both endothelial and vascular smooth muscle cells, we investigated 
the function of Nogo-B in the contractile machinery of vascular 
system and thus in the regulation of blood pressure.  
We found that Nogo-A/B
-/-
 mice were markedly hypotensive 
compared to WT mice. It is well established that blood vessels 
undergo remodeling when chronically exposed to pressure changes. 
Indeed, blood vessels adapt to the hemodynamic stress in order to 
maintain constant the circumferential wall stress, which is the blood 
pressure value per media wall thickness. Thus, the lumen diameter of 
resistance arteries is governed not only by the magnitude of 
vasoconstriction, but also by vascular remodeling, providing a chronic 
change in wall geometry [228], Therefore, we looked at mesenteric 
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arteries morphometry and we  found that Nogo-A/B
-/-
 mesenteric 
arteries displayed a decreased media thickness as well as media 
thickness:radius ratio compared to WT mice. 
It is well known that vessel tone is regulated by both intrinsic and 
extrinsic mechanisms. Circulating vasoactive mediators such as 
cathecholamines, as well as locally released mediators from 
autonomic nervous system, confer extrinsic regulation of smooth 
muscle contraction. Intrinsic regulation of vessel diameter is mainly 
mediated by two mechanosensitive mechanisms. One is the sensing of 
shear stress on the endothelium caused by an increase in blood flow. 
This leads to release of vasodilators from the endothelium including 
NO or EDHF, which relaxes the smooth muscle cells themselves, 
resulting in narrowing of the vessel lumen. The other mechanism 
involves stretch sensing by the smooth muscle cells themselves, 
resulting in narrowing of the vessel lumen. The latter mechanism is 
referred to as myogenic tone, the intrinsic ability of vessels to 
constrict in response to increased intraluminal pressuret.  
We found that both Ach-induced vasorelaxation and Phe-induced 
vasoconstriction were not affected in mesenteric arteries from Nogo-
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A/B
-/-
 mice, suggesting that both cholinergic and adrenergic systems 
are not involved in vascular effects of Nogo-B. On the other hand, we 
found that myogenic tone in response to the increase of intraluminal 
pressure was notably lower in KO than in WT mesenteric vessels. 
This suggests that Nogo-B can be involved in the regulation of 
mechanotransduction rather than participates in the signaling triggered 
by extrinsic factors such as catecholamines or NO.. 
In conclusion, the present study reports a previously unidentified role 
of Nogo-B plays in the regulation of blood pressure in physiological 
conditions. Further studies are needed to understand the mechanism 
defining the physiological and biological function of Nogo-B. 
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